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Introduction	  
	  
1.1.	  General	  information	  
The	   skin	  performs	  critical	  homeostatic	   functions	   including	   thermoregulation,	   sensory	  
perception,	  protection	  against	  microbial	  invasion,	  and	  protection	  against	  absorption	  of	  
potentially	   toxic	   environmental	   agents.	   To	   perform	   these	   functions,	   the	   skin	   must	  
maintain	   a	   structural	   and	   functional	   integrity	   that	   derives	   from	   an	   array	   of	   complex	  
cellular	  and	  biochemical	  interactions	  (Chu	  et	  al.	  2003).	  	  
The	  structural	  homeostasis	  of	  the	  skin	  is	  partly	  the	  result	  of	  regulated	  cell	  proliferation	  
and	  differentiation	  within	  the	  topmost	  segment	  of	  the	  skin	  called	  the	  epidermis	  (Fig.	  
1.1).	   The	   epidermis	   is	   a	   cornifying	   stratified	   epithelium	  with	   the	   keratinocyte	   as	   the	  
major	  cell	  type.	  It	  has	  a	  basal	  layer	  of	  cells	  (basal	  keratinocytes)	  that	  have	  the	  capacity	  
to	  proliferate.	  These	  divide	  periodically	  and	   the	  daughter	   cells	  move	  upwards	   to	   the	  
skin	  surface.	  Once	  suprabasal,	  cells	  lose	  their	  ability	  to	  proliferate.	  To	  form	  the	  barrier,	  
they	  pass	  through	  different	  stages	  of	  terminal	  differentation	  and	  finally	  die	  and	  scale	  
off.	   In	   the	   course	   of	   terminal	   differentiation,	   keratins	   and	   other	   epidermis-­‐specific	  
proteins	  (i.	  e.,	  involucrin,	  loricrin)	  are	  cross-­‐linked	  to	  form	  the	  unique	  protein	  envelope	  
of	   cornified	   cells.	   In	   addition,	   a	   complex	   lipid	   envelope	   is	   deposited	   between	   the	  
cornified	   cells	   to	   control	   trans-­‐epidermal	  water	   loss	   and	  permeability	   for	   exogenous	  
material.	   Thus,	   the	   cornified	   cell	   envelope	   represents	   a	   structural	   and	   functional	  
interface	  between	   the	  body	  and	   the	  external	  environment	   (Candi	  et	  al.	  2005,	  Koster	  
and	  Roop	  2007,	  Feingold	  2007)	  
Alterations	   in	   the	  proliferating	  and	  differentiating	   “compartments”	  of	   the	  epidermis,	  
whether	  from	  endogenous	  and/or	  exogenous	  triggers,	  are	  associated	  with	  a	  number	  of	  
skin	  diseases	  including	  skin	  cancer.	  It	  is	  therefore	  important	  to	  identify	  and	  understand	  
the	   molecular	   mechanisms	   that	   influence	   and	   control	   cell	   proliferation	   and	  
differentiation	  within	  the	  epidermis.	  	  
1.2.	  COX-­‐mediated	  signaling	  
The	   prostaglandins	   (PG),	   comprising	   one	   of	   the	   major	   classes	   of	   eicosanoids,	   are	  
synthesized	  primarily	  from	  arachidonic	  acid	  (AA),	  an	  essential	  fatty	  acid,	  via	  activity	  	  








Figure	  1.1:	  Schematic	  diagram	  of	  mammalian	  skin.	  The	  outer	  layer	  of	  the	  skin,	  
or	   epidermis,	   is	   made	   up	   mainly	   by	   keratinocytes	   (85%	   of	   epidermal	   cells).	  
Kerationcytes	  are	  organized	   in	   layers,	  and	  are	  named,	   from	   inner	   to	  outer,	  as	  
follows:	   basal	   layer	   (stratum	   basale),	   spinous	   layer	   (stratum	   spinosum),	  
granular	  layer	  (stratum	  granulosum)	  and	  cornified	  layer	  (stratum	  corneum).	  
	  
that	   initially	   was	   thought	   to	   reflect	   a	   single	   enzyme	   called	   cyclooxygenase	   (COX)	  
(Fig.1.2).	  As	  a	  pre-­‐requisite	   for	  PG	  biosynthesis,	  AA	  has	   to	  be	  released,	  a	  step	  that	   is	  
mostly	   catalyzed	   by	   the	   actions	   of	   phospholipases	   A2	   (PLA2)	   (Bonventre	   et	   al.	   1997,	  
Hirabashi	  et	  al.	  2004).	  Since	  prostaglandin	  E2	  (PGE2)	  was	  identified	  in	  rat	  and	  human	  
skin,	   (Ziboh	   and	   Shia	   1971,	   Jonsson	   and	   Anggard	   1972),	   numerous	   studies	   have	  
attempted	  to	  identify	  its	  role	  in	  both	  normal	  and	  pathologic	  skin	  responses.	  One	  of	  the	  
obstacles	   to	  achieving	  this	  understanding	  has	  been	  the	   fact	   that	  almost	  all	  cell	   types	  
synthesize	   some	  profile	  of	  PG	  and	   the	   skin	   is	  no	  exception;	   consequently	   identifying	  
the	   cellular	   source(s)	   and	   the	   cellular	   target(s)	   of	   PG	   generation	   in	   the	   context	   of	  
specific	   skin	   responses	   is	   paramount.	  While	   this	   process	   of	   identification	   is	   far	   from	  
complete,	   developments	   in	   the	   enzymology	   of	   PG	   generation	   as	   well	   as	   in	   the	  
elucidation	  of	  PG	  receptors	  provide	  new	  avenues	  to	  explore	  in	  the	  attempt	  to	  define	  
how	  PG	  modulate	  mammalian	  skin	  function.	  
Two	   isoforms	   of	   COX,	   commonly	   referred	   to	   as	   COX-­‐1	   and	   COX-­‐2	   are	   currently	  

















Figure	  1.2:	  Pathway	  of	  prostaglandin	  E2	  (PGE2)	  synthesis	  and	  roles	  of	  PGE2	  
in	   cancer	   development.	   Cyclooxignease	   (COX)-­‐1	   and	   COX-­‐2	   mediate	   the	  
conversion	  of	  arachidonic	  acid	   into	  PGG2	  and	  PGH2,	  whereas	  the	  enzyme	  
PGE2	  synthase	  converts	  PGH2	  into	  PGE2.	  PGE2	  contributes	  to	  oncogenesis	  
by	   acting	   on	   cell	   proliferation,	   tumour	   angiogenesis,	   cell	   invasion	   and	  
metastasis,	  and	  immune	  modulation.	  
	  
isozymes	  focused	  on	  inflammatory	  cells.	   Investigators	  found	  that	  whereas	  COX-­‐1	  was	  
constitutively	  expressed,	  COX-­‐2	  required	  stimulus-­‐based	  induction	  (Simith	  and	  DeWitt	  
1996,	   Herschman	   et	   al.	   1997,	   Needleman	   and	   Isakson	   1997).	   Consequently,	   it	   was	  
postulated	   that	   the	   PG	   that	   participate	   in	   homeostatic	   regulation	   derive	   from	   the	  
constitutive	   COX-­‐1	  whereas	   the	   PG	   that	   participate	   in	   inflammation	  derive	   from	   the	  
inducible	   COX-­‐2.	   However,	   research	   on	   tissues	   and	   organs	   other	   than	   inflammatory	  
cells	  challenged	  the	  concept	  of	  COX-­‐2	  functioning	  only	  as	  an	  inducible	  enzyme	  under	  
pathophysiological	   circumstances.	   In	   fact,	   it	   is	   currently	   accepted	   that	   the	   two	  
isoforms	  of	  active	  COX	  enzymes	  display	  similar	  enzymatic	  properties	  but	  differ	  in	  their	  
expression	  and	  regulation	  (Smith	  et	  al.	  2000,	  Simmons	  et	  al.	  2004).	  Both	  isoforms	  are	  
active	  under	  physiological	  and	  pathophysiological	  situations.	  COX-­‐1	  as	  a	  housekeeping	  
gene	   is	  expressed	  constitutively	  and	  ubiquitously	  and	  according	  to	  numerous	  genetic	  
and	   pharmacological	   studies	   is	   thought	   to	   generate	   PG	   that	   control	   normal	  
physiological	   functions	   such	   as	   maintenance	   of	   the	   gastric	   mucosa	   and	   platelet	  
function,	  vascular	  homeostasis,	  as	  well	  as	  renal	  blood	  flow	  (Simmons	  et	  al.	  2004,	  Loftin	  
Arachidonic	  acid	  
PGG2	  /	  PGH2	  
PGE2	  
↑	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   ↑	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   Immune	  modulation	  
COX-­‐1	  and	  COX-­‐2	  
PGE2	  synthase	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et	   al.	   2002).	   Although	   not	   well-­‐understood,	   COX-­‐1-­‐mediated	   PG	   synthesis	   seems	   to	  
contribute	   to	   tumor	   progression	   in	   various	   tissues	   including	   skin	   (Loftin	   et	   al.	   2002,	  
Cha	  and	  Dubois	  2007).	  In	  contrast,	  COX-­‐2,	  an	  immediate-­‐early	  gene,	  is	  below	  detection	  
levels	   in	   many	   tissues	   except,	   for	   example,	   brain,	   pancreatic	   islets,	   ovary,	   uterus,	  
kidney,	   and	   skin	   with	   anagen	   hair	   follicles	   (see	   below).	   As	   a	   rule,	   COX-­‐2	   becomes	  
strongly	   induced	   by	   a	   huge	   number	   of	   diverse	   stimuli	   including	   hormones,	  
environmental	   stress	   factors	   such	   as	   physical	   or	   chemical	   carcinogens,	   and	   in	   the	  
course	  of	  inflammatory	  processes	  and	  tissue	  repair	  (Simmons	  et	  al.	  2004).	  Genetic	  and	  
pharmacological	   approaches	   demonstrate	   a	   physiological	   role	   of	   COX-­‐2	   in	   renal	  
development,	   in	   salt	   and	  water	   regulation	   by	   the	   kidney,	   in	   female	   reproduction,	   in	  
bone	  metabolism	  and	  in	  energy	  homeostasis	  (Loftin	  et	  al.	  2002,	  Simmons	  et	  al.	  2004,	  
Loftin	  et	  al.	  2002,	  Cha	  and	  Dubois	  2007,	  Blackwell	  et	  al.	  2010,	  Vegiopoulus	  et	  al.	  2010).	  
Furthermore,	   studies	   on	   the	   expression	   of	   COX-­‐2	   in	   human	   and	   mammalian	   skin	  
suggest	  that	  this	  isozyme	  may	  participate	  in	  homeostatic	  function	  of	  the	  epidermis	  and	  
moreover,	   overexpression	   may	   be	   a	   feature	   of	   certain	   types	   of	   skin	   dysplasia	   and	  
cancer	  (see	  bellow)	  (Loftin	  et	  al.	  2002,	  Cha	  and	  DuBois	  2007,	  Wang	  and	  DuBois	  2010a,	  
Wang	  and	  Dubois	  2010b).	  	  
1.3.	  COXs	  in	  the	  skin	  
Early	   studies	   of	   AA	   deficiency	   in	   animals	   and	   later	   in	   humans	   receiving	  
hyperalimentation	  documented	  profound	  effects	  on	   skin	   structure	  and	   function.	  The	  
epidermis	   became	   hyperkeratotic,	   hair	   loss	   ensued,	   and	   barrier	   function	   was	   lost	  
(reviewed	  by	  Prendiville	  and	  Manfredi	  1992).	  The	  observation	  that	  topical	  application	  
of	   PGE2	   could	   reverse	   epidermal	   hyperkeratosis	   in	   the	   rat	   (Ziboh	   and	   Hsia	   1972),	  
although	   not	   restore	   barrier	   integrity	   (Elias	   et	   al.	   1980),	   was	   probably	   the	   first	  
indication	  that	  PG	  and,	  in	  turn,	  COX	  activity,	  contributed	  to	  skin	  homeostasis.	  Later	  on,	  
it	  was	  demonstrated	   that	   the	   skin	  was	   a	  major	   site	   of	   PG	   synthesis	   (Goldyne	  2000).	  
Keratinocytes	   synthesize	   PGE2,	   but	   also	   PGF2α	   and	   PGD2.	   While	   melanocytes	   also	  
produce	  PGE2	  along	  with	  PGD2	  (Glehhill	  et	  al.	  2010),	  Langerhans	  cells	  and	  mast	  cells	  
produce	  PGD2	   (Maciejewski-­‐Lenoir	  et	  al.	  2006,	  Shimura	  et	  al.	  2010),	   fibroblasts,	  and	  
endothelial	   cells	   mainly	   synthesize	   PGI2	   (Ziboh	   1996).	   The	   epidermis	   constitutively	  
expresses	   COX-­‐1	   in	   individual	   keratinocytes	   of	   the	   interfollicular	   epidermis	   and	   the	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distal	   part	   of	   the	   hair	   follicle	   (Müller-­‐Decker	   et	   al.	   1998,	  Müller-­‐Decker	   et	   al.	   1999,	  
Müller-­‐Decker	  et	  al.	  2003).	  Depending	  on	  the	  study,	  COX-­‐2	  expression	  is	  low	  in	  normal	  
unchallenged	  skin	  and	  found	  if	  at	  all	  predominantly	  in	  basal	  outer	  root	  sheath	  cells	  and	  
basal	  sebocytes	  of	  the	  growing	  hair	  follicle	  or	  only	  in	  the	  upper	  epidermis	  (Leong	  et	  al.	  
1996,	  Müller-­‐Decker	  et	  al.	  1998,	  Müller-­‐Decker	  et	  al.	  1999,	  Abd-­‐El-­‐Aleem	  et	  al.	  2001,	  
Kagoura	  et	  al.	  2001,	  Müller-­‐Decker	  et	  al.	  2003,	  Akunda	  et	  al.	  2004,	  Alestas	  et	  al.	  2006,	  
Xu	   et	   al.	   2008).	   In	   vitro,	   human	   and	  mouse	   skin	   keratinocytes	   have	   been	   shown	   to	  
modulate	  their	  proliferation	  through	  COX-­‐2	  expression	  and	  PG	  synthesis	  (Pentland	  et	  
al.	  1986,	  Leong	  et	  al.	  1996).	  
COX-­‐1	   and	   COX-­‐2	   isozymes	   can	   both	   be	   expressed	   in	   mouse	   and	   human	   epidermis	  
(Scholz	  et	  al.	  1995,	  Goldyne	  2000).	  In	  neonatal	  skin,	  the	  COX-­‐1	  protein	  was	  increasingly	  
expressed	  with	  differentiation	  whereas	   it	  was	  equally	  expressed	   in	  all	   layers	   in	  adult	  
skin.	   In	   the	   adult	   keratinocytes,	   COX-­‐2	   mRNA	   was	   barely	   detectable	   and	   no	   COX-­‐2	  
protein	  could	  be	  demonstrated.	  Based	  on	  these	  results,	  it	  appears	  that	  in	  mouse	  skin,	  
COX-­‐2	  expression	  seems	  to	  follow	  the	  inducible	  pattern	  found	  in	  inflammatory	  cells.	  In	  
fact,	   expression	   of	   COX-­‐2	   protein	   appeared	   in	   the	   basal	   layer	   of	   mouse	   epidermis	  
following	   treatment	  with	  acetone	   that	  disrupts	   the	  barrier	   function	  of	   the	  epidermis	  
(Leong	  et	  al.	  1996).	   In	  human	  skin,	  COX-­‐1	   immunostaining	  was	  observed	   throughout	  
the	   epidermis	   whereas	   COX-­‐2	   immunostaining	   was	   more	   prominent	   in	   the	   more	  
differentiated	  layers	  of	  the	  epidermis	  and	  hair	  follicle	  (Leong	  et	  al.	  1996,	  Buckman	  and	  
Gresham	  1998,	  Muller-­‐Decker	  et	  al.	  1999).	  Thus,	  unlike	  mouse	  skin,	  COX-­‐2	  protein	   in	  
human	  skin	  may	  be	  constitutively	  expressed	   in	   the	  more	  differentiated	   layers	  of	   the	  
epidermis.	  In	  keeping	  with	  this	  concept,	  increased	  expression	  of	  COX-­‐2	  was	  present	  in	  
biopsies	   of	   squamous	   cell	   carcinomas	   that	   derive	   from	   more	   differentiated	  
keratinocytes;	   in	  contrast,	   little	   if	  any	  expression	  of	  COX-­‐2	  was	  observed	   in	  basal	  cell	  
carcinomas	   that	   derive	   from	   the	   least	   differentiated	   basal	   cells	   (Leong	   et	   al.	   1996,	  
Buckman	  and	  Gresham	  1998,	  Muller-­‐Decker	  et	  al.	  1999).	  One	  study	  that	  also	  evaluated	  
keratoacanthomas,	  another	  type	  of	  squamous	  proliferation	  that	  has	  many	  features	  of	  
squamous	  cell	  carcinoma,	  showed	  increased	  expression	  of	  COX-­‐2	  (Muller-­‐Decker	  et	  al.	  
1999).	  A	  recent	  study	  with	  rat	  epidermis,	  and	  according	  with	  what	  observed	  in	  human	  
skin,	   the	  COX-­‐2	  protein	  expression	  was	   strongly	  detected	   in	   the	   suprabasal	   layers	  of	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the	  stratified	  epidermis	  (Xu	  et	  al.	  2008).	  	  
A	  part	  from	  these	  studies	   in	  human	  and	  rodent	  skin	  and	  although	  constitutive	  COX-­‐2	  
expression	  has	  been	  reported	  in	  dog,	  cat	  and	  horse	  kidney	  (Khan	  et	  al.	  1998,	  Newman	  
and	  Mrkonjich	  2006,	  Thamm	  et	  al.	  2008,	  Hamamoto	  et	  al.	  2009),	  no	  studies	  has	  been	  
performed	  in	  small	  animal	  or	  equine	  medicine	  regarding	  COX-­‐2	  and	  PGE2	  expression	  in	  
non-­‐diseased	   skin.	   From	   the	   information	   available	   on	   COX-­‐2	   expression	   in	   canine	  
studies	   on	   wound	   healing	   or	   neoplastic	   disease,	   it	   appears	   that	   this	   protein	   is	   not	  
expressed	  in	  normal	  canine	  skin	  (Hamamoto	  et	  al.	  2009,	  Pires	  et	  al.	  2010).	  However,	  in	  
the	   feline	  and	  equine	  studies	  on	  cutaneous	  neoplasias	   there	   is	  no	  mention	  of	  COX-­‐2	  
expression	  in	  non-­‐diseased	  epidermis	  and	  there	  are	  no	  pictures	  to	  allow	  us	  to	  evaluate	  
it	  (Beam	  et	  al.	  2003,	  Thamm	  et	  al.	  2008).	  	  
1.4.	  Physiologic	  implications	  of	  COX	  expression	  in	  the	  skin	  
The	   extracellular	   concentration	   of	   calcium	   seems	   to	   be	   critical	   for	   induction	   of	  
keratinocyte	   differentiation	   (Yuspa	   et	   al.	   1989,	   Pillai	   et	   al.	   1990).	   In	   fact,	   an	  
extracellular	   calcium	   gradient	   exists	   in	   normal	   human	   skin	   with	   the	   lowest	  
concentration	  present	   in	   the	  basal	   cell	   region	  and	   the	  highest	   concentration	  evident	  
around	   the	   more	   differentiated	   keratinocytes	   higher	   in	   the	   epidermis	   (Menon	   and	  
Elias	   1991).	   A	   relationship	   between	   COX-­‐2,	   the	   epidermal	   calcium	   gradient,	   and/or	  
keratinocyte	  differentiation	  is	  suggested	  by	  several	  studies.	  Research	  with	  human	  and	  
mouse	   keratinocyte	   cultures,	   leaded	   to	   the	   observation	   that	   increasing	   extracellular	  
calcium	  resulted	  in:	  1)	  increased	  expression	  of	  COX-­‐2	  mRNA	  and	  protein,	  but	  not	  COX-­‐
1	  protein	  (Leong	  et	  al.	  1996),	  2)	   increased	  PGE2	  synthesis	   (Evans	  et	  al.	  1993),	  and	  3)	  
induction	   of	   cornified	   envelope	   or	   expression	   of	   keratin-­‐1	   (K1)	   formation	  which	   are	  
recognized	  markers	  of	  keratinocyte	  differentiation	  (Sun	  and	  Green	  1976,	  Akunda	  et	  al.	  
2003).	   In	   the	   presence	   of	   indomethacin	   or	   celecoxib	   (a	   COX-­‐2	   selective	   inhibitor),	  
however,	  cornified	  envelope	  formation	  or	  K1	  expression	  was	  significantly	  suppressed,	  
but	  could	  be	  reestablished	  by	  adding	  exogenous	  PGE2	  (Evans	  et	  al.	  1993,	  Akunda	  et	  al.	  
2003).	   This	   finding	   of	   a	   possible	   link	   between	   PGE2,	   COX-­‐2	   expression,	   and	  
keratinocyte	  differentiation	   is	   in	   keeping	  with	   another	   study	   looking	   at	   the	   effect	   of	  
cholecalciferol	  on	  human	  keratinocytes	  (Kanekura	  et	  al.	  1998).	  A	  similar	  link	  between	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COX-­‐2	  and	  PGE2	  synthases	  expression	  and	  cell	  differentiation	  and	  proliferation	  is	  also	  
suggested	   in	   several	   other	   studies	   (Hume	   et	   al.	   1991,	   Hoff	   et	   al.	   1993,	   Zhang	   et	   al.	  
1997,	  Ansari	  et	  al.	  2008,	  Hara	  et	  al.	  2010).	  However,	  this	  link	  has	  not	  been	  studied	  in	  
small	  animal	  keratinocytes.	  
It	   is	   important	   to	   point	   out	   that	   there	   are	   types	   of	   cells	   in	   which	   differentiation	  
appears	   to	   involve	   COX-­‐1,	   rather	   than	   COX-­‐2,	   induction	   (Simth	   et	   al.	   1993).	  
Consequently,	  the	  physiologic	  roles	  of	  the	  COX	  isozymes	  are	  most	  likely	  cell,	  tissue	  and	  
specie	  specific,	  and	  to	  extrapolate	  the	  findings	  from	  one	  type	  of	  cell,	  tissue	  or	  specie	  to	  
other	  untested	  needs	  to	  be	  undertaken	  with	  caution.	  While	  this	  approach	  appears	  self-­‐
evident,	  COX-­‐2	  is	  still	  often	  described	  in	  the	  general	  literature	  as	  the	  inducible	  form	  of	  
COX	   (Doré	   2011,	   Schneider	   and	   Pozzi	   2011)	   when,	   as	   cited	   previously,	   it	   has	   been	  
recognized	  as	  constitutively	  expressed	  in	  a	  number	  of	  tissues	  (Lipsky	  1999,	  O’Neill	  and	  
Ford-­‐Hutchinson	  1993,	  Goldyne	  2000,	  Müller-­‐Decker	  2011).	  
1.5.	  COX	  in	  acute	  skin	  inflammation	  
The	   skin	   responds	   to	   a	   spectrum	   of	   harmful	   environmental	   stimuli	   with	   an	   acute	  
inflammatory	  reaction	  characterized	  by	  erythema,	  heat,	  edema,	  and	  pain	  followed	  by	  
a	   reactive	   epidermal	   hyperplasia	   and	   hyperkeratosis	   (Hruza	   and	   Pentland	   1993).	  
Erythema	   and	   heat	   are	   due	   to	   the	   dilatation	   of	   local	   arterioles	   and	   subsequent	  
increased	   blood	   flow,	  while	   edema	   and	   infiltration	   of	   the	   dermis	   by	   neutrophils	   are	  
caused	  by	  an	  increased	  vascular	  permeability	  at	  the	  level	  of	  the	  venules.	  Once	  thought	  
to	   be	   inert,	   keratinocytes,	   the	   predominant	   cells	   in	   the	   epidermis,	   have	   an	   active	  
participation	  in	  the	  cutaneous	  immune	  and	  inflammatory	  response.	  Keratinocytes	  can	  
mount	  an	  immune	  response	  throught	  secretion	  of	  antimicrobial	  peptides,	  eicosanoids,	  
neuropeptides,	   reactive	   oxygen	   species,	   growth	   factors	   and	   inflammatory	   cytokines	  
involved	   in	   lipid-­‐derived	   proinflammatory	   mediator	   synthesis	   (Williams	   and	   Kupper	  
1996,	  Barker	  et	  al.	  1991,	  Steinhoff	  et	  al.	  2001,	  Kim	  and	  Modlin	  2003,	  Albanesi	  2010,	  
Nestlé	   2010).	   Keratinocytes	   constitutively	   release	   very	   low	   levels	   of	   cytokines	   and	  
independent	   of	   the	   type	   of	   stimulus	   for	   induction	   of	   an	   acute	   inflammation	   and	  
present	   the	  predominant	   responsive	   cell	   types	  of	   the	  epidermis	   (Nestle	  et	  al.	   2009).	  
Upon	   injury	  or	   stimulation	  with	  exogenous	   factors	   such	  as	   lipopolysaccharides	   (LPS),	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silica,	   poison	   ivy	   cathecols,	   Staphyloccocus	   toxins	   and	   UV	   radiation,	   keratinocytes	  
secrete	   high	   levels	   of	   interleukin	   (IL)	   -­‐1,	   IL-­‐6,	   IL-­‐8,	   IL-­‐10	   and	   tumour	   necrosis	   factor	  
(TNF)-­‐α.	   These	   cytokines	   can	   induce	  differentiation	  and	  growth	  of	   keratinocytes	  and	  
other	   resident	   or	  migrating	   cells	   in	   the	   epidermis,	   dermis	   and	   vessles.	   Furthermore,	  
they	   are	   important	  mediators	   of	   both	   local	   and	   systemic	   inflammatroy	   and	   immune	  
responses	   (Williams	   and	   Kupper	   1996,	   Barker	  et	   al.	   1991,	   Steinhoff	  et	   al.	   2001,	   Kim	  
and	  Modlin	  2003,	  Nestle	  et	  al.	  2009).	  	  
As	  mentioned	  previously,	  a	  part	  from	  cytokines,	  keratinocytes	  can	  also	  synthetize	  and	  
secrete	  PGs.	  These	  eicosanoids	  have	  been	  shown	  to	  have	  a	  modulatory	  role	   in	  acute	  
skin	   inflammation.	   Cutaenous	   irritants,	   such	   as	   ultraviolet	   (UV)	   B	   and	  
tetradecanoylphorbol-­‐acetate	   (TPA),	   increase	  PG	   levels	   not	  only	   in	   keratinocytes	  but	  
also	  in	  melanocytes	  and	  mesenchymal	  cells	  (Ruzicka	  et	  al.	  1983,	  Pentland	  and	  Jacobs	  
1991,	  Goldyne	  et	  al.	  1994,	  Müller-­‐Decker	  et	  al.	  1995,	  Kuwamoto	  et	  al.	  2000,	  Gledhill	  et	  
al.	  2010).	  The	  concentration	  of	  PGE2	  and	  PGI2	  in	  the	  skin	  increases	  at	  the	  same	  time	  
that	   erythema	   and	   edema	   develop	   (Black	   et	   al.	   1978).	   And	   it	   is	   been	   shown	   that	  
intradermal	   injection	   of	   PGE2,	   PGD2,	   and	   PGI2	   induces	   different	   aspects	   of	   the	  
inflammatory	   response	   including	   erythema	   and	   edema	   (Black	   et	   al.	   1978,	   Williams	  
1979).	   Moreover,	   individual	   PGs	   act	   synergistically	   with	   other	   eicosanoids	   and	   with	  
structurally	   unrelated	   pro-­‐inflammatory	   mediators	   (Williams	   1979,	   Pentland	   et	   al.	  
1990,	  Rhodes	  et	  al.	  2001).	  Early	  PGE2	  synthesis	  as	  catalyzed	  by	  COX-­‐1	  depends	  on	  both	  
the	  activation	  of	  PLA2	  by	  phosphorylation	  and	  increased	  PLA2	  synthesis	  (Gresham	  et	  al.	  
1996).	   The	   induction	   of	   epidermal	   hyperproliferation	   by	   TPA	   also	   depends	   on	  
immediate	  COX-­‐1-­‐mediated	  PGE2	  synthesis	  and,	  upon	  progression	  of	  the	  inflammatory	  
response,	   COX-­‐2	   protein	   is	   shown	   to	   be	   transiently	   upregulated	   in	   epidermis	  
(Fürstenberg	  and	  Marks	  1980,	  Scholz	  et	  al.	  1995	  ,	  Buckman	  et	  al.	  1998,	  Müller-­‐Decker	  
et	   al.	   1998,	   Soriani	   et	   al.	   1999,	   Athar	   et	   al.	   2001,	   An	   et	   al.	   2002,	   Tripp	   et	   al.	   2003,	  
Dazard	  et	  al.	  2003,	  Akunda	  et	  al.	  2007).	  In	  reactive	  epidermal	  hiperplasia,	  an	  increased	  
number	   of	   COX-­‐2-­‐expressing	   keratinocytes	   within	   the	   basal	   but	   not	   the	   suprabasal	  
compartment	   of	   the	   interfollicular	   epidermis	   is	   found,	   coinciding	   with	   increased	  
proliferation	  and	  apoptosis	  rates	  in	  basal	  keratinocytes.	  Simultaneously,	  the	  pattern	  of	  
suprabasal	  COX-­‐1	  expression	  remains	  unchanged	  (Müller-­‐Decker	  et	  al.	  2003,	  Tripp	  et	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al.	  2003,	  Akunda	  et	  al.	  2007).	  
In	   inflammatory	   settings,	   PGE2	   molecules	   produced	   via	   COX-­‐2	   and	   COX-­‐1	   have	  
different	  biological	  effects.	  At	   least	   in	  UV	  B-­‐irradiated	  skin,	  COX-­‐2	   rather	   than	  COX-­‐1	  
supports	  keratinocyte	  proliferation	  and	  survival	  (Tripp	  et	  al.	  2003,	  Pentland	  et	  al.	  2004,	  
Akunda	   et	   al.	   2007).	   Like	   in	   other	   cell	   types,	   keratinocyte	   apoptosis	   seems	   to	   be	  
inhibited	   by	   COX-­‐2	   through	   the	   activation	   of	   the	   PGE2	   receptors	   EP2	   and	   EP4.	  
Subsequent	  activation	  of	  downstream	  effector	  kinases	  culminates	   in	   increased	   levels	  
of	   anti-­‐apoptotic	   phospho-­‐Bad,	   an	   effect	   that	   switches	   the	   pro-­‐apoptotic	   Bad	   into	   a	  
survival	   factor	  (Hoshino	  et	  al.	  2003,	  Houchen	  et	  al.	  2003,	  Chun	  et	  al.	  2007).	   In	  UV	  B-­‐
irradiated	  mouse	   skin,	   COX-­‐2-­‐selective	   inhibitors	   effectively	   suppress,	   along	  with	   PG	  
synthesis,	  signs	  of	  acute	  inflammation	  including	  proliferation	  of	  keratinocytes,	  edema,	  
infiltration	   and	   activation	   of	   dermal	   neutrophils,	   the	   formation	   of	   acute	   oxidative	  
damage,	  and	  DNA-­‐damaged	  sunburn	  cells	  (Wilgus	  et	  al.	  2000,	  Wilgus	  et	  al.	  2002,	  Tripp	  
et	  al.	  2003,	  Wilgus	  et	  al.	  2003).	  Moreover,	  the	  topical	  application	  of	  non-­‐steroidal	  anti-­‐
inflammatory	   drugs	   (NSAIDs)	   is	   also	   potent	   in	   inhibiting	   the	   UV	   light-­‐induced	   acute	  
sunburn	  reactions	  such	  as	  redness	  (Snyder	  and	  Eaglestein	  1974,	  Black	  et	  al.	  1980).	  And	  
the	  COX-­‐2-­‐inhibition	  also	  leads	  to	  a	  reduction	  of	  the	  epidermal	  proliferation	  index	  and	  
increases	  apoptosis	  in	  basal	  cells	  (Tripp	  et	  al.	  2003,	  Rodriguez-­‐Buford	  et	  al.	  2005).	  	  
The	  impact	  of	  PGE2	  present	  during	  an	  inflammatory	  response	  on	  both	  immune	  effec-­‐	  
tor	  cells	  and	  surrounding	  stromal	  cells	  is	  determined	  by	  the	  array	  of	  receptors	  the	  cells	  
express	  and	  the	  intracellular	  pathways	  to	  which	  they	  are	  coupled.	  Activation	  of	  these	  
receptors,	   even	  when	   coupled	   to	   similar	   pathways,	  might	   evoke	   different	   responses	  
because	   of	   different	   levels	   of	   expression	   (both	   constitutive	   and	   induced),	   different	  
patterns	   of	   desensitization,	   and	   differential	   affinity	   to	   metabolites	   of	   the	   primary	  
ligand	   (Rundaugh	   et	   al.	   2011).	   Thus,	   determining	   the	   role	   of	   prostanoids	   in	   a	   given	  
inflammatory	  response	  requires	  not	  only	  knowledge	  of	  the	  lipid	  mediators	  present	  in	  
the	   lesion,	   but	   also	   the	   receptor	   profile	   on	   surroding	   cells	   and	   the	   biochemical	  
signaling	   of	   these	   receptors	   under	   specific	   ligand	   concentrations.	   The	   potential	   pro-­‐	  
and	   anti-­‐inflammatory	   roles	   of	   PGE2	   highlights	   these	   complexities.	   A	   part	   from	   the	  
pro-­‐inflammatory	   effects	   of	   PGE2	   explained	   above,	   this	   PG	   has	   also	   been	   shown	   to	  
possess	   anti-­‐inflammatory	   properties	   (Tilley	   et	   al.	   2001,	   Tizard	   2004).	   In	   particular,	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PGE2	  has	  been	  shown	  to	  inhibit	  a	  wide	  range	  of	  T	  and	  B	  cell	  funcions	  (Chouaib	  et	  al.	  
1985,	  Pène	  et	  al.	  1988,	  Roper	  et	  al.	  1994)).	  PGE2	  has	  also	  been	  reported	  to	  attenuate	  
inflammatory	  responses	  initiated	  by	  mast	  cell	  degranulation	  (Hitchocock	  1978,	  Raud	  et	  
al.	  1988)	  and	   in	  models	  of	   inflammatory	  colitis,	  hepatitis	  and	  allergic	  airway	  disease,	  
an	  overall	  anti-­‐inflammatory	  role	  for	  PGE2	  and	  COX-­‐2	  has	  been	  suggested	  (Morteau	  et	  
al.	  2000,	  Yin	  et	  al.	  2007).	  
1.6.	  COX	  in	  wound	  healing	  
Similar	   to	   the	   transient	   upregulation	   of	   COX-­‐2	   in	   UV	   B	   or	   TPA-­‐induced	   acute	  
inflammation,	   it	   is	  COX-­‐2	  expression	  that	   is	  predominantly	  upregulated	   in	  a	  transient	  
manner	   in	   basal	   epidermal	   keratinocytes	   as	   well	   as	   fibroblasts,	   macrophages,	   and	  
endothelial	   cells	   at	   the	   wound	   site,	   independent	   of	   whether	   wounding	   has	   been	  
superficial,	   incisional,	   or	   excisional	   in	   mouse,	   human	   and	   canine	   skin	   (Scholz	   et	   al.	  
1995,	   Abd-­‐El-­‐Aleem	   et	   al.	   2001,	   Fugatami	   et	   al.	   2002,	   Müller-­‐Decker	   et	   al.	   2002,	  
Blomme	  et	  al.	  2003,	  Kämper	  et	  al.	  2003,	  Schäfer	  and	  Werner	  2008,	  Hamamoto	  et	  al.	  
2009).	  	  
1.7.	  COX	  in	  cancer	  
One	   of	   the	   more	   intensively	   studied	   fields	   of	   COX	   function	   is	   that	   relating	   to	  
carcinogenesis	   (Fig.	   1.2.).	   A	   large	   body	   of	   evidence	   suggests	   that	   COX-­‐derived	   PG	  
contribute	   to	   tumorigenesis	   in	   humans	   (Greenhough	   et	   al.	   2009).	   Colorectal	   cancer	  
represents	   the	   first	   cancer	   where	   the	   role	   of	   COX-­‐2	   and	   PG	   was	   suspected	   after	  
epidemiological	   studies	   had	   revealed	   that	   the	   regular	   intake	   of	   low	   doses	   of	   aspirin	  
reduced	   the	   risk	   of	   developing	   this	   neoplasia	   (Thun	   and	   Heath	   1995,	   Cuzick	   et	   al.	  
2009).	  This	  initial	  indication	  of	  a	  role	  for	  COX-­‐2	  in	  colorectal	  cancer	  was	  then	  followed	  
by	   a	   series	   of	   studies	   demonstrating	   that	   COX-­‐2	   is	   overexpressed	   in	   these	   cancers	  
(Eberhart	  et	   al.	  1994,	   Kargman	  et	   al.	   1995,	   Sano	  et	   al.	   1995).	   Immunohistochemical	  
studies	  revealed	  that	  COX-­‐2	  was	  present	  in	  colonic	  epithelial	  neoplastic	  cells	  (Sano	  et	  
al.	   1995).	   Moreover,	   the	   levels	   of	   PGE2	   are	   elevated	   in	   cancerous	   colonic	   tissues	  
compared	  to	  normal	  tissues	  (Rigas	  et	  al.	  1993,	  Pugh	  and	  Thomas	  1994).	  
PGE2	   exerts	   its	   actions	   via	   binding	   to	   4	   specific	   cell	   surface	   G	   protein-­‐coupled	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receptors	   (designated	   EP1	   to	   EP4)	   and	   can	   influence	   many	   cellular	   events	   that	  
contribute	   to	   cancer	   development.	   Characterization	   of	   the	   precise	   role	   of	   each	   EP	  
subtype	   in	   carcinogenesis	   is	   another	   field	   of	   investigation.	   Different	   EP	   receptors	  
appear	   to	   be	   involved	   at	   various	   stages	   of	   carcinogenesis	   and	   in	   different	   types	   of	  
cancer	   (Fulton	   et	   al.	   2006,	   Wang	   and	   DuBois	   2006,	   Rundhaug	   et	   al.	   2011).	   For	  
example,	  experimental	  evidence	  indicates	  that	  EP1	  and	  EP4	  play	  a	  role	  in	  colon	  cancer,	  
whereas	   EP2	   is	   involved	   in	  mouse	   skin	   tumor	  development	   (Sung	  et	   al.	   2005,	  Wang	  
and	   DuBois	   2006,	   Brouxhon	   et	   al.	   2007).	   The	   presence	   of	   EP1	   has	   also	   been	  
demonstrated	  in	  human	  breast	  cancer	  cells,	  and	  EP4	  antagonists	  have	  been	  shown	  to	  
inhibit	  breast	  cancer	  metastasis	  (Ma	  et	  al.	  2006,	  Thorat	  et	  al.	  2008).	  Via	  its	  receptors,	  
PGE2	  is	  able	  to	  promote	  cell	  proliferation	  and	  survival	  (through	  different	  mechanisms,	  
including	   suppression	   of	   apoptosis),	   promote	   tumor	   angiogenesis	   (through	   the	  
production	  of	  proangiogenic	  growth	  factors	  such	  as	  vascular	  endothelial	  growth	  factor	  
and	  basic	  fibroblast	  growth	  factor),	  increase	  cell	  invasion	  and	  metastasis,	  and	  suppress	  
the	   immune	   response	   in	   order	   for	   the	   tumor	   cells	   to	   escape	   immunosurveillance	  
(Fig.1.2)	   (Tsuji	   et	   al.	   1998,	   Harris	   et	   al.	   2002,	   Gupta	   et	   al.	   2007,	   Greenhough	   et	   al.	  
2009).	  	  
In	   addition	   to	   colorectal	   cancer,	   numerous	   studies	   document	   the	   aberrant	  
overexpression	   of	   COX-­‐2	   as	   a	   consistent	   feature	   of	   a	   significant	   number	   of	   human	  
premalignant	  and	  malignant	  tumors	  of	  epithelial	  and	  non-­‐epithelial	  origin	  such	  as	  such	  
as	   breast,	   pulmonary,	   head	   and	   neck,	   pancreatic,	   prostatic,	   and	   gastric	   cancers	  
including	   various	   tumor	   entities	   of	   the	   skin,	   while	   in	   general,	   COX-­‐1	   expression	   is	  
unaltered	  as	  compared	  to	  healthy	  tissue	  (Hida	  et	  al.	  1998,	  Gupta	  et	  al.	  2000,	  Soslow	  et	  
al.	  2000,	  Half	  et	  al.	  2002,	  Gallo	  et	  al.	  2002,	  Denkert	  et	  al.	  2003,	  Forones	  et	  al.	  2008,	  
Hermanova	   et	   al.	   2009,	   Müller-­‐Decker	   2011).	   Regarding	   the	   skin,	   COX-­‐2	  
overexpression	  has	  been	  detected	  in	  human	  Merkell	  cell	  carcinoma,	  melanoma,	  basal	  
cell	  carcinomas	  and	  and	  has	  been	  found	  strongly	  overexpressed	  in	  a	  high	  percentage	  
of	  squamous	  cell	  carcinomas	   (SCC)	  and	   in	  cutaneous	  epitheliotropic	  T	  cell	   lymphoma	  
(CETL)	  (revised	  in	  Müller-­‐Decker	  2011,	  Kopp	  et	  al.	  2010).	  In	  most	  of	  these	  neoplasias,	  a	  
direct	   relationship	   between	   COX-­‐2	   overexpression	   and	   neoplasia	   malignancy	   and	  
progression	  has	  been	  postulated.	  Most	  importantly,	  COX-­‐2	  overexpression	  is	  observed	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in	  precursor	  lesions	  of	  SCC	  such	  as	  actinic	  keratosis	  (AK)	  and	  Bowens’s	  disease	  clearly	  
indicating	  that	  COX-­‐2	  upregulation	  is	  an	  early	  premalignant	  event	  in	  the	  development	  
of	  SCC	  (Müller-­‐Decker	  et	  al.	  1999,	  An	  et	  al.	  2002,	  Akita	  et	  al.	  2004,	  O’Grady	  et	  al.	  2004,	  
Nijsten	   et	   al.	   2004).	   UV	   B-­‐induced	   COX-­‐2	   seems	   to	   be	   causally	   related	   to	   the	  
development	   of	   AK,	   since	   UV	   B	   exposure	   leads	   to	   a	   strong	   upregulation	   of	   COX-­‐2	  
expression	  in	  a	  significant	  portion	  of	  these	  benign	  tumors	  and	  AK	  are	  primarily	  found	  
on	  chronically	  sun-­‐exposed	  skin	  sites	  (Black	  et	  al.	  1978,	  Buckmann	  et	  al.	  1998,	  Athar	  et	  
al.	  2001,	  Chun	  et	  al.	  2007,	  Fischer	  et	  al.	  2007,	  Müller-­‐Decker	  2011).	  
Regarding	   canine	   cancers,	   COX-­‐2	   elevated	   expression	   has	   been	   detected	   in	   several	  
neoplasias	  (revised	  in	  Doré	  2011).	  COX-­‐2	  is	  overexpressed	  with	  different	  intensities	  in	  
several	   canine	   epitethelial	   neoplasias,	   including	   mammary	   tumors,	   prostatic	  
carcinomas,	   transitional	   cell	   carcinomas,	   intestinal	   adenocarcinomas,	   nasal	   tumours,	  
renal	   cell	   carcinomas,	  ovarian	   carcinomas	  and	  SCC.	  Other	  neoplasias	   in	  which	  COX-­‐2	  
overexpression	   has	   been	   detected	   are	   oral	   and	   cutaneous	   melanomas,	  
osteorsarcomas	   and	   meningiomas	   (Mohammed	   et	   al.	   2004,	   Mullins	   et	   al.	   2004,	  
Rossmeisl	  et	  al.	  2009,	  Martínez	  et	  al.	  2011).	  As	  in	  humans,	  COX-­‐2	  expression	  in	  SCC	  has	  
also	  been	  shown	  to	  be	  present	   in	  a	   large	  proportion	   (56–100%)	  of	  canine	  neoplastic	  
growths	  originating	  from	  various	  locations	  (oral,	  cutaneous,	  or	  digital	  SCCs)	  (Pestili	  de	  
Almeida	   et	   al.	   2001,	  Mohammed	   et	   al.	   2004).	   One	   clinical	   study	   has	   evaluated	   the	  
effect	  of	  a	  nonspecific	  COX-­‐2	  inhibitor	  (piroxicam)	  with	  a	  reported	  remission	  (including	  
complete	  or	  partial)	  rate	  of	  18%	  and	  stable	  disease	  in	  29%	  of	  dogs	  suffering	  from	  oral	  
SCCs	   (Schmidt	   et	   al.	   2001).	   A	   higher	   remission	   rate	   (56%)	  was	   obtained	  when	   dogs	  
suffering	   from	   oral	   SCCs	   were	   treated	   with	   piroxicam	   in	   combination	   with	   cisplatin	  
(Boria	   et	   al.	   2004).	   Oral	   fibrosarcomas,	   lymphomas,	   hemangiosarcomas,	   histioctytic	  
sarcomas,	  and	  mast	  cell	  tumors	  of	  dogs	  do	  not	  express	  COX-­‐2	  (Mohammed	  et	  al.	  2004,	  
Heller	  et	  al.	  2005).	  Definitive	  intraneoplastic	  COX-­‐2	  expression	  was	  found	  only	  in	  3.5%	  
of	   canine	   uveal	  melanocytic	   neoplasms,	   but	   the	   presence	   of	   COX-­‐2	   in	  many	   normal	  
ocular	  structures	  made	  the	  exact	  determination	  of	  COX-­‐2	  positivity	  in	  neoplastic	  cells	  
difficult	  (Paglia	  et	  al.	  2009).	  	  
Studies	  of	  COX-­‐2	  expression	  in	  feline	  neoplasias	  are	  less	  numerous	  and	  have	  included	  
mostly	  epithelial	   tumours	   (revised	   in	  Doré	  2011).	  Mammary	  carcinoma,	  oral	  SCC	  and	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transitional	   cell	   carcinoma	   showed	   different	   degrees	   of	   positivity	   to	   COX-­‐2	  
immunostaining.	   On	   the	   contrary,	   other	   carcinomas	   including	   cutaneous	   SCC,	  
pulmonary	   and	   intestinal	   adenocarcinomas,	   lymphomas	   and	   vaccine-­‐associated	  sarcomas	  were	  reported	  COX-­‐2	  negative	  on	  IHC	  (Beam	  et	  al.	  2003).	  A	  study	  of	  8	  feline	  
pancreatic	  adenocarcinomas	  reported	  that	  only	  2	  were	  COX-­‐2	  positive,	  with	  less	  than	  
10%	  of	  the	  cells	  expressing	  an	  intense	  staining	  (Newman	  and	  Mrkonjich	  2006).	  
Equine	  SCC	  positivity	   to	  COX-­‐2	   IHC	  has	   reported	  conflicting	   results,	   from	  negative	   to	  
strong	   staining	   neoplasias	   depending	   on	   the	   study	   (revised	   in	   Doré	   2011).	  Only	   one	  
study	  has	  examined	  COX-­‐2	  expression	  in	  other	  equine	  tumors	  finding	  that	  melanomas	  
were	  positive	  for	  COX-­‐2	  (28%	  with	  a	  moderate	  to	  strong	  staining)	  and	  that	  COX-­‐2	  was	  
weakly	  expressed	  in	  very	  few	  equine	  sarcoids	  (14%)	  (Thamm	  et	  al.	  2008).	  
	   	  
	   26	  
References:	  
Abd-­‐El-­‐Aleem	  SA,	  Ferguson	  MWJ,	  Appleton	  I,	  Bhowmick	  A,	  McCollum	  CN	  et	  al.	  (2001).	  
Expression	   of	   cyclooxygenase	   isoforms	   in	   normal	   human	   skin	   and	   chronic	   venous	  
ulcers.	  The	  Journal	  of	  Pathology,	  195:	  616–23.	  
Akita	   Y,	   Kozaki	   K,	   Nakagawa	   A,	   Saito	   T,	   Ito	   S	   et	   al.	   (2004).	   Cyclooxygenase-­‐2	   is	   a	  
possible	  target	  of	   treatment	  approach	   in	  conjunction	  with	  photodynamic	  therapy	  for	  
various	  disorders	  in	  skin	  and	  oral	  cavity.	  British	  Journal	  of	  Dermatology,	  151:	  472–80.	  
Akunda	   JK,	  Lao	  H,	  Lee	  CA,	  Sessoms	  AR,	  Slade	  RM	  et	  al.	   (2004).	  Genetic	  deficiency	  or	  
pharmacological	   inhibition	   of	   cyclooxygenase	   -­‐1	   or	   -­‐2	   induces	   mouse	   keratinocyte	  
differentiation	  in	  vitro	  and	  in	  vivo.	  The	  FASEB	  Journal,	  18:	  185-­‐7.	  
Akunda	  JK,	  Chun	  KS,	  Sessoms	  AR,	  Lao	  HC,	  Fischer	  SM	  et	  al.	   (2007).	  Cyclooxygenase-­‐2	  
deficiency	   increases	   epidermal	   apoptosis	   and	   impairs	   recovery	   following	   acute	   UVB	  
exposure.	  Molecular	  Carcinogenesis,	  46:	  354–62.	  
Albanesi	   C.	   Keratinocytes	   in	   allergic	   skin	   diseases	   (2010).	   Current	   Opinion	   in	   Allergy	  
and	  Clinical	  Immunology,	  10:	  452-­‐6.	  
Alestas	  T,	  Ganceviciene	  R,	   Fimmel	   S,	  Müller-­‐Decker	  K,	   Zouboulis	  CC	   (2006).	   Enzymes	  
involved	   in	   the	   biosynthesis	   of	   leukotriene	   B4	   and	   prostaglandin	   E2	   are	   active	   in	  
sebaceous	  glands.	  Journal	  of	  Molecular	  Medicine,	  84:	  75–87.	  
An	  KP,	  Athar	  M,	  Tang	  X,	  Katiyar	  SK,	  Russo	  J	  et	  al.	  (2002).	  Cyclooxygenase-­‐2	  expression	  
in	   murine	   and	   human	   nonmelanoma	   skin	   cancers:	   implications	   for	   therapeutic	  
approaches.	  Photochemistry	  and	  Photobiology,	  76:	  73–80.	  
Ansari	   KM,	   Rundhaug	   JE,	   Fischer	   SM	   (2008).	   Multiple	   signaling	   pathways	   are	  
responsable	  for	  prostaglandin	  E2-­‐induced	  murine	  keratinocyte	  proliferation.	  Molecular	  
Cancer	  Research,	  6:	  1003-­‐6.	  
Athar	  M,	  An	  KP,	  Morel	  KD,	  Kim	  AL,	  Aszterbaum	  M,	  et	  al.	   (2001).	  Ultraviolet	  B	   (UVB)-­‐
induced	  COX-­‐2	  expression	  in	  murine	  skin:	  an	  immunohistochemical	  study.	  Biochemical	  
and	  Biophysical	  Research	  Communication,	  280:	  1042–7.	  
Barker	  JNWN,	  Mitra	  RS,	  Griffiths	  CEM,	  Dixit	  VM,	  Nickoloff	  BJ	  (1991).	  Keratinocytes	  as	  
initiators	  of	  inflammation.	  The	  Lancet,	  337:	  211-­‐214.	  
Beam	   SL,	   Rassnick	   KM,	  Moore	   AS,	  McDonough	   SP	   (2003).	   An	   immunohistochemical	  
study	   of	   cyclooxygenase-­‐2	   expression	   in	   various	   feline	   neoplasms.	   Veterinary	  
Patholology,	  40:	  496–500.	  
Black	  AK,	  Greaves	  MW,	  Hensby	  CN,	  Pummer	  NA	   (1978).	   Increased	  prostaglandins	  E2	  
and	  F2	  in	  human	  skin	  at	  6	  and	  24	  h	  after	  ultraviolet	  B	  irradiation	  (290–320	  nm).	  British	  
Journal	  of	  Clinical	  Pharmacology,	  5:	  431–6.	  
Black	  AK,	  Greaves	  MW,	  Hensby	  CN	  (1980).	  The	  anti-­‐inflammatory	  and	  pharmacological	  
	   27	  
effects	   of	   topically	   applied	   flurbiprofen	   on	   human	   skin	   24	   hours	   after	   ultraviolet	   B	  
irradiation.	  Prostaglandins	  and	  Medicine,	  5:	  405–413.	  
Blackwell	  KA,	  Raisz	  LG,	  Pilbeam	  CC	  (2010).	  Prostaglandins	  in	  bone:	  bad	  cop,	  good	  cop?	  
Trends	  in	  Endocrinoogy	  and	  Metabolism,	  21:	  294–300.	  
Blomme	   EA,	   Chinn	   KS,	   Hardy	   MM,	   Casler	   JJ,	   Kim	   SH	   et	   al.	   (2003).	   Selective	  
cyclooxygenase-­‐2	   inhibition	   does	   not	   affect	   the	   healing	   of	   cutaneous	   full-­‐thickness	  
incisional	  wounds	  in	  SKH-­‐1	  mice.	  Britisch	  Journal	  of	  Dermatology,	  148:	  211–23.	  
Bonventre	   JV,	   Huang	   Z,	   Taheri	   MR,	   O’Leahy	   E	   et	   al.	   (1997).	   Reduced	   fertility	   and	  
postischaemic	  brain	  injury	  in	  mice	  deficient	  in	  cytosolic	  phospholipase	  A2.	  Nature,	  390:	  
622–5.	  
Boria	  PA,	  Murry	  DJ,	  Bennett	  PF,	  Glickman	  NW,	  Snyder	  PW	  et	  al.	  (2004).	  Evaluation	  of	  
cisplatin	  combined	  with	  piroxicam	  for	  the	  treatment	  of	  oral	  malignant	  melanoma	  and	  
oral	   squamous	   cell	   carcinoma	   in	   dogs.	   Journal	   of	   the	   American	   Veterinary	   Medical	  	  
Association,	  224:	  388–94.	  
Brouxhon	   S,	   Konger	   RL,	   VanBuskirk	   J,	   Sheu	   T,	   Ryan	   J	   et	   al.	   (2007).	   Deletion	   of	  
prostaglandin	  E2	  EP2	  receptor	  protects	  against	  ultraviolet	  induced	  carcinogenesis,	  but	  
increases	  tumor	  aggressiveness.	  Journal	  of	  Investigative	  Dermatolology,	  127:	  439–46.	  	  
Buckman	  SY,	  Gresham	  A,	  Hale	  P,	  Hruza	  G,	  Anast	   J	  et	   al.	   (1998).	   COX-­‐2	  expression	   is	  
induced	  by	  UVB	  exposure	   in	  human	  skin:	   Implica-­‐	   	  tions	   for	   the	  development	  of	   skin	  
cancer.	  Carcinogenesis,	  19:	  723–9.	  	  
Candi	  E,	  Schmidt	  R,	  Melino	  G	  (2005).	  The	  cornified	  envelope:	  a	  model	  of	  cell	  death	  in	  
the	  skin.	  Nature,	  6:	  328–40.	  
Cha	  YI,	  DuBois	  RN	  (2007).	  NSAIDs	  and	  cancer	  prevention:	  targets	  downstream	  of	  COX-­‐
2.	  Annual	  Reviews	  of	  Medicine,	  58:	  239–52.	  
Chen	   X,	   Gresham	   A,	   Morrison	   A,	   Pentland	   A	   (1996).	   Oxidative	   stress	   mediates	  
synthesis	  of	  cytosolic	  phospholipase	  A2	  after	  UVB	   injury.	  Biochimica	  Biophysica	  Acta,	  
1299:	  22–33.	  	  
Chouaib	   S,	  Welte	   K,	  Mertelsmann	   R,	   Dupont	   B	   (1985).	   Prostaglandin	   E2	   acts	   at	   two	  
distinct	  pathways	  of	  T	  lymphocyte	  activation:	  inhibition	  of	  interleukin	  2	  production	  and	  
down-­‐regulation	   of	   transferrin	   receptor	   expression.	   Journal	   of	   Immunology,	   135:	  
1172–9.	  
Chu	  DH,	   Haake	   AR,	   Holbrook	   K,	   Loomis	   CA.	   The	   estructure	   and	   development	   of	   the	  
skin.	   In	   Freedberg	   IM,	   Eisen	  AZ,	  Wolff	   K,	  Austen	  KF,	  Goldsmith	   LA	   and	  Katz	   SI	   (Eds).	  
Fitzpatrick’s	  Dermatology	  in	  General	  Medicine	  (6th	  Ed).	  McGraw-­‐Hill,	  New	  York:	  58-­‐88.	  
Chun	   KS,	   Akunda	   JK,	   Langenbach	   R	   (2007).	   Cyclooxygenase-­‐2	   inhibits	   UVB-­‐induced	  
apoptosis	   in	   mouse	   skin	   by	   activating	   the	   PGE2	   receptors	   EP2	   and	   EP4.	   Cancer	  
Research,	  67:	  2015–20.	  
	   28	  
Cuzick	   J,	  Otto	   F,	   Baron	   JA,	   Brown	  PH,	   Burn	   J	  et	   al.	   (2009).	   Aspirin	   and	  non-­‐steroidal	  
anti-­‐inflammatory	  drugs	  for	  cancer	  prevention:	  an	  international	  consensus	  statement.	  
Lancet	  10:	  501–7,	  2009.	  
Dazard	   JE,	   Gal	   H,	   Amariglio	   N,	   Rechavi	   G,	   Domany	   E,	   Givol	   D	   (2003).	   Genome-­‐wide	  
comparison	   of	   human	   keratinocyte	   and	   squamous	   carcinoma	   responses	   to	   UVB	  
irradiation:	  implication	  for	  skin	  and	  epithelial	  cancer.	  Oncogene,	  22:	  2993–3006.	  
Denkert	  C,	  Winzer	  KJ,	  Muller	  BM,	  Weichert	  W,	  Pest	  S	  et	  al.	  (2003).	  Elevated	  expression	  
of	   cyclooxygensase-­‐2	   is	   a	   negative	   prognostic	   factor	   for	   disease	   free	   survival	   and	  
overall	  survival	  in	  patients	  with	  breast	  carcinoma.	  Cancer	  97:2978–87.	  
Doré	  M	  (2011).	  Cyclooxygenase-­‐2	  expression	  in	  animal	  cancers.	  Veterinary	  Pathology,	  
48:	  254-­‐65.	  
DuBois	   RN,	   Radhika	  A,	   Reddy	  BS,	  et	   al.	   (1996).	   Increased	   cyclooxygenase–2	   levels	   in	  
carcinogen-­‐induced	  rat	  	  colonic	  tumors.	  Gastroenterology,	  110:	  1259–62.	  	  
Eberhart	   CE,	   Coffey	   RJ,	   Radhika	   A,	   et	   al.	   (1994)	   Up-­‐regulation	   of	   cyclooxygenase-­‐2	  
expression	   in	   human	   	  colorectal	   adenomas	   and	   adenocarcinomas.	   Gastroenterology,	  
107:	  1183–7.	  	  
Elias	   PM,	   Brown	   B,	   Ziboh	   VA	   (1980).	   The	   permeability	   barrier	   in	   essential	   fatty	   acid	  
deficiency:	   evidence	   for	   a	   	  direct	   role	   for	   linoleic	   acid	   in	   barrier	   function.	   Journal	   of	  
Investigative	  Dermatology,	  74:	  230–3.	  	  
Evans	   CB,	   Pillai	   S,	   Goldyne	   ME	   (1993)	   Endogenous	   prostaglandin	   E2	   modulates	  
calcium-­‐induced	   differentiation	   	  in	   human	   skin	   keratinocytes.	   Prostaglandins	  
Leukotriens	  and	  Essential	  Fatty	  Acids,	  49:777–81.	  
Fischer	  SM,	  Lo	  HH,	  Gordon	  G,	  et	  al.	   (1999).	  Chemopreventive	  activity	  of	   celecoxib,	  a	  
specific	  cyclooxygenase-­‐2	  inhibitor,	  and	  indomethacin	  against	  ultraviolet	  light-­‐induced	  
skin	  carcinogenesis.	  Molecular	  Carcinogenesis,	  25:	  231–	  40.	  	  
Fischer	   SM,	   Pavone	   AP,	   Mikulec	   C,	   Langenbach	   R,	   Rundhaug	   JE	   (2007).	  
Cyclooxygenase-­‐2	   expression	   is	   critical	   for	   UV-­‐induced	   murine	   skin	   carcinogenesis.	  
Molecular	  Carcinogenesis,	  46:	  363–71.	  
Feingold	   KR	   (2007).	   The	   role	   of	   epidermal	   lipids	   in	   cutaneous	   permeability	   barrier	  
homeostasis.	  Journal	  of	  Lipid	  Research,	  48:	  2531–46.	  
Forones	   NM,	   Kawamura	   KY,	   Segreto	   HR,	   Neto	   RA,	   de	   Azevedo	   GR	   et	   al.	   (2008).	  
Expression	   of	   COX-­‐2	   in	   stomach	   carcinogenesis.	   Journal	   of	   Gastrointestinal	   Cancer,	  
39:4–10.	  
Fulton	  AM,	  Ma	  X,	   Kundu	  N	   (2006).	   Targeting	  prostaglandin	   E	   EP	   receptors	   to	   inhibit	  
metastasis.	  Cancer	  Research,	  66:	  9794–7.	  
Fürstenberger	  G,	  Marks	  F	  (1978).	  Indomethacin	  inhibition	  of	  cell	  proliferation	  induced	  
by	   the	  phorbolester	  TPA	   is	   reversed	  by	  prostaglandin	  E2	   in	  mouse	  epidermis	   in	  vivo.	  
	   29	  
Biochemical	  and	  	  Biophysical	  Research	  Communications,	  84:	  	  1103–11.	  	  
Fürstenberger	  G,	  Marks	  F	  (1980).	  Early	  prostaglandin	  E	  synthesis	  is	  an	  obligatory	  event	  
in	   the	   induction	  of	   cell	   proliferation	   in	  mouse	  epidermis	   in	   vivo	  by	   the	  phorbolester	  
TPA.	  Biochemical	  and	  Biophysical	  Research	  Communication,	  92:	  749–56.	  
Futagami	   A,	   Ishizaki	   M,	   Fukuda	   Y,	   Kawana	   S,	   Yamanaka	   N	   (2002).	   Wound	   healing	  
involves	  induction	  of	  cyclooxygenase-­‐2	  expression	  in	  rat	  skin.	  Laboratory	  Investigation,	  
82:	  1503–13.	  
Gallo	   O,	   Masini	   E,	   Bianchi	   B,	   Bruschini	   L,	   Paglierani	   M	   et	   al.	   (2002).	   Prognostic	  
significance	   of	   cyclooxygenase-­‐2	   pathway	   and	   angiogenesis	   in	   head	   and	   neck	  
squamous	  cell	  carcinoma.	  Human	  Pathology,	  33:	  708–14.	  
Gledhill	   K,	   Rhodes	   LE,	   Brownrigg	   M,	   Haylett	   AK,	   Masoodi	   M	   et	   al.	   (2010).	  
Prostaglandin-­‐E2	   is	  produced	  by	  adult	  human	  epidermal	  melanocytes	   in	   response	   to	  
UVB	   in	  a	  melanogenesis-­‐independent	  manner.	  Pigment	  and	  Melanoma	  Research,	  23:	  
394–403.	  
Goldyne	   ME,	   Evans	   CB	   (1994).	   12-­‐OTetradecanoylphorbol-­‐13-­‐acetate	   and	   the	  
induction	   of	   prostaglandin	   E2	   generation	   by	   human	   keratinocytes:	   A	   reevaluation.	  
Carcinogenesis,	  15:	  141–3.	  
Goldyne	  ME	   (2000).	   Cyclooxygenase	   isoforms	   in	  human	   skin.	   Prostaglandins	  &	  other	  
Lipid	  Mediators,	  63:	  15-­‐23.	  
Greenhough	  A,	  Smartt	  HJM,	  Moore	  AE,	  Roberts	  HR,	  Williams	  AC	  et	  al.	  (2009)	  The	  COX-­‐
2/PGE2	  pathway:	  key	   roles	   in	   the	  hallmarks	  of	   cancer	  and	  adaptation	   to	   the	   tumour	  
microenvironment.	  Carcinogenesis,	  30:	  377-­‐86.	  
Gresham	  A,	  Masferrer	  J,	  Chen	  X,	  Leal-­‐Khouri	  S,	  Pentland	  AP	  (1996).	  Increased	  synthesis	  
of	   high-­‐molecular	   weight	   cPLA2	   mediates	   early	   UV-­‐induced	   PGE2	   in	   human	   skin.	  
American	  Journal	  of	  Physiology,	  270:	  C1037–50.	  
Gupta	  GP,	  Nguyen	  DX,	  Chiang	  AC,	  Bos	  PD,	  Kim	  JY	  et	  al.	   (2007).	  Mediators	  of	  vascular	  
remodelling	  co-­‐opted	  for	  sequential	  steps	  in	  lung	  metastasis.	  Nature,	  446:	  765–70.	  
Half	  E,	  Tang	  XM,	  Gwyn	  K,	  Sahin	  A,	  Wathen	  K	   (2002).	  Cyclooxygenase-­‐2	  expression	   in	  
human	   breast	   cancers	   and	   adjacent	   ductal	   carcinoma	   in	   situ.	   Cancer	   Research,	   62:	  
1676–81.	  
Hamamoto	   T,	   Yabuki	   A,	   Yamato	   O,	   Fujiki	   M,	   Misumi	   K	   et	   al.	   (2009).	  
Immunohistochemical	  analysis	  of	  cyclooxygenase-­‐2	  induction	  during	  wound	  healing	  in	  
dog	  skin.	  Research	  in	  Veterinary	  Science,	  87:	  349-­‐54.	  
Hara	   S,	   Kamei	   D,	   Sasaki	   Y,	   Tanemoto	   A,	   Nakatani	   Y	   et	   al.	   (2010).	   Prostaglandin	   E	  
synthases:	   understanding	   their	   pathophysiological	   roles	   through	   mouse	   genetics.	  
Biochimie,	  92:	  651-­‐9.	  
Harris	  RE,	  Chlebowski	  RT,	  Jackson	  RD,	  Frid	  DJ,	  Ascenseo	  JL	  et	  al.	  (2003).	  Breast	  cancer	  
	   30	  
and	   nonsteroidal	   anti-­‐inflammatory	   drugs:	   prospective	   results	   from	   the	   Women’s	  
Health	  Initiative.	  Cancer	  Research,	  63:	  6096–101.	  
Heller	   DA,	   Clifford	   CA,	   Goldschmidt	   MH,	   Holt	   DE,	   Manfredi	   MJ	   et	   al.	   (2005).	  
Assessment	   of	   cyclooxygenase-­‐2	   expression	   in	   canine	   hemangiosarcoma,	   histiocytic	  
sarcoma,	  and	  mast	  cell	  tumor.	  Veterinary	  Pathology,	  	  42:	  350–3.	  
Hermanova	  M,	  Karasek	  P,	  Nenutil	  R,	  Kyr	  M,	  Tomasek	  J	  et	  al.	  (2009).	  Clinicopathological	  
correlations	  of	  cyclooxygenase-­‐2,	  MDM2,	  and	  p53	  expressions	  in	  surgically	  resectable	  
pancreatic	  invasive	  ductal	  adenocarcinoma.	  Pancreas,	  38:	  565–71.	  
Herschman	   HR,	   Reddy	   ST,	   Xie	   W	   (1997).	   Function	   and	   regulation	   of	   prostaglandin	  
synthase-­‐2.	  Advances	  in	  Experimental	  Medicine	  and	  Biology,	  62:	  61–	  6.	  	  
Hida	  T,	  Yatabe	  Y,	  Achiwa	  H,	  Muramatsu	  H,	  Kozaki	  K	  et	  al.	  (1998).	  Increased	  expression	  
of	   cyclooxygenase	   2	   occurs	   frequently	   in	   human	   lung	   cancers,	   specifically	   in	  
adenocarcinomas.	  Cancer	  Research,	  58:	  3761–4.	  
Hirabashi	  T,	  Murayama	  T,	  Shimizu	  T	   (2004).	  Regulatory	  mechanism	  and	  physiological	  
role	  of	  cytosolic	  phospholipase	  A2.	  Biological	  and	  Pharmacological	  Bulletin,	  27:	  1168–
73.	  
Hitchcock	  M	   (1978).	  Effect	  of	   inhibitors	  of	  prostaglandin	   synthesis	  and	  prostaglandin	  
E2	   and	   F2α	   on	   the	   immunologic	   release	   of	  mediators	   of	   inflammation	   from	   actively	  
sensitized	   guinea-­‐pig	   lung.	   Journal	   of	   Pharmacology	   and	   Experimental	   Therapeutics,	  
207:	  630–40.	  
Hoff	   T,	   DeWitt	   D,	   Kaever	   V,	   Resch	   K,	   Goppelt-­‐Struebe	   M	   (1993).	   Differentation-­‐
associated	  expression	  of	  prostaglandin	  G/H	  synthase	  in	  monocytic	  cells.	  FEBS	  Letters,	  
320:38–42.	  
Hoshino	  T,	  Tsutsumi	  S,	  Tomisato	  W,	  Hwang	  HJ,	  Tsuchiya	  T	  et	  al.	  (2003).	  Prostaglandin	  
E2	  protects	  gastric	  mucosal	  cells	   from	  apoptosis	  via	  EP2	  and	  EP4	  receptor	  activation.	  
Journal	  of	  Biological	  Chemistry,	  278:	  12752–8.	  
Houchen	  CW,	  Sturmoski	  MA,	  Anant	  S,	  Breyer	  RM,	  Stenson	  WF	  (2003).	  Prosurvival	  and	  
antiapoptotic	   effects	   of	   PGE2	   in	   radiation	   injury	   are	   mediated	   by	   EP2	   receptor	   in	  
intestine.	  American	  Journal	  of	  Gastrointestinal	  and	  Liver	  Physiology,	  284:	  G490–8.	  
Hruza	   LL,	   Pentland	   AP	   (1993).	   Mechanisms	   of	   UV	   induced	   inflammation.	   Journal	   of	  
Investigative	  Dermatology,	  100:	  35S–41S.	  
Hume	  R,	  Kelly	  R,	  Cossar	  D,	  Giles	  M,	  Hallas	  A	  et	  al.	  (1991).	  	  Self-­‐differentation	  of	  human	  
fetal	  lung	  organ	  culture:	  the	  role	  of	  prostaglandins	  PGE2	  and	  PF2	  alpha.	  Experimental	  
Cell	  Research,	  194:	  111–117.	  
Ichikawa	   A,	   Sugimoto	   Y,	   Negishi	  M	   (1996).	  Molecular	   aspects	   of	   the	   structures	   and	  
functions	   of	   the	   prostaglandin	   E	   receptors.	   Journal	   of	   Lipids	   Mediators	   and	   Cell	  
Signaling,	  14:	  83–7.	  	  
	   31	  
Jacoby	  RF,	  Marshall	  DJ,	  Newton	  MA,	  et	  al.	   (1996).	  Chemoprevention	  of	   spontaneous	  
intestinal	   adenomas	   in	   the	   	  Apc	   Min	   mouse	   model	   by	   the	   nonsteroidal	  
antiinflammatory	  drug	  piroxicam.	  Cancer	  Research,	  56:	  710–4.	  	  
Jin	  J,	  Mao	  GF,	  Ashby	  B	  (1997).	  Constitutive	  activity	  of	  human	  prostaglandin	  E	  receptor	  
EP3	  isoforms.	  Bristish	  Journal	  of	  Pharmacology,	  121:	  317–23.	  	  
Jonsson	   C-­‐E,	   Anggard	   E	   (1972).	   Biosynthesis	   and	  metabolism	   of	   prostaglandin	   E2	   in	  
human	  skin.	  Scandinavian	  Journal	  of	  Clinical	  and	  Laboratory	  Investigation,	  29:	  289–96.	  	  
Kagoura	   M,	   Toyoda	   M,	   Matsui	   C,	   Morohashi	   M	   (2001).	   Immunohistochemical	  
expression	   of	   cyclooxygenase-­‐2	   in	   skin	   cancers.	   Journal	   of	   Cutaneous	   Pathology,	   28:	  
298–302.	  
Kämpfer	  H,	  Bräutigam	  L,	  Geisslinger	  G,	  Pfeilschifter	  J,	  Frank	  S	  (2003).	  Cyclooxygenase-­‐
1-­‐coupled	   prostaglandin	   biosynthesis	   constitutes	   an	   essential	   prerequisite	   for	   skin	  
repair.	  Journal	  of	  Investigative	  Dermatology,	  12:	  880–90.	  
Kanekura	   T,	   Laulederkind	   SJ,	   Kirtikara	   K,	   et	   al.	   (1998)	   Cholecalciferol	   induces	  
prostaglandin	  E2	  biosynthesis	  and	   	  transglutaminase	  activity	   in	  human	  keratinocytes.	  
Journal	  of	  Investigative	  Dermatology,	  111:	  634–9.	  	  
Kargman	   SL,	  O’Neill	   GP,	   Vickers	   PJ,	   Evans	   JF,	  Mancini	   JA	  et	   al.	   (1995).	   Expression	   of	  
prostaglandin	  G/H	  synthase-­‐1	  and	  -­‐2	  protein	  in	  human	  colon	  cancer.	  Cancer	  Research,	  
55:	  2556–9.	  
Kawamori	  T,	  Rao	  CV,	  Seibert	  K,	  et	  al.	  (1998).	  Chemopreventive	  activity	  of	  celecoxib,	  a	  
specific	  cyclooxygenase-­‐2	  inhibitor,	  against	  colon	  carcinogenesis.	  Cancer	  Research,	  58:	  
409–12.	  	  
Khan	   KNM,	   Venturini	   CM,	   Bunch	   RT,	   Brassard	   JA,	   Koki	   AT	  et	   al.	   (1998).	   Interspecies	  
differences	   in	   renal	   localization	   of	   cyclooxygenase	   isoforms:	   implications	   in	  
nonsteroidal	   antiinflammatorydrug-­‐related	   nephrotoxicity.	   Toxicologic	   Pathology,	   26:	  
612–20.	  
Kim	   J,	  Modlin	   RL	   (2003).	   Innate	   Immunity	   and	   the	   Skin.	   In	   Freedberg	   IM,	   Eisen	   AZ,	  
Wolff	   K,	   Austen	   KF,	   Goldsmith	   LA	   and	   Katz	   SI	   (Eds).	   Fitzpatrick’s	   Dermatology	   in	  
General	  Medicine	  (6th	  Ed).	  McGraw-­‐Hill,	  New	  York:	  247-­‐252.	  
Konger	   RL,	   Malaviya	   R,	   Pentland	   AP	   (1998).	   Growth	   regulation	   of	   primary	   human	  
keratinocytes	   by	   prostaglandin	   E	   receptor	   EP2	   and	   EP3	   subtypes.	   Biochimica	   et	  
Biophysica	  Acta,	  1401:	  221–34.	  	  
Kopp	   KLM,	   Kauczok	   CS,	   Lauenborg	   B	   et	   al.	   (2010)	   COX-­‐2-­‐dependent	   PGE2	   acts	   as	   a	  
growth	  factor	  in	  mycosis	  fungoides	  (MF).	  Leukemia,	  24:	  1179-­‐85.	  
Koster	   MI,	   Roop	   DR	   (2007).	   Mechanisms	   regulating	   epithelial	   stratification.	   Annual	  
Review	  of	  Cell	  and	  Developmental	  Biology,	  23:	  93–113.	  
Kuwamoto	  K,	  Miyauchi-­‐Hashimoto	  H,	  Tanaka	  K,	  Eguchi	  N,	  Inui	  T	  et	  al.	  (2000).	  Possible	  
	   32	  
involvement	   of	   enhanced	   prostaglandin	   E2	   production	   in	   the	   photosensitivity	   in	  
xeroderma	  pigmentosum	  group	  A	  model	  mice.	   Journal	  of	   Investigative	  Dermatology,	  
114:	  241–6.	  
Leong	   J,	   Hughes-­‐Fulford	  M,	   Rakhlin	   N,	   et	   al.	   (1996)	   Cyclooxygenases	   in	   human	   and	  
mouse	   skin	  and	   cultured	  human	  keratinocytes:	   association	  of	  COX-­‐2	  expression	  with	  
human	  keratinocyte	  differentiation.	  Experimental	  Cell	  Research,	  224:	  79–87.	  	  
Lipsky	   PE	   (1999).	   The	   clinical	   potential	   of	   cyclooxygenase-­‐2-­‐specific	   inhibitors.	   The	  
American	  Journal	  of	  Medicine,	  106(5B):	  51S–	  57S.	  	  
Loftin	   CD,	   Tiano	   HF,	   Langenbach	   R	   (2002).	   Phenotypes	   of	   the	   COX-­‐deficient	   mice	  
indicate	   physiological	   and	   pathophysiological	   roles	   for	   COX-­‐1	   and	   COX-­‐2.	  
Prostaglandins	  and	  Lipid	  Mediators,	  68–69:	  177–85.	  
Ma	   X,	   Kundu	   N,	   Rifat	   S,	   Walser	   T,	   Fulton	   AM	   (2006).	   Prostaglandin	   E	   receptor	   EP4	  
antagonism	  inhibits	  breast	  cancer	  metastasis.	  Cancer	  Research,	  66:	  2923–7.	  
Maciejewski-­‐Lenoir	   D,	   Richman	   JG,	   Habak	   Y,	   Gaidarov	   I,	   Behan	   DP	   et	   al.	   (2006).	  
Langerhans	   cells	   release	   prostaglandin	   D2	   in	   response	   to	   nicotinic	   acid.	   Journal	   of	  
Investigative	  Dermatology,	  126:	  2637–46.	  
Marks	  F,	  Fürstenberger	  G,	  Neufang	  G,	  Müller-­‐Decker	  K.	  (2003).	  Mouse	  skin	  as	  a	  model	  
for	  cancer	  chemoprevention	  by	  nonsteroidal	  anti-­‐inflammatory	  drugs.	  Recent	  Results	  
in	  Cancer	  Research,	  163:	  46–57.	  
Martínez	   CN,	   Peñafiel-­‐Verdú	   C,	   Vilafranca	   M,	   Ramírez	   G,	   Méndez-­‐Gállego	   M	   et	   al.	  
(2011).	   Cyclooxygenase-­‐2	   expression	   is	   related	   with	   localization,	   proliferation,	   and	  
overall	   survival	   in	  canine	  melanocytic	  neoplasms.	  Veterinary	  Pathology,	  48	   (6):	  1204-­‐
11.	  
Menon	   GK,	   Elias	   PM	   (1991).	   Ultrastructural	   localization	   of	   calcium	   in	   psoriatic	   and	  
normal	  human	  epidermis.	  	  Archives	  of	  Dermatology,	  127:	  57–63.	  	  
Mohammed	  SI,	  Khan	  KNM,	  Sellers	  RS,	  Hayek	  MG,	  DeNicola	  DB	  et	  al.	  (2004).	  Expression	  
of	   cyclooxygenase-­‐1	   and	   2	   in	   naturally-­‐occurring	   canine	   cancer.	   Prostaglandins	  
Leukotriens	  and	  Essential	  Fatty	  Acids,	  70:	  479–83.	  
Morham	   SG,	   Langenbach	   R,	   Loftin	   CD,	   et	   al.	   (1995).	   Prostaglandin	   synthase	   2	   gene	  
disruption	  causes	  severe	  renal	  pathology	  in	  the	  mouse.	  Cell,	  83:	  473–82.	  	  
Morteau	  O,	  Morham	  SG,	  Sellon	  R,	  Dieleman	  LA,	  Langenbach	  R	  et	  al.	  (2000).	  Impaired	  
mucosal	   defense	   to	   acute	   colonicinjury	   in	   mice	   lacking	   cyclooxygenase-­‐1	   or	  
cyclooxygenase-­‐2.	  Journal	  of	  Clinical	  Investigation,	  105:	  469–78.	  
Müller-­‐Decker	  K,	  Scholz	  K,	  Marks	  F,	  Fürstenberger	  G	  (1995).	  Differential	  expression	  of	  
prostaglandin	   h	   synthase	   isozymes	   during	   multistage	   carcinogenesis	   in	   mouse	  
epidermis.	  Molecular	  Carcinogenesis,	  12:	  31–41.	  
Müller-­‐Decker	   K,	   Kopp-­‐Schneider	   A,	   Marks	   F,	   et	   al.	   (1998).	   Localization	   of	  
	   33	  
prostaglandin	  H	  synthase	  isoenzymes	  in	  murine	  epidermal	  tumors:	  suppression	  of	  skin	  
tumor	  promotion	  by	  PGHS-­‐2	  inhibition.	  Molecular	  Carcinogenesis,	  22:	  36	  –	  44.	  	  
Müller-­‐Decker	  K,	  Reinerth	  G,	  Krieg	  P,	  et	  al.	   (1999)	  Prostaglandin-­‐H-­‐synthase	   isozyme	  
expression	  in	  normal	  and	  	  neoplastic	  human	  skin.	  International	  Journal	  of	  Cancer,	  82:	  
648–56.	  	  
Müller-­‐Decker	   K,	   Hirschner	   W,	   Marks	   F,	   Fürstenberger	   G	   (2002).	   The	   effects	   of	  
cyclooxygenase	  isozyme	  inhibition	  on	  incisional	  wound	  healing	  in	  mouse	  skin.	  Journal	  
of	  Invstigative	  Dermatology,	  119:	  1189–95.	  
Müller-­‐Decker	  K,	  Leder	  C,	  Neumann	  M,	  Neufang	  G,	  Bayerl	  C	  et	  al.	  (2003).	  Expression	  of	  
cyclooxygenase	   isozymes	  during	  morphogenesis	  and	  cycling	  of	  pelage	  hair	   follicles	   in	  
mouse	   skin:	   precocious	   onset	   of	   the	   first	   catagen	   phase	   and	   alopecia	   upon	  
cyclooxygenase-­‐2	  overexpression.	  Journal	  of	  Investigative	  Dermatology,	  121:	  661–8.	  
Müller-­‐Decker	  K	  (2011).	  Cyclooxygenase-­‐dependent	  signalling	  is	  causally	  linked	  to	  non-­‐
melanoma	  skin	  carcinogenesis:	  pharmacological,	  genetic	  and	  clinical	  evidence.	  Cancer	  
Metastasis	  Reviews,	  30:	  343-­‐61.	  
Mullins	  MN,	  Lana	  SE,	  Dernell	  WS,	  Ogilvie	  GK,	  Withrow	  SJ	  et	  al.	  (2004).	  Cyclooxygenase-­‐
2	   expression	   in	   canine	   appendicular	   osteosarcomas.	   Journal	   of	   Veterinary	   Internal	  
Medicine,	  18:	  859–65.	  
Needleman	   P,	   Isakson	   PC	   (1997).	   The	   discovery	   and	   function	   of	   COX-­‐2.	   Journal	   of	  
Rheumatology,	  24	  (suppl	  49):	  6–8.	  
Nestle	  FO,	  Meglio	  PD,	  Qin	  J,	  Nickoloff	  BJ	  (2009).	  Skin	  immune	  sentinels	   in	  health	  and	  
disease.	  Nature	  Reviews	  Immunology,	  9:	  679-­‐91.	  
Newman	   SJ,	   Mrkonjich	   L	   (2006).	   Cyclooxygenase-­‐2	   expression	   in	   feline	   pancreatic	  
adenocarcinomas.	  Journal	  of	  Veterinary	  Diagnostic	  Investigation,	  18:	  590-­‐3.	  
Nijsten	   T,	   Colpaert	   CG,	   Vermeulen	   PB,	   Harris	   AL,	   Van	   Marck	   E	   et	   al.	   (2004).	  
Cyclooxygenase-­‐2	  expression	  and	  angiogenesis	  in	  squamous	  cell	  carcinoma	  of	  the	  skin	  
and	  its	  precursors:	  a	  paired	  immunohistochemical	  study	  of	  35	  cases.	  British	  Journal	  of	  
Dermatology,	  151:	  837–45.	  
O’Grady	   A,	   O’Kelly	   P,	   Murphy	   GM,	   Leader	   M,	   Kay,	   E	   (2004).	   COX-­‐2	   expression	  
correlates	  with	  microvessel	  density	  in	  non-­‐melanoma	  skin	  cancer	  from	  renal	  transplant	  
recipients	  and	  immunocompetent	  individuals	  (2004).	  Human	  Pathology,	  35:	  1549–55.	  
O’Neill	  GP,	  Ford-­‐Hutchinson	  AW	  (1993).	  Expression	  of	  mRNA	  for	  cyclooxygenase-­‐1	  and	  
cyclooxygenase-­‐2	  in	  	  human	  tissues.	  FEBS	  Letters,	  330:	  156–60.	  	  
Paglia	  D,	  Dubielzig	  RR,	  Kado-­‐Fong	  HK,	  Maggs	  DJ	  (2009).	  Expression	  of	  cyclooxygenase-­‐2	  
in	  canine	  uveal	  melanocytic	  neoplasms.	  American	   Journal	  of	  Veternary	  Research,	  70:	  
1284–90.	  
Pène	   J,	   Rousset	   F,	   Brière	   F,	   Chrétien	   I,	   Bonnefoy	   JY	   et	   al.	   (1988).	   IgE	   production	   by	  
	   34	  
normal	  human	  lymphocytes	  is	  induced	  by	  interleukin	  4	  and	  suppressed	  by	  interferons	  
γ	  and	  α	  and	  prostaglandin	  E2.	  Proceedings	  of	  the	  National	  Academy	  of	  Sciences	  of	  the	  
United	  States	  of	  America,	  85:	  6880–4.	  
Pentland	  AP,	  Needleman	  P	  (1986).	  Modulation	  of	  keratinocyte	  proliferation	  in	  vitro	  by	  
endogenous	  prostaglandin	  	  synthesis.	  Journal	  of	  Clinical	  Investigation,	  77:	  246–51.	  
Pentland	   AP,	   Mahoney	  M,	   Jacobs	   S,	   Holtzmann	  MJ	   (1990).	   Enhanced	   prostaglandin	  
synthesis	   after	   ultraviolet	   injury	   is	   mediated	   by	   endogenous	   histamine	   stimulation.	  
Journal	  of	  Clinical	  Investigation,	  86:	  566–74.	  
Pentland	  AP,	  Jacobs	  SC	  (1991).	  Bradykinin-­‐induced	  prostaglandin	  synthesis	  is	  enhanced	  
in	   keratinocytes	   and	   fibroblasts	   by	   UV	   injury.	   American	   Journal	   of	   Physiology,	   261:	  
R543–R547.	  
Pentland	   AP,	   Schoggins	   JW,	   Scott	   GA,	   et	   al.	   (1999).	   Reduction	   of	   UV-­‐induced	   skin	  
tumors	  in	  hairless	  mice	  by	  selective	  COX-­‐2	  inhibition.	  Carcinogenesis,	  20:	  1939–44.	  
Pentland	  AP,	  Scott	  G,	  VanBuskirk	  J,	  Tranck	  C,	  LaRossa	  G	  et	  al.	  (2004).	  Cyclooxygenase-­‐1	  
deletion	   enhances	   apoptosis	   but	   does	   not	   protect	   against	   ultraviolet	   light-­‐induced	  
tumors.	  Cancer	  Research,	  64:	  5587–91.	  
Pestili	  de	  Almeida	  EM,	  Piché	  C,	  Sirois	  J,	  Doré	  M	  (2001).	  Expression	  of	  cyclooxygenase-­‐2	  
in	  naturally	  occurring	  squamous	  cell	  carcinomas	  in	  dogs.	  Journal	  of	  Histochemistry	  and	  	  
Cytochemistry,	  49:	  867–75.	  
Pillai	   S,	   Bickle	   D,	   Mancianti	   ML,	   et	   al.	   (1990)	   Calcium	   regulation	   of	   growth	   and	  
differentiation	   of	   normal	   human	   keratinocytes:	   modulation	   of	   differentiation	  
competence	  by	  stages	  of	  growth	  and	  extracellular	  calcium.	  	  Journal	  of	  Cell	  Physiology,	  
143:	  294–302.	  	  
Pires	   I,	  Garcia	  A,	  Prada	   J,	  Queiroga	  FL	   (2010).	  COX-­‐1	  and	  COX-­‐2	  expression	   in	  canine	  
cutaneous,	   oral	   and	   ocular	  melanocytic	   tumours.	   Journal	   of	   Comparative	   Pathology,	  
143(2–3):	  142–49.	  
Planchon	   P,	   Veber	   N,	   Magnien	   V,	   Israel	   L,	   Starzec	   AB	   (1995).	   Alteration	   of	  
prostaglandin	  E	  receptors	   in	  advanced	  breast	  tumor	  cell	   lines.	  Molecular	  and	  Cellular	  
Endocrinology,	  111:	  219–23.	  	  
Prendiville	   JS,	   Manfredi	   LN	   (1992).	   Skin	   signs	   of	   nutritional	   disorders.	   Seminars	   in	  
Dermatology,	  11:	  88–97.	  
Pugh	   S,	   Thomas	  GA	   (1994).	   Patients	  with	   adenomatous	  polyps	   and	   carcinomas	  have	  
increased	  colonic	  mucosal	  prostaglandin	  E2.	  Gut,	  35:	  675–8.	  
Raud	   J,	   Dahlen	   SE,	   Sydbom	  A,	   Lindbom	   L,	  Hedqvist	   P	   (1988).	   Enhancement	   of	   acute	  
allergic	   inflammation	   by	   indomethacin	   is	   reversed	   by	   prostaglandin	   E2:	   apparent	  
correlation	  with	   in	  vivo	  modulation	  of	  mediator	   release.	  Proceedings	  of	   the	  National	  
Academy	  of	  Sciences	  of	  the	  United	  States	  of	  America,	  85:	  2315–9.	  
	   35	  
Rhodes	   LE,	   Belgi	   G,	   Parslew	   R,	   McLoughlin	   L,	   Clough	   GF,	   Friedman	   PS	   (2001).	  
Ultraviolet-­‐B	   induced	   erythema	   is	   mediated	   by	   nitric	   oxide	   and	   prostaglandin	   E2	   in	  
combination.	  Journal	  of	  Investigative	  Dermatology,	  117:	  880–5.	  
Rigas,	  B,	  Goldman	  IS,	  Levine	  L	  (1993).	  Altered	  eicosanoid	  levels	  in	  human	  colon	  cancer.	  
Journa	  of	  Laboratory	  and	  Clinical	  Medicine,	  122:	  518–23.	  
Rodriguez-­‐Burford	   C,	   Tu	   JH,	   Mercurio	   MG,	   Carey	   D,	   Han	   R,	   et	   al.	   (2005).	   Selective	  
cyclooxygenase-­‐2	   inhibition	  produces	  heterogenous	  erythema	  response	  to	  ultraviolet	  
irradiation.	  Journal	  of	  Investigative	  Dermatology,	  125:	  1317–9.	  
Roper	   RL,	   Ludlow	   JW,	   Phipps	   RP	   (1994).	   Prostaglandin	   E2	   inhibits	   B	   lymphocyte	  
activation	   by	   a	   cAMP-­‐dependent	   mechanism:	   PGE-­‐inducible	   regulatory	   proteins.	  
Cellular	  Immunology,	  154:	  296–308.	  
Rossmeisl	   JH	   Jr,	   Robertson	   JL,	   Zimmerman	   KL,	   Higgins	   MA,	   Geiger	   DA	   (2009).	  
Cyclooxygenase-­‐2	   (COX-­‐2)	   expression	   in	   canine	   intracranial	  meningiomas.	   Veterinary	  
and	  Comparative	  Oncology,	  7:	  173–80.	  
Rundhaug	   JE,	  Simper	  MS,	  Surh	   I,	   Fischer	  SM	  (2011).	  The	   role	  of	   the	  EP	   receptors	   for	  
prostaglandin	  E2	  in	  skin	  and	  skin	  cancer.	  Cancer	  Metastasis	  Reviews,	  30:	  465-­‐80.	  
Ruzicka	  T,	  Walter	  JF,	  Printz	  MP	  (1983).	  Changes	  in	  arachidonic	  acid	  metabolism	  in	  UV-­‐
irradiated	  hairless	  mouse	  skin.	  Journal	  of	  Investigative	  Dermatology,	  81:	  300–3.	  
Sano	  H,	   Kawahito	   Y,	  Wilder	   RL,	   Hashiramoto	  A,	  Mukai	   S	  et	   al.	   (1995).	   Expression	   of	  
cyclooxygenase-­‐1	  and	  -­‐2	  in	  human	  colorectal	  cancer.	  Cancer	  Research,	  55:	  3785–9.	  
Schäfer	   M,	   Werner	   S	   (2008).	   Cancer	   as	   an	   overhealing	   wound:	   an	   old	   hypothesis	  
revisited.	  Nature	  Reviews	  of	  Molecular	  and	  Cellular	  Biology,	  9:	  629–38.	  
Schmidt	  BR,	  Glickman	  NW,	  De	  Nicola	  DB,	  de	  Gortari	  AE,	  Knapp	  DW	  (2001).	  Evaluation	  
of	  piroxicam	  for	  the	  treatment	  of	  oral	  squamous	  cell	  carcinoma	  in	  dogs.	  Journal	  of	  the	  
American	  Veterinary	  Medical	  Association,	  218:	  1783–6.	  
Schneider	   C,	   Pozzi	   A	   (2011).	   Cyclooxygenases	   and	   lipoxygenases	   in	   cancer.	   Cancer	  
Metastasis	  Reviews,	  30:	  277-­‐94.	  
Scholz	   K,	   Furstenberger	   G,	   Muller-­‐Decker	   K,	   et	   al.	   (1995)	   Differential	   expression	   of	  
prostaglandin-­‐H	   synthase	   	  isoenzymes	   in	   normal	   and	   activated	   keratinocytes	   in	   vivo	  
and	  in	  vitro.	  The	  Biochemical	  Journal,	  309:	  263–69.	  	  
Simmons	   DL,	   Botting	   RM,	   Hla	   T	   (2004).	   Cyclooxygenase	   isozymes:	   the	   biology	   of	  
prostaglandin	  synthesis	  and	  inhibition.	  Pharmacological	  Reviews,	  56:	  387–437.	  
Shimura	  C,	  Satoh	  T,	   Igawa	  K,	  Aritake	  K,	  Urade	  Y,	  et	  al.	   (2010).	  Dendritic	  cells	  express	  
hematopoietic	  prostaglandin	  D	  synthase	  and	  function	  as	  a	  source	  of	  prostaglandin	  D2	  
in	  the	  skin.	  American	  Journal	  of	  Pathology,	  176:	  227–37.	  
Smith	   CJ,	   Morrow	   JD,	   Roberts	   LJ,	   Marmett	   LJ	   (1993).	   Differentation	   of	   monocytoid	  
	   36	  
THP-­‐1	   cells	   with	   phorbol	   ester	   induces	   expression	   of	   prostaglandin	   endoperoxide	  
synthase-­‐1	  (COX-­‐1).	  Biochemical	  and	  Biophysical	  Research	  Communications,	  182:787–
93.	  
Smith	   WL,	   DeWitt	   DL	   (1996).	   Prostaglandin	   endoperoxide	   H	   synthases-­‐1	   and	   –2.	  
Advances	  in	  Immunology,	  62:	  167–215.	  
Smith	  WL,	  Dewitt	  D	  L,	  Garavito	  RM	  (2000).	  Cyclooxygenases:	   structural,	   cellular,	  and	  
molecular	  biology.	  Annual	  Reviews	  of	  Biochemistry,	  69:	  145–82.	  
Snyder	  DS,	  Eaglestein	  WH	  (1974).	   Intradermal	  antiprostaglandin	  agents	  and	  sunburn.	  
Journal	  of	  Investigative	  Dermatology,	  62:	  47–50.	  
Soriani	  M,	   Luscher	   P,	   Tyrrell	   RM	   (1999).	   Direct	   and	   indirect	  modulation	   of	   ornithine	  
decarboxylase	   and	   cyclooxygenase	   by	   UVB	   radiation	   in	   human	   skin	   cells.	  
Carcinogenesis,	  20:	  727–32.	  	  
Soslow	   RA,	   Dannenberg	   AJ,	   Rush	   D,	   Woerner	   BM,	   Khan	   KN	   et	   al.	   (2000).	   COX-­‐2	   is	  
expressed	  in	  human	  pulmonary,	  colonic	  and	  mammary	  tumors.	  Cancer,	  89:	  2637–45.	  
Steinhoff	   M,	   Brzoska	   T,	   Luger	   TA	   (2001).	   Keratinocytes	   in	   epidermal	   immune	  
responses.	  Current	  Opinion	  in	  Allergy	  and	  Clinical	  Immunology,	  1:	  469	  –	  76.	  
Sun	  TT,	  Green	  H	   (1976).	  Differentiation	  of	   the	  epidermal	  keratinocyte	   in	  cell	   culture:	  
formation	  of	  the	  cornified	  	  envelope.	  Cell,	  9:	  511–21.	  
Sung	  YM,	  He	  G,	  Fisher	  SM	  (2005).	  Lack	  of	  expression	  of	  the	  EP2	  but	  not	  EP3	  receptor	  
for	   prostaglandin	   E2	   results	   in	   suppression	   of	   skin	   tumor	   development.	   Cancer	  
Research,	  65:	  9304–11.	  
Thamm	  DH,	  Ehrhart	  EJ	   III,	  Charles	   JB,	  Elce	  YA	  (2008).	  Cyclooxygenase-­‐2	  expression	   in	  
equine	  tumors.	  Veterinary	  Patholology,	  45:	  825–8.	  
Thorat	  MA,	  Morimiya	  A,	  Mehrotra	  S,	  Konger	  R,	  Badve	  SS	  (2008).	  Prostanoid	  receptor	  
EP1	  expression	  in	  breast	  cancer.	  Modern	  Pathology,	  21:	  15–21.	  
Tilley	  SL,	  Coffman	  TM,	  Koller	  BH	  (2001).	  Mixed	  messages:	  modulation	  of	  inflammation	  
and	   immune	   responses	   by	   prostaglandins	   and	   thromboxanes.	   Journal	   of	   Clinical	  
Immunology,	  108:	  15-­‐23.	  
Tizard	   IR	   (2004)	   (Ed).	   Veterinary	   Immunology:	   an	   introduction	   (7th	   ed).	   Saunders	  
(Elseiver),	  Philadelphia:	  10-­‐23.	  
Tripp	  CS,	  Blomme	  EAG,	  Chinn	  KS,	  Hardy	  MM,	  LaCelle	  P	  et	  al.	  (2003).	  Epidermal	  COX-­‐2	  
induction	  following	  ultraviolet	  irradiation:	  suggested	  mechanism	  for	  the	  role	  of	  COX-­‐2	  
inhibition	  in	  photoprotection.	  Journal	  of	  Investigative	  Dermatology,	  121:	  1–9.	  
Tsuji	  M,	  Kawano	  S,	  Tsujii	  S,	  Sawaoka	  H,	  Hori	  M	  et	  al.	  (1998).	  Cyclooxygenase	  regulates	  
angiogenesis	  induced	  by	  colon	  cancer	  cells.	  Cell	  93:	  705-­‐16.	  
	   37	  
Vegiopoulos	   A,	  Müller-­‐Decker	   K,	   Strzoda	   D,	   Schmitt	   I,	   Chichelnitskiy	   E	   et	   al.	   (2010).	  
Cyclooxygenase-­‐2	   controls	   energy	   homeostasis	   in	   mice	   by	   de	   novo	   recruitment	   of	  
brown	  adipocytes.	  Science,	  328:	  1158–61.	  
Wang	  D,	  DuBois	  RN	  (2005).	  Prostaglandins	  and	  cancer.	  Gut	  55:	  115–22.	  
Wang	   D,	   DuBois	   RN	   (2010a).	   The	   role	   of	   COX-­‐2	   in	   intestinal	   inflammation	   and	  
colorectal	  cancer.	  Oncogene,	  29:781–8.	  
Wang	  D,	  DuBois	  RN	  (2010b).	  Eicosanoids	  and	  cancer.	  Nature	  Reviews.	  Cancer,	  10:	  181–
94.	  
Watanabe	  K,	  Kawamori	  T,	  Nakatsugi	   S,	  Ohta	  T,	  Ohuchida	  S	  et	  al.	   (1999).	  Role	  of	   the	  
prostaglandin	   E	   receptor	   subtype	   EP1	   in	   colon	   carcinogenesis.	   Cancer	   Research,	   59:	  
5093–6.	  	  
Wilgus	   TA,	  Ross	  M,	  Parrett	  M,	  Oberyszyn	  T	   (2000).	   Topical	   application	  of	   a	   selective	  
cyclooxygenase-­‐2	   inhibitor	   suppresses	   UVB	   mediated	   cutaneous	   inflammation.	  
Prostaglandins	  &	  Other	  Lipid	  Mediators,	  62:	  367–84.	  
Wilgus	   TA,	   Parrett	  ML,	   Ross	  MS,	   Tober	   KL,	   Robertson	   FM	  et	   al.	   (2002).	   Inhibition	   of	  
ultraviolet	   light	   B-­‐induced	   cutaneous	   inflammation	   by	   a	   specific	   cyclooxygenase-­‐2	  
inhibitor.	  Advances	  in	  Experimental	  Medicine	  and	  Biology,	  507:	  85–92.	  
Wilgus	   TA,	   Koki	   AT,	   Zweifel	   BS,	   Kusewitt	   DF,	   Rubal	   PA	   et	   al.	   (2003).	   Inhibition	   of	  
cutaneous	  ultraviolet	  light-­‐B-­‐mediated	  inflammation	  and	  tumor	  formation	  with	  topical	  
celecoxib	  treatment.	  Molecular	  Carcinogenesis,	  38:	  49–58.	  
Williams	   TJ	   (1979).	   Prostaglandin	   E2,	   prostaglandin	   I2,	   and	   the	   vascular	   changes	   of	  
inflammation.	  British	  Journal	  of	  Pharmacology,	  65:	  517–24.	  
Williams	   IR,	   Kupper	  TS	   (1996).	   Immunity	   at	   the	   surface:	  homeostatic	  mechanisms	  of	  
the	  skin	  immune	  system.	  Life	  Sciences,	  58:	  1485-­‐507.	  
	  
Xu	   Y,	   Yang	   L,	   Yang	   T,	   Xiang	   M,	   Huang	   E	   et	   al.	   (2008).	   Expression	   pattern	   of	  
cyclooxygenase-­‐2	   in	   normal	   rat	   epidermis	   and	   pilosebaceous	   unit	   during	   hair	   cycle.	  
Acta	  Histochemica	  et	  Cytochemica,	  41:	  157-­‐163.	  
Yin	   H,	   Cheng	   L,	   Langenbach	   R,	   Ju	   C	   (2007).	   Prostaglandin	   I2	   and	   E2	   mediate	   the	  
protective	   effects	   of	   cyclooxygenase-­‐2	   in	   a	   mouse	   model	   of	   immunemediated	   liver	  
injury.	  Hepatology,	  45:	  159-­‐69.	  
Yuspa	   SH,	   Kilkenny	   AE,	   Steinert	   PM,	   et	   al.	   (1989).	   Expression	   of	   murine	   epidermal	  
differentiation	   markers	   is	   	  tightly	   regulated	   by	   restricted	   extracellular	   calcium	  
concentrations	  in	  vitro.	  Journal	  of	  Cell	  Biology,	  109:	  1207–17.	  	  
Zhang	   MZ,	   Wang	   JL,	   Cheng	   HF,	   et	   al.	   (1997).	   Cyclooxygenase-­‐2	   in	   rat	   nephron	  
development.	  Am	  J	  Physiol,	  273(6	  Pt	  2):F994–F1002.	  	  
Ziboh	   VA,	   Shia	   SL	   (1971).	   Prostaglandin	   E2:	   biosynthesis	   and	   effects	   on	   glucose	   and	  
	   38	  
lipid	  metabolism	  in	  rat	  skin.	  Archives	  of	  Biochemistry,	  146:	  100–9.	  	  
Ziboh	  VA,	  Hsia	   SL	   (1972).	   Effects	   of	   prostaglandin	   E2	  on	   rat	   skin:	   inhibition	  of	   sterol	  
ester	   biosynthesis	   and	   	  clearing	   of	   scaly	   lesions	   in	   essential	   fatty	   acid	   deficiency.	  
Journal	  of	  Lipid	  Research,	  13:	  458–67.	  	  
Ziboh	  VA	  (1996).	  The	  significance	  of	  polyunsaturated	  fatty	  acids	  in	  cutaneous	  biology.	  





2.	  OBJECTIVES	  	  	  	  	  	  	   	  
	  
	   41	  
Objectives	  
As	  explained	  above,	  there	  are	  multiple	  evidences	  linking	  the	  system	  COX-­‐2/PGE2	  with	  
physiologic,	  inflammatory	  and	  neoplastic	  processes.	  With	  this	  background,	  we	  planned	  
to	   investigate	   the	   route	   COX2/PGE2	   in	   epidermal	   involving	   neoplasia	   and	   epidermal	  
inflammation.	  
The	  two	  objectives	  of	  the	  thesis	  were:	  
1. To	   investigate	   COX-­‐2	   expression	   in	   cutaneous	   neoplasia	   with	   epidermal	  
involvement	  in	  dogs,	  cats	  and	  horses.	  
2. To	   investigate	  the	  route	  COX-­‐2/PGE2	   in	  the	  canine	  keratinocyte	   inflammatory	  
response.	  
In	  order	  to	  reach	  these	  objectives,	  two	  different	  studies	  were	  designed	  and	  carried	  on	  
(see	  scheme	  in	  the	  following	  page):	  
1. Experiment	  1:	  	  
To	   investigate	   COX-­‐2	   expression	   in	   cutaneous	   pre-­‐neoplastic	   (actinic	  
keratosis)	   and	   neoplastic	   processes	   (squamous	   cell	   carcinoma,	  melanoma	  
and	   cutaneous	   epitheliotropic	   T	   cell	   lymphoma)	   and	   in	   inflammatory	  
dermatoses	  an	   immunohistochemical	  study	  was	  carried	  on.	  The	  pattern	  of	  
COX-­‐2	  expression	  and	  its	  association	  to	  inflammation	  was	  studied.	  
	  
2. Experiment	  2:	  
To	   investigate	   the	   participation	   of	   keratinocytes	   in	   the	   inflammatory	  
cutaneous	   response	   an	   in	   vitro	   model	   of	   keratinocytes	   culture	   was	  
implemented.	   To	   establish	   the	   role	   of	   keratinocytes	   in	   the	   inflammatory	  
response	   through	   the	   COX-­‐2/PGE2	   route,	   this	   in	   vitro	  model	  was	   used	   to	  
evaluate	  PGE2	  production	  by	  keratinocytes	  in	  response	  to	  different	  stimuli	  
(lipopolysaccharide	  and	  inflammatory	  cells).	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Overall	  structure	  of	  the	  thesis	  (objectives	  and	  experiments	  to	  carry	  on):	  
	  
	  







To	  investigate	  COX-­‐2	  
expression	  in	  cutaneous	  
neoplasia	  with	  epidermal	  





To	  investigate	  the	  role	  of	  






Set	  up	  an	  in	  vitro	  model	  
to	  study	  the	  keratinocyte	  
inflammatory	  response.	  
	  
Evaluate	  in	  vitro	  
production	  of	  PGE2	  in	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3.1.	   Immunohistochemical	   demonstration	   of	   COX-­‐2	   expression	   in	   cutaneous	  





In	   this	   first	   experiment	  we	   aimed	   to	   investigate	  COX-­‐2	   expression	   in	   cutaneous	  pre-­‐
neoplastic,	   neoplastic	   and	   inflammatory	   dermatoses	   involving,	   all	   of	   them,	   the	  
epidermis.	  	  
	  
First	   of	   all,	   pre-­‐neoplastic	   (AK)	   and	   neoplastic	   (SCC)	   disorders	   in	   which	   the	  
keratinocytes	  are	  primarly	   involved	  were	   studied.	  As	  explained	  previously,	   in	  human	  
and	  rodent	  beings,	   it	  has	  been	  demonstrated	   that	  COX-­‐2	   is	  overexpressed	   in	  AK	  and	  
SCC,	   and	   COX-­‐2	   has	   been	   postulated	   as	   being	   causally	   related	   to	   its	   development	  
(Buckman	  et	   al.	   1998,	   An	  et	   al.	   2002,	  Müller-­‐Decker	   2011).	   However,	   no	   studies	   on	  
COX-­‐2	   expression	   in	   companion	   animals	   AK	   have	   been	   performed.	   Moreover,	  
immunohistochemical	   studies	   regarding	   SCC	   and	   COX-­‐2	   expression	   in	   dogs	   and	   cats	  
have	   yielded	   divergent	   results.	   COX-­‐2	   has	   been	   shown	   to	   be	   present	   in	   a	   large	  
proportion	  of	  canine	  SCCs	  but	  cutaneous	  feline	  SCC	  are	  reported	  to	  be	  COX-­‐2	  negative	  
(Pestili	  de	  Almeida	  et	  al.	  2001,	  Mohamed	  et	  al.	  2004,	  Beam	  et	  al.	  2003).	  	  
	  
In	  the	  second	  place,	  another	  epidermal	  proliferative	  disorder	  affecting	  the	  epidermal	  
resident	  cell	  melanocyte	  was	  studied.	  Cutaneous	  melanocytic	  neoplasias	  are	  common	  
cutaneous	  disorders	  of	  dogs	  and	  horses	  but	  uncommon	  in	  cats	  (Scott	  et	  al.	  2001,	  Gross	  
et	  al.	  2005,	  Scott	  and	  Miller	  2011).	  Regarding	  COX-­‐2	  expression	  in	  human	  bening	  and	  
malignant	   melanocytic	   neoplasias	   conflicting	   results	   have	   been	   obtained	   from	   nine	  
different	  studies	  (Vogt	  et	  al.	  2001,	  Denkert	  et	  al.	  2001,	  Goulet	  et	  al.	  2003,	  Jung	  et	  al.	  
2005,	  Kuzbicki	  et	  al.	  2006,	  Johansson	  et	  al.	  2008,	  Lee	  et	  al.	  2008,	  Becker	  et	  al.	  2009).	  
And	   like	   in	   human	   medicine,	   veterinary	   studies	   on	   canine	   and	   equine	   melanocytic	  
neoplasias	   have	   yielded	   divergent	   results.	   Depending	   on	   the	   study,	   COX-­‐2	  
immunoreactivity	  has	  been	  detected	   in	   few	   to	  numerous	  neoplasms	   (Mohammed	  et	  
al.	  2004,	  Thamm	  et	  al.	  2008,	  Paglia	  et	  al.	  2009,	  Pires	  et	  al.	  2010,	  Martínez	  et	  al.	  2011).	  
We	  included	  this	  neoplasia	  in	  the	  experiment	  because	  it	  is	  a	  common	  neoplasia	  in	  dogs	  
*	  Part	  of	  the	  results	  have	  been	  published	  in	  Journal	  of	  Comparative	  Pathology	  2012;	  
146	  (1):	  11-­‐7.	  See	  annex.	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and	   horses	   that	   affect	   a	   resident	   cell	   in	   the	   epidermis	   and	   because	   the	   conflicting	  
results	  reported	  in	  previous	  veterinary	  and	  human	  studies.	  
	  
The	   last	   neoplasia	   studied	   was	   the	   lymphocytic	   proliferative	   disorder	   CETL.	   The	  
neoplastic	   lymphocyte	   is	   not	   an	   epidermal	   resident	   cell,	   but	   due	   to	   its	  	  
epitheliotropism,	   the	   epidermis	   becomes	   primarly	   involved	   in	   its	   pathogenesis.	  
Moreover,	  a	  recent	  study	  has	  reported	  COX-­‐2	  overexpression	  in	  human	  CETL	  (Kopp	  et	  
al.	  2010).	  This	  neoplasia	  seemed	  interesting	  to	  us	  because	  its	  epidermal	  involvement,	  
and	  because	  invasion	  of	  the	  epidermis	  by	  neoplastic	  cells	  often	  causes	  erosion	  and/or	  
ulceration.	   This	   could	   allow	   us	   to	   study,	   a	   part	   of	   COX-­‐2	   expression	   in	   neoplastic	  
lymphocytes,	   the	   relationship	   between	   COX-­‐2	   expression	   and	   the	   presence	   of	  
inflammation	  in	  eroded	  or	  ulcerated	  neoplastic	  lesions	  as	  we	  have	  seen	  in	  the	  previous	  
experiment.	  
	  
Finally,	  we	  aimed	  to	  study	  COX-­‐2	  expression	  in	  inflammatory	  dermatoses	  of	  dogs	  and	  
cats.	  We	  wanted	  to	  study	  them	  because	  eventhough	  there	   is	  evidence	  that	  the	  COX-­‐
2/PGE2	   route	  has	   important	   roles	   in	   the	  cutaneous	   inflammatory	   response	   (Goldyne	  
2000,	  Müller-­‐Decker	  2011),	  no	  studies	  in	  either	  humans	  or	  animals	  have	  been	  reported	  
regarding	   different	   cutaneous	   inflammatory	   diseases.	   This	   study	   would	   allow	   us	   to	  








All	   samples	   were	   selected	   from	   the	   Veterinary	   Pathology	   Diagnostic	   Service	   of	   the	  
Universitat	   Autònoma	   de	   Barcelona.	   A	   careful	   file	   history	   review	  was	   carried	   out	   to	  
exclude	  from	  the	  study	  those	  samples	  from	  animals	  for	  which	  the	  history	  stated	  or	  was	  
indicative	  of	  steroid	  or	  NSAID	  treatment	  previous	  to	  biopsy	  retrieval.	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Canine	  and	  feline	  actinic	  keratosis	  and	  squamous	  cell	  carcinoma:	  18	  were	  AK	  (9	  feline	  
and	  9	  canine)	  and	  36	  SCC	  (27	  feline	  and	  9	  canine).	  
	  
Canine	   and	   equine	   melanocytic	   neoplasms:	   22	   samples	   were	   selected.	   Twelve	   (6	  
melanocytomas	   and	   6	   melanomas)	   were	   canine	   samples	   and	   10	   (8	   melanocytomas	  
and	  2	  melanomas)	  were	  equine.	  	  
	  
Canine	  cutaneous	  epitheliotropic	  T	  cell	   lymphoma:	  20	  samples	  were	  selected.	  Two	  of	  
them	  were	  classified	  as	  Pagetoid	  reticulosis	   (PR)	  (neoplastic	   infiltrate	  confined	  to	  the	  
epidermis	   and	   adnexal	   structures)	   and	   the	   rest	   (18)	   as	   “classical”	  mycosis	   fungoides	  
(with	   neoplastic	   infiltrates	   present	   in	   the	   epidermis,	   adnexa	   and	   underlying	   dermis)	  
(Gross	  et	  al.	  2005).	  
	  
Canine	  and	  feline	  inflammatory	  dermatoses:	  24	  samples	  were	  selected.	  These	  included	  
pemphigus	   foliaceous	   (2	   feline	   and	   3	   canine),	   pustular	   staphyloccocal	   infection	   (1	  
feline	  and	  5	  canine),	   superficial	  hyperplastic	  perivascular	  dermatitis	  without	  pustules	  




The	  standard	  streptavidin	  biotin	  technique	  was	  used	  for	  detecting	  COX-­‐2	  protein	  in	  all	  
samples.	  	  
	  
Five-­‐micron-­‐thick	   paraffin	   wax	   embedded	   tissue	   sections	   were	   cut	   and	   placed	   on	  
positively	   charged	   glass	   slides.	   Sections	   were	   deparaffinised	   and	   endogenous	  
peroxidase	  activity	  was	  quenched	  by	  exposure	  to	  3%	  hydrogen	  peroxide	  for	  5	  minutes.	  
Bleaching	  with	  0.25%	  potassium	  permanganate	  for	  30	  minutes	  followed	  by	  1%	  oxalic	  
acid	   for	  5	  minutes	  was	  performed.	  Heat-­‐induced	  epitope	  retrieval	  was	  carried	  out	  at	  
90	   to	   100ºC	   in	   citrate	   buffer	   solution	   for	   10	  minutes	  with	   30	  minutes	   of	   cooling	   at	  
ambient	  temperature.	  The	  sections	  were	  then	  blocked	  with	  2%	  bovine	  serum	  albumin	  
(Sigma-­‐Aldrich,	   Germany).	   The	   primary	   antibody	   (polyclonal	   murine	   COX-­‐2	   (Cayman	  
Chemical,	   Ann	  Arbor,	  MI))	  was	   applied,	   and	   slides	  were	   incubated	   overnight	   at	   4ºC.	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Slides	  were	   then	   incubated	  with	  a	  biotinylated	  polyclonal	   goat	  anti-­‐rabbit	   secondary	  
antibody	   (Dako,	   Denmark)	   for	   one	   hour	   and	   then	   with	   an	   avidin-­‐biotin-­‐peroxidase	  
complex	  (ImmunoPure,	  Thermo	  Fisher	  Scientific,	  Rockford,	  IL)	  for	  another	  hour.	  Slides	  
were	   developed	   with	   3,3-­‐diamino-­‐benzidine	   tetrahydrochloride	   	   (Sigma-­‐Aldrich,	  
Germany)	  and	  counterstained	  with	  haematoxylin.	  
	  
The	   rabbit	   anti-­‐COX-­‐2	   polyclonal	   antibody	   used	   in	   this	   study	   had	   been	   previously	  
shown	  to	  detect	  COX-­‐2	  in	  feline	  and	  canine	  cells	  of	  the	  macula	  densa	  and	  validated	  in	  
the	  horse	  specie	  (Newman	  and	  Mrkonjich	  2006,	  McInnis	  et	  al.	  2007,	  Hammamoto	  et	  
al.	  2009).	  
	  
In	  the	  CETL	  study,	  for	  each	  sample	  included,	  two	  consecutive	  five-­‐micron-­‐thick	  paraffin	  
wax	  embedded	  tissue	  sections	  were	  cut	  and	  placed	  on	  silane-­‐coated	  glass	  slides.	  COX-­‐
2	  IHC	  was	  performed	  in	  one	  section,	  and	  for	  those	  samples	  positive	  to	  this	  IHC,	  a	  CD-­‐3	  
IHC	   was	   performed	   on	   the	   other	   consecutive	   section.	   As	   in	   COX-­‐2	   IHC,	   a	   standard	  
streptavidin	   biotin	   technique	  was	   used	   for	   detecting	   CD-­‐3	  molecules.	   Sections	  were	  
deparaffinised	  and	  endogenous	  peroxidase	  activity	  was	  quenched	  by	  exposure	  to	  3%	  
hydrogen	  peroxide	  for	  30	  minutes.	  Bleaching	  with	  0.25%	  potassium	  permanganate	  for	  
30	  minutes	  followed	  by	  1%	  oxalic	  acid	  for	  5	  minutes	  was	  performed.	  The	  sections	  were	  
treated	  with	  protease	  0.1%	  in	  Tris	  buffer	  for	  8	  minutes	  at	  37ºC	  and	  incubated	  with	  a	  
rabbit	  polyclonal	  anti-­‐CD-­‐3	  antibody	   (Dako,	  Copenhagen,	  Denmark)	  overnight	  at	  4ºC.	  
The	   sections	   were	   then	   incubated	   with	   a	   biotinylated	   polyclonal	   goat	   anti-­‐rabbit	  
secondary	   antibody	   (Dako,	   Denmark)	   for	   one	   hour	   and	   then	   with	   an	   avidin-­‐biotin-­‐
peroxidase	   complex	   (ImmunoPure®,	   ABC	   Peroxidase	   Staining	   Kit	   Standard,	   Pierce,	  
Thermo	  Fisher	  Scientific,	  Rockford,	  IL)	  for	  another	  hour.	  The	  immunologic	  reaction	  was	  
developed	  with	   3,3-­‐diamino-­‐benzidine	   tetrahydrochloride	   	   (Sigma-­‐Aldrich,	   Germany)	  
and	  counterstained	  with	  haematoxylin.	  The	  positive	  controls	  were	  paraffin-­‐embedded	  
sections	   of	   a	   canine	   lymph	   node.	   The	   negative	   controls	   were	   sections	   incubated	   in	  
normal	  rabbit	  serum	  in	  place	  of	  specific	  CD-­‐3	  antiserum.	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All	   samples	   were	   closely	   assessed	   in	   an	   attempt	   to	   define	   whether	   neoplastic	   and	  
epidermal	   cells	   were	   specifically	   labelled	   with	   COX-­‐2	   antibody	   and,	   in	   the	   CETL	  





Immunoreactivity	   to	   COX-­‐2	   was	   observed	   in	   pre-­‐neoplastic	   and	   neoplastic	  
keratinocytes	  (AK	  and	  SCC	  samples)	  and	  melanocytes	  (melanocytic	  neoplasm	  samples)	  
but	  not	   in	  neoplastic	   lymphocytes	   (CETL	   samples).	  However,	  positive	  neoplastic	   cells	  
where	   those	   found	   in	   association	   with	   a	   granulocytic	   infiltrate.	   On	   the	   contrary,	  
positive	   pre-­‐neoplastic	   keratinocytes	   of	   the	   AK	   samples	   were	   not	   associated	   to	  
inflammatory	   infiltrate.	   In	   the	   inflammatory	   dermatoses	   samples,	   all	   keratinocytes	  
that	  were	  positive	  to	  COX-­‐2	  	  had	  a	  granulocytic	  inflammatory	  infiltrate	  around	  them.	  	  
	  
The	  cellular	  pattern	  of	  COX-­‐2	  immunoreactivity	  was	  in	  all	  cases	  granular	  cytoplasmatic	  
and	  located	  mainly	  in	  the	  perinuclear	  zone.	  
	  
Actinic	  keratosis	  	  and	  squamous	  cell	  carcinoma:	  
	  
Regarding	  AK,	  4	  out	  of	  9	  feline	  and	  3	  out	  of	  the	  9	  canine	  samples	  were	  positive	  to	  COX-­‐
2	   IHC	   (Table	   3.1).	   Immunoreactivity	   was	   observed	   in	   basal	   epidermal	   cells,	   but	  
scattered	  suprabasal	  positive	  cells	  were	  also	  detected	  (Fig	  3.1).	  The	  positive	  cells	  were	  
in	  the	  proximity	  of	  an	  inflammatory	  infiltrate	  only	  in	  one	  canine	  sample.	  
	  
All	   feline	  and	  canine	  SCC	  showed	  COX-­‐2	  positive	  neoplastic	  cells	   (Table	  3.1).	  Staining	  
was	   heterogeneous	   throughout	   the	   tumour	   sections.	   Basal	   cells	   and	   more	  
differentiated	  cells	  were	   found	  to	  be	  positive,	  mainly	   in	  and	  below	  areas	  were	  there	  
was	  superficial	  erosion	  or	  ulceration	  of	   tumours,	  but	  positive	   tumour	  cells	  were	  also	  
observed	  to	  be	  scattered	  deeper	  in	  all	  samples	  (Fig	  3.2).	  In	  most	  cases,	  the	  positive	  IHC	  
reaction	   in	   keratinocytes	   was	   associated	   with	   the	   presence	   of	   polymorphonuclear	  
(PMN)	   cells	   (Fig	   3.2).	   No	   COX-­‐2	   positive	   reaction	   was	   observed	   in	   the	   non-­‐
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eroded/ulcerated	  margins	  of	   the	  tumours.	   In	  6/27	   feline	  cases	  and	  1/9	  canine	  cases,	  




SAMPLES	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  COX-­‐2	  IHC	  
Disease	   Specie	  	   n	   Positive	  samples	  (%)	  
Positivity	  associated	  to	  PMN	  
infiltrate	  (%	  of	  positive	  
samples)	  
AK	   F	   9	   4/9	  (44)	   0/4	  (0)	  
AK	   C	  	   9	   3/9	  (33)	   1/3	  (33)	  
SCC	   F	  	   27	   27/27	  (100)	   21/27	  (77)	  
SCC	   C	   9	   9/9	  (100)	   8/9	  (88)	  
	  
Table	  3.1:	  Summarize	  of	  results	  of	  COX-­‐2	  immunohistochemistry	  (IHC)	  on	  canine	  and	  
feline	  actinic	  keratosis	  (AK)	  and	  squamous	  cell	  carcinoma	  (SCC)	  samples.	  (C,	  canine;	  F,	  




Figure	   3.1.	   Representative	   photomicrographs	   of	   COX-­‐2	   immunohistochemistry	   of	  
actinic	   keratoses	   samples.	   A	   and	   B:	   feline	   and	   canine	   samples	   respectively.	   COX-­‐2	  
immunoreactivity	   is	   observed	   mainly	   in	   the	   basal	   (arrows)	   and	   in	   few	   suprabasal	  
keratinocytes	  (arrowheads).	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Figure	   3.2.	   Representative	   photomicrographs	   of	   COX-­‐2	   immunohistochemistry	   of	  
squamous	   cell	   carcinoma	   (SCC)	   samples.	   A	   and	   B:	   feline	   SCC.	   C:	   canine	   SCC.	  
Immunoreactivity	  of	  neoplastic	  keratinocytes	  to	  COX-­‐2	  antibody	  is	  observed	  mainly	  at	  
the	  eroded	  surface	  of	  the	  tumours	  (arrows)	  but	  also	  scattered	  deeper	  positive	  cells	  are	  
detected	   (arrowheads).	   Positive	   immunoreactivity	   of	   keratinocytes	   is	   associated	  
mainly	  with	  the	  presence	  of	  polymorphonuclear	  cells	  (asterix).	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Melanocytic	  neoplasms:	  
	  
Expression	  of	  COX-­‐2	  protein	  in	  neoplastic	  melanocytes	  was	  found	  in	  only	  36%	  (8	  of	  22)	  
of	   the	  samples	  examined	  and	  64%	  (14	  of	  22)	  showed	  negative	  staining	  results	   (table	  
3.2).	  	  
	  
In	   these	   positive	   sections,	   immunoreactivity	   was	   detected	   in	   scattered	   neoplastic	  
melanocytes	   (5	   to	   15	   per	   section).	   These	   positive	   neoplastic	   cells	   were	   detected	   in	  
areas	  were	  ulceration	  and	  polymorphonuclear	  (PMN)	  infiltrate	  was	  present	  (Fig.	  3.3).	  
However,	   not	   all	   ulcerated	   areas	   had	   COX-­‐2	   positive	   cells.	   No	   positive	   cells	   were	  
detected	  in	  the	  centre	  of	  any	  neoplasia.	  If	  the	  neoplasia	  was	  not	  ulcerated,	  there	  were	  
no	  COX-­‐2	  positive	  neoplastic	  melanocytes	  or	  keratinocytes.	  	  
	  
In	   the	   canine	   neoplasias,	   the	   five	   samples	   that	   were	   positive	   corresponded	   to	  
melanomas	   (3	   oral,	   1	   mucocutaneous	   and	   2	   cutaneous)	   and	   none	   of	   the	  
melanocytomas	  (which	  were	  not	  ulcerated)	  showed	  immunoreactivity	  to	  COX-­‐2.	  Only	  
one	  melanoma,	  which	  was	  not	  ulcerated,	  was	  negative.	  	  
	  
In	  the	  equine	  samples,	  the	  3	  positive	  specimens	  were	  ulcerated	  melanomas.	  As	  in	  the	  
canine	   samples,	   one	   not	   ulcerated	   melanoma	   and	   all	   melanocytomas	   (which	   all	   of	  
them	  were	  not	  ulcerated),	  were	  negative	  to	  COX-­‐2	  IHC.	  	  
	  
Regarding	   epidermal	   keratinocytes,	   their	   positivity	   paralleled	   that	   of	   neoplastic	  
melanocytes.	  All	  those	  samples	  that	  had	  positive	  neoplastic	  melanocytes,	  had	  positive	  
epidermal	  keratinocytes	   in	  the	  same	  areas.	  Like	  the	  positive	  neoplastic	  cells,	  positive	  





















COX-­‐2	  positivity	  	  
associated	  to	  	  
PMN	  infiltrate,	  ulcers,	  
both	  or	  neither	  
1	  
2	  
C	   M	   Oral	   Yes	   +	  	   Kcs	  &	  mel	   both	  
C	   Mc	   M-­‐cut	   No	   -­‐	   n/a	   n/a	  
3	   C	   Mc	  	   Cut	   No	   -­‐	   n/a	   n/a	  
4	   C	   M	   Cut	  	   Yes	   +	   Kcs	  &	  mel	   both	  
5	   C	   Mc	   Cut	   No	   -­‐	   n/a	   n/a	  
6	  
7	  
C	   M	   M-­‐cut	   Yes	   +	  	   Kcs	  &	  mel	   both	  
C	   M	   Oral	   Yes	   +	   Kcs	  &	  mel	   both	  
8	  	   C	   Mc	   Cut	   No	   -­‐	   n/a	   n/a	  
9	  	   C	   M	   Cut	   Yes	   +	   Kcs	  &	  mel	   both	  
10	   C	   Mc	   Cut	   No	   -­‐	   n/a	   n/a	  
11	  	   C	   Mc	   Cut	   No	   -­‐	   n/a	   n/a	  
12	   C	   M	   M-­‐cut	   No	   -­‐	   n/a	   n/a	  
13	   E	   Mc	   Cut	   No	   -­‐	   n/a	   n/a	  
14	  	   E	   M	   Cut	   Yes	   +	  	   Kcs	  &	  mel	   both	  
15	   E	   M	   Cut	   Yes	   +	  	   Kcs	  &	  mel	   both	  
16	   E	   M	   Cut	   Yes	   +	  	   Kcs	  &	  mel	   both	  
17	   E	   Mc	   Cut	   No	   -­‐	   n/a	   n/a	  
18	   E	   Mc	   Cut	   No	   -­‐	   n/a	   n/a	  
19	   E	   Mc	   Cut	   No	   -­‐	   n/a	   n/a	  
20	   E	   Mc	   Cut	   No	   -­‐	   n/a	   n/a	  
21	   E	   Mc	   Cut	   No	   -­‐	   n/a	   n/a	  
22	   E	   M	   Sclera	   No	   -­‐	   n/a	   n/a	  
	  
Table	  3.2:	  Summarize	  of	  results	  of	  COX-­‐2	  immunohistochemistry	  (IHC)	  on	  canine	  and	  
equine	   melanocytic	   neoplasms	   samples.	   (-­‐,	   negative;	   +,	   positive;	   C,	   canine;	   Cut:	  
cutaneous;	   E:	   equine;	   kcs:	   keratinocytes;	   	   n/a,	   not	   applicable;	   Sp:	   specie;	   M:	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Figure	   3.3.	   Representative	   photomicrographs	   of	   COX-­‐2	   immunohistochemistry	   of	  
canine	   (A,	   C,	   E)	   and	   equine	   (B,	   D,	   F)	   melanomas..	   Immunoreactivity	   of	   neoplastic	  
melanocytes	   (arrows)	   and	   of	   keratinocytes	   (arrowheads)	   to	   COX-­‐2	   antibody	   is	  
observed	  mainly	  at	  the	  eroded	  surface	  of	  the	  tumours.	  Images	  C	  and	  E	  are	  closer	  views	  
of	  keratinocytes	  (C)	  and	  melanocytes	  (E)	  of	  sample	  A.	  Images	  	  D	  and	  F	  are	  closer	  views	  
of	  	  kerationcytes	  (D)	  and	  melanocytes	  (F)	  of	  sample	  B.	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Cutaneous	  epitheliotropic	  T	  cell	  lymphoma:	  
	  
COX-­‐2	   immunoreactivity	  was	  absent	   in	   the	  neoplastic	   cell	  population	   in	  19/20	  cases.	  
The	  only	  case	  in	  which	  immunoreactivity	  was	  detected	  in	  the	  neoplastic	  infiltrate	  was	  
a	  very	  mild	  case	  with	  only	  2	  cells	  being	  positive.	  No	  microscopic	  signs	  of	  inflammation	  
were	  detected	  around	  these	  positive	  cells	  (table	  3.3).	  	  
	  
Few	  keratinocytes	  (5-­‐15	  cells/section)	   in	  10/20	  samples	  expressed	  COX-­‐2	  (Fig.	  3.4).	   It	  
was	   confirmed	   that	   they	   were	   keratinocytes	   because	   they	   were	   CD-­‐3	   negative	   and	  
phenotypically	  compatible	  with	  epidermal	  cells.	  
	  
COX-­‐2	   expression	   in	   kerationcytes	  was	   associated	  with	   ulcers	   or	   polymorphonuclear	  
(PMN)	   infiltration	   in	   9/10	   of	   cases	   (Fig.	   2.4).	   From	   them,	   6	   were	   associated	   to	   the	  
presence	  of	  ulcers	  and	   in	  2	   there	  were	  no	  ulcers	  but	  PMN	  were	  present	  around	   the	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Sample	  
number	  
PR	  or	  	  
CMF	  	  
COX-­‐2	  +	  	  
(E	  or	  D)	  
COX-­‐2	  positive	  
cells	  
COX-­‐2	  positivity	  associated	  to	  
PMN	  infiltrate,	  	  
ulcers	  or	  neither	  
1	  
2	  
CMF	   +	  (E)	   keratinocytes	   ulcer	  
CMF	   -­‐	   n/a	   n/a	  
3	   CMF	  	   +	  (E)	   keratinocytes	   ulcer	  
4	   PR	   -­‐	   n/a	   n/a	  
5	   CMF	   -­‐	   n/a	   n/a	  
6	  
7	  
CMF	   +	  (E)	   keratinocytes	   ulcer	  
CMF	   -­‐	   n/a	   n/a	  
8	  	   CMF	   +	  (E)	   keratinocytes	   ulcer	  
9	  	   CMF	   -­‐	   n/a	   n/a	  
10	   CMF	   -­‐	   n/a	   n/a	  
11	  	   CMF	   -­‐	   n/a	   n/a	  
12	   CMF	   -­‐	   n/a	   n/a	  
13	   PR	   +	  (E)	   kerationcytes	   PMN	  
14	  	   CMF	   +	  (E)	   keratinocytes	   neither	  
15	   CMF	   +	  (D)	   lymphocytes	   neither	  
16	   CMF	   +	  (E)	   keratinocytes	   Ulcer	  
17	   CMF	   -­‐	   n/a	   n/a	  
18	   CMF	   +	  (E)	   keratinocytes	   PMN	  
19	   CMF	   -­‐	   n/a	   n/a	  
20	   CMF	   +	  (E)	   keratinocytes	   Ulcer	  
	  
Table	   3.3:	   Summarize	   of	   results	   of	   COX-­‐2	   immunohistochemistry	   (IHC)	   on	   canine	  
cutaneous	   epitheliotropic	   T	   cell	   lymphoma	   samples.	   (-­‐,	   negative;	   +,	   positive;	   CMF,	  
classical	   mycosis	   fungoides;	   E,	   epidermis;	   D,	   dermis;	   n/a,	   not	   applicable;	   n/k,	   not	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Figure	  3.4.	  Representative	  photomicrographs	  of	  COX-­‐2	  immunohistochemistry	  (A	  and	  
C)	   and	   CD3	   immunohistochemistry	   (B	   and	   D)	   of	   a	   cutaneous	   epitheliotropic	   T	   cell	  
lymphoma	  samples.	  C	  and	  D	  are	  high-­‐power	  magnifications	  of	  the	  indicated	  areas	  of	  A	  
and	   B,	   respectively.	   COX-­‐2	   is	   expressed	   by	   keratinocytes	   at	   the	   eroded	   surface	  
(arrows).	  COX-­‐2	  positive	  cells	  are	  CD3	  negative	  (arrowheads).	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Inflammatory	  dermatoses:	  
	  
Of	  the	  24	  samples	  of	  inflammatory	  dermatoses	  tested,	  IHC	  positive	  keratinocytes	  were	  
observed	  in	  4	  feline	  (2	  pemphigus	  foliaceous	  and	  2	  dermatophytoses)	  and	  6	  canine	  (3	  
pemphigus	  foliaceous,	  2	  pustular	  staphyloccal	  infections	  and	  1	  dermatophytosis)	  cases	  
(Table	  3.4).	   In	   all	   positive	   samples,	   basal	   and	   suprabasal	   positive	   keratinocytes	  were	  
always	   associated	   with	   the	   exocytosis	   of	   PMN	   neutrophils	   or	   eosinphils	   in	   the	  
epidermis	   or	   follicular	   epithelium	   (Fig.	   3.5).	   In	   the	   absence	   of	   PMN	   exocytosis,	   the	  
epithelium	   was	   invariably	   negative	   to	   IHC.	   In	   3	   cases	   (1	   feline	   and	   2	   canine	  
dermatophytoses)	  there	  was	  focal	  and	  mild	  exocytosis	  of	  neutrophils	  to	  the	  follicular	  
epithelium	  but	  no	  positive	  keratinocytes	  were	  observed.	  Lymphocytic	  mural	  folliculitis	  
in	  dermatophytosis	  was	  not	  associated	  with	  immunoreaction	  in	  the	  epithelium	  in	  any	  
of	  the	  samples.	  
	  
	  
SAMPLES	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  COX-­‐2	  IHC	  
Disease	   Specie	  	   n	   Positive	  samples	  (%)	  
Positivity	  associated	  to	  PMN	  
infiltrate	  (%	  of	  positive	  
samples)	  
Pemphigus	  foliaceous	   F	   2	   2/2	  (100)	   2/2	  (100)	  
Pemphigus	  foliaceous	  	   C	   3	   3/3	  (100)	   3/3	  (100)	  
Pustular	  staphyloccocal	  
infection	  	   F	  
1	   0/1	  (0)	   n/a	  
Pustular	  staphyloccocal	  
infection	   C	  
5	   2/5	  (40)	   2/2	  (100)	  
SHPVD	  without	  pustules	  	   F	   2	   0/2	  (0)	   n/a	  
SHPVD	  without	  pustules	   C	   3	   0/3	  (0)	   n/a	  
Dermatophytosis	   F	   3	   2/3	  (66)	   2/2	  (100)	  
Dermatophytosis	  	   C	   5	   1/5(20)	   1/1	  (100)	  
	  
Table	  3.4:	  Summarize	  of	  results	  of	  COX-­‐2	  immunohistochemistry	  (IHC)	  on	  canine	  and	  
feline	   inflammatory	  dermatoses.	   (C,	  canine;	  F,	   feline;	  n,	  number	  of	  samples;	  n/a,	  not	  
applicable;	   PMN,	   polymorphonuclear;	   SPVD,	   superficial	   hyperplastic	   perivascular	  
dermatitis)	  
	   	  





Figure	   3.5.	   Representative	   photomicrographs	   of	   COX-­‐2	   immunohistochemistry	   of	  
Inflammatory	  dermatoses.	  A:	   feline	  pemphigus	   foliaceous.	  B:	   feline	  dermatophytosis.	  
C:	  canine	  pemphigus	  foliaceous.	  COX-­‐2	  immunoreactivity	  of	  keratinocytes	  is	  associated	  
with	   the	   exocytosis	   of	   polymorphonuclear	   cells	   in	   the	   epidermis	   and	   follicular	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3.2.	  Study	  of	  the	  COX-­‐2/PGE2	  mechanism	  in	  the	  keratinocyte	  inflammatory	  response	  
	  
3.2.1.	  Establishment	  of	  a	  model	  to	  investigate	  the	  biology	  of	  the	  canine	  keratinocyte	  




As	  mentioned	  in	  chapter	  1,	  keratinocytes	  are	  more	  than	  barrier	  cells	  that	  protect	  the	  
body	  from	  the	  external	  environrment	  and	  dehidratation.	  Keratinocytes	  have	  numerous	  
immunologic	   functions	   and	   produce	   numerous	   inflammatory	   and	   immunologic	  
mediators.	  Like	  the	  immune	  systems	  cells,	  keratinocytes	  are	  also	  considered	  immune	  
sentinels	   and	   have	   a	   very	   important	   role	   in	   the	   cutaneous	   inflammatory	   immune	  
response	   (Nestle	  et	   al.	   2009).	   Keratinocytes	   are	   pro-­‐inflammatory	   effector	   cells	   that	  
are	   strategically	   positioned	   at	   the	   outermost	   layer	   of	   the	   body	   to	   react	   in	   a	   timely	  
fashion	   to	   harmful	   insults	   by	   the	   coordinated	   production	   of	   antimicrobial	   peptides,	  
pro-­‐inflammatory	   cytokines	   (including	   type	   I	   interferons,	   interleukins	   (IL)-­‐1β,	   IL-­‐6,	   IL-­‐
10,	   IL-­‐18,	   tumour	  necrosis	   factor),	  eicosandois	   (PGE2	  being	   the	  more	   important)	  and	  
chemokines	  that	  selectively	  attract	  T	  cells,	  neutrophils	  or	  Langerhan	  cells.	  Moreover,	  
keratinocytes	  display	   features	  of	  antigen	  presenting	   cells	  with	   the	  potential	   for	  both	  
antigen-­‐specific	   tolerization	   and	   activation.	   In	   fact,	   keratinocytes	   can	   function	   as	  
instigators	  of	  cutaneous	  inflammation	  (Barker	  et	  al.	  1991,	  Williams	  and	  Kupper	  1996,	  
Steinhoff	  et	  al.	   2001,	  Nestle	  et	  al.	   2009).	  As	  mentioned	   in	   chapter	  1,	  PGE2	  has	  both	  
physiologic	   and	   pathologic	   roles	   in	   the	   skin.	   PGE2	   and	   its	   precursor	   COX-­‐2	   are	  
implicated	   in	   numerous	   cutaneous	   inflammatory	   conditions,	   including	   solar	   induced	  
dermatitis	  and	  irritant	  contact	  dermatitis	  (reviewed	  in	  Müller-­‐Decker	  2011).	  
	  
Identification	   of	   keratinocytes	   as	   instigators	   and	   modulators	   of	   cutaneous	  
inflammation	  has	   lead	   to	   investigate	  on	  different	  drugs	  and	  nutrients	   that	  modulate	  
their	   inflammatory	   response	   (like	  cyclosporine	  A,	  cortisol,	   vitamin	  D,	  polysaccharides	  
and	  grape	  extract	  as	  examples)	  (Tomaino	  et	  al.	  2006,	  Cirillo	  and	  Prime	  2011,	  Dai	  et	  al.	  
2011,	  Hibino	  et	  al.	  2011,	  Miodovnik	  et	  al.	  2012).	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Within	   this	   mark,	   appears	   the	   need	   to	   have	   a	   simple,	   well	   standardized	   and	  
characterized	   in	  vitro	  model	   to	  allow	  assessing	   the	  effects	  of	  different	  agents	  on	   the	  
inflammatory	   response	   of	   canine	   kerationcytes.	   In	   the	   present	  model	  we	   elected	   to	  
assess	  PGE2	  production	  by	  kerationcytes.	  PGE2	  is	  a	  well	  known	  mediator	  of	  cutaneous	  
inflammatory	   and	   neoplastic	   processes	   (Müller-­‐Decker	   2011).	   PGE2	   inhibit	  
keratinocyte	  apoptosis	   in	   inflammatory	  and	  neoplastic	   settings	  and	  produces	  dermal	  
edema	   and	   keratinocyte	   proliferation	   among	   other	   actions.	   A	   part	   of	   the	  
proinflammatory	  properties,	  PGE2	  has	  also	  anti-­‐inflammatory	  activites	  in	  other	  tissues	  
including	   lung,	   liver	   or	   gut	   (reviewed	   in	   Tilley	   et	   al.	   2001).	   However,	   the	   anti-­‐
inflammatory	   properties	   of	   PGE2	   in	   the	   skin,	   if	   present,	   remain	   to	   be	   clarified	   and	  
explained.	  
	  
Against	  this	  background,	  we	  decided	  to	  develop	  a	  simple	  model	  of	  canine	  keratinocyte	  
culture	  and	  its	  PGE2	  production.	  
	  
In	  the	  late	  1990s	  the	  CPEK	  cell	  line	  was	  developed	  by	  CELLnTEC	  laboratories	  (Advanced	  
Cell	   Systems,	   Bern,	   Switzerland).	   CPEK	   is	   a	   spontaneously	   immortalised	   kerationcyte	  
cell	  line	  derived	  from	  the	  epidermis	  of	  an	  adult	  Beagle	  dog.	  To	  date,	  this	  keratinocyte	  
cell	   line	   is	   the	  only	   one	   available	   for	   veterinary	   research.	   It	   has	   been	  phenotypically	  
characterized	  and	  used	  in	  three	  different	  in	  vitro	  studies	  (Shibata	  et	  al.	  2008,	  Maeda	  et	  
al.	  2009,	  Shibata	  et	  al.	  2011a,	  Shibata	  et	  al.	  2011b).	  We	  decided	   to	  use	   this	   cell	   line	  
and	  PGE2	  concentration	  in	  the	  supernatant	  as	  a	  marker	  of	  activation	  and	  production	  of	  
inflammatory	  mediators.	  	  
	  
However,	  the	  use	  of	  this	  cell	  line	  presented	  two	  limitations:	  1)	  Being	  an	  immortalised	  
cell	  line,	  may	  present	  some	  differences	  with	  primary	  keratinocytes	  and	  2)	  It	  would	  not	  
allow	  to	  perform	   intervetions	  and	   in	  vivo/in	  vitro	   studies	   in	   living	  dogs.	  For	  example,	  
working	  with	  the	  cell	  line	  would	  not	  allow	  performing	  studies	  to	  assess	  the	  response	  of	  
keratinocytes	   after	   a	   dietary	   or	   pharmacologic	   interventions	   to	   the	   living	   animal.	   In	  
consequence,	  we	  decided	   to	   develop	   also	   a	  more	   complex	  model	   to	  work	   also	  with	  
primary	  cultures	  of	  canine	  kerationcytes.	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3.2.1.2.	  Materials	  and	  Methods	  
	  
a.	  	  Culture	  and	  maintenance	  of	  the	  CPEK	  cell	  line.	  
	  
CPEK	   frozen	   cells	   and	   the	   CnT-­‐09	   kerationcyte	   culture	   medium	   were	   purchased	   at	  
CELLnTEC	   Advanced	   Cell	   Systems	   (Bern,	   Switzerland).	   The	   CnT-­‐09	   medium	   is	   a	  
keratinocyte	   growth	   medium	   developed	   by	   CELLnTEC	   Advanced	   Cell	   Systems.	   It	   is	  
composed	  by	  medium	  with	  bovine	  fetal	  calf	  serum,	  growth	  factors	  and	  has	  low	  calcium	  
content.	  	  
	  
Immediately	   upon	   reception	   the	   frozen	   1mL	   vial	   was	   transferred	   to	   liquid	   nitrogen	  
storage	  tank	  until	  thawed.	  Before	  thawing	  the	  cells,	  30	  mL	  of	  CnT-­‐09	  medium	  divided	  
into	  two	  culture	  flasks	  of	  75	  cm2	  (T-­‐75)	  were	  equilibrated	  for	  30	  minutes	  in	  a	  5%	  CO2	  
and	  37ºC	  incubator.	  This	  process	  pre-­‐warms	  the	  medium	  and	  adjusts	  its	  physiological	  
pH.	   Frozen	   cells	   were	   thawed	   with	   gently	   swirling	   in	   water	   bath	   at	   37ºC	   during	   90	  
seconds	   until	   just	   melted	   while	   still	   a	   small	   amount	   of	   ice	   was	   left.	   Cells	   were	  
resuspended	   in	   the	   cryovial	   by	   pipetting	   up	   and	   down	   three	   times	   and	   500	   µL	  
transferred	  to	  each	  T-­‐75	  cell	  culture	  flask	  with	  the	  equilibrated	  CnT-­‐09	  medium.	  After	  
24	   hours	   the	   medium	   was	   changed	   to	   remove	   the	   residual	   DMSO	   of	   the	   freezing	  
medium.	  Seventy-­‐two	  hours	  after	  thawing,	  the	  cells	  were	  90%	  confluency.	  	  
	  
At	  this	  stage	  the	  first	  passaging	  was	  carried	  on.	  CnT-­‐09	  medium	  was	  aspirated	  from	  the	  
T-­‐75	   culture	   flasks.	   The	   cells	   were	   washed	   with	   8	   mL	   of	   PBS	   (without	   calcium	   and	  
magnesium)	  at	  37ºC.	  Five	  mL	  of	  detachment	  enzyme	  (TrypLE	  Express,	  Gibco,	  Rockville,	  
MD,	  USA)	  were	  added	  to	  the	  cells	  and	  incubated	  at	  37ºC	  until	  cells	  were	  rounded	  and	  
started	  to	  detach	  (10	  minutes).	  The	  culture	  flask	  was	  tapped	  and	  under	  the	  microscope	  
it	   was	   checked	   that	   cells	   had	   been	   detached.	   In	   order	   to	   inhibit	   the	   detachment	  
enzyme,	  8	  mL	  of	  CnT-­‐09	  medium	  was	  added	  to	  the	  cell	  suspension.	  Cell	  suspensions	  of	  
the	  two	  T-­‐75	  culture	  flasks	  were	  transferred	  to	  a	  centrifugation	  tube	  and	  centrifuged	  5	  
minutes	  at	  1200	  rpm	  at	  room	  temperature.	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The	  supernatant	  was	  aspirated	  and	  the	  pellet	  resuspended	  in	  2	  mL	  of	  CnT-­‐09.	  The	  cells	  
were	  placed	  on	   ice	  and	  a	  20	  µL	  sample	   taken	  to	  perform	  cell	   count	  with	   tripan	  blue	  
dye.	   Cell	   counting	   yielded	   10*106	   cells/mL	   approximately.	   For	   passaging,	   cell	  
concentration	  was	  adjusted	  to	  0.8*106	  cells/mL	  and	  1mL/culture	  flask	  was	  seeded	  into	  
four	   T-­‐75	   culture	   flasks.	   For	   freezing,	   cell	   concentration	   was	   adjusted	   to	   2	   x	   106	  
cells/mL	  with	  cold	  (4ºC)	  CnT-­‐09	  medium.	  The	  same	  amount	  of	  freezing	  medium	  (CnT-­‐
CRYO-­‐50,	  CELLnTEC	  Advanced	  Cell	  Systems,	  Bern,	  Switzerland)	  was	  drop-­‐wisely	  added	  
while	  gently	  swirling	  the	  tube.	  One	  mL	  of	  the	  suspension	  was	  added	  to	  labelled,	  sterile	  
and	  4ºC	  pre-­‐cooled	  cryotubes.	  Cryotubes	  were	  immediately	  transferred	  to	  a	  Nalgene®	  
Cryo	  1ºC-­‐freezing	  container	  “Mr.Frosty”	  pre-­‐cooled	  at	  4ºC	  and	  the	  “Mr.Frosty”	  placed	  
at	   -­‐80ºC	   overnight.	   Afterwards,	   the	   cryotubes	  were	   transferred	   from	   -­‐80ºC	   to	   liquid	  
nitrogen	  for	  long-­‐term	  storage.	  	  
	  
These	   procedures	   (passaging	   and	   freezing)	   were	   repeated	   eight	   times	   during	   the	  
following	  two	  months.	  This	  allowed	  us	  to	  create	  a	  bank	  of	  frozen	  CPEK	  cells	  stored	  in	  a	  
liquid	  nitrogen	  tank.	  
	  
	  
b.	  Isolation	  and	  culture	  of	  canine	  primary	  keratinocytes:	  
	  
Excission	  of	  cutaneous	  tissue:	  
	  
Cutaneous	  tissue	  was	  obtained	  from	  canine	  patients	  undergoing	  surgery	  under	  general	  
anesthesia	   or	   from	   canine	   patients	   recently	   euthanasied	   for	   humane	   reasons.	   In	   all	  
cases	   a	   previous	   signed	   consent	   form	   of	   their	   owners	   was	   obtained.	   The	   hair	   was	  
clipped	   and	   the	   surgical	   site	   prepared	   aseptically.	   	   A	   skin	   square	   of	   6x3	   cm2	   was	  
excissed	   according	   to	   standard	   surgical	   methods.	   Immediately	   after	   excision,	   the	  
cutaneous	   tissue	   was	   placed	   in	   DMEM	   culture	  medium	   (Gibco,	   Rockville,	  MD,	   USA)	  
containg	   1%	   Penicillin-­‐streptomycin	   (Pen	   Strep,	   Gibco,	   Rockville,	   MD,	   USA)	   and	  
transferred	  to	  the	  cell	  culture	  laboratory.	  Time	  from	  excision	  to	  further	  processing	  of	  
the	  cells	  was	  from	  15	  to	  60	  minutes.	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Isolation	  of	  primary	  canine	  keratinocytes:	  
	  
Under	   aseptic	   conditions,	   skin	   samples	  were	   cleaned	  with	   70%	  etanol	   bath	  during	  8	  
minutes	   followed	  with	  a	  povidone-­‐iodine	  bath	  during	  8	  minutes	  before	   starting	  with	  
cell	   isolation.	  Fat	   tissue	  and	  blood	  vessels	  were	   removed	   from	  the	   skin	  using	  curved	  
scissors	   and	   then	   samples	   were	   washed	   with	   PBS	   in	   Petri	   dishes	   (3	   washes	   of	   10	  
minutes	  each	  one)	  and	  then	  cut	  into	  small	  fragments	  (0.5	  cm2).	  Fragments	  were	  placed	  
in	   a	   sterile	   recipient	   with	   a	  magnet	   inside	   and	   25	  mL	   of	   0.05%	   trypsin-­‐0.02%	   EDTA	  
(Gibco,	  Rockville,	  MD,	  USA).	  After	  45	  minutes	  of	  incubation	  at	  37ºC	  under	  agitation	  25	  
mL	  of	  DMEM	   (Gibco,	   Rockville,	  MD,	  USA)	  were	   added	   to	   the	   tissue	   suspension.	   The	  
supernatant	  was	  collected	  and	  spun	  at	  1200	  rpm	  during	  10	  minutes.	  The	  supernatant	  
was	   discharged	   and	   the	   pellet	  was	   re-­‐suspended	  with	   5	  mL	   of	   cell	   culture	  medium.	  
Culture	  medium	  was	   composed	   of	   DMEM/F12	   (3:1)	  with	   10%	   fetal	   calf	   serum	   (FCS)	  
(Gibco,	  Rockville,	  MD,	  USA),	  10-­‐6	  M	  hydrocortisone,	  10-­‐6	  M	   isoproterenol	  and	  10-­‐7	  M	  
insulin	   (Sigma,	  St.	  Louis,	  MO,	  USA).	  The	  5	  mL	  suspension	  of	  cell	   culture	  medium	  and	  
cells	  was	  then	  transferred	  to	  a	  25	  cm2	  (T-­‐25)	  cell	  culture	  flask.	  
Fresh	   medium	   was	   added	   to	   cells	   after	   discharging	   the	   previous	   one	   every	   48-­‐72	  
hours.	   Twenty-­‐four	   hours	   after	   the	   seeding	   of	   the	   cells	   few	   cells	   were	   observed	  
attached	   to	   the	   base	   of	   the	   culture	   flask.	   Seventy-­‐two	   hours	   later,	   islands	   of	  
keratinocytes	   and	   fibroblasts	  were	   observed.	   At	   this	   point,	   epidermal	   growth	   factor	  
(EGF)	  at	  10	  ng/mL	  was	  added	  to	  the	  medium	  to	  stimulate	  the	  growth	  of	  keratinocytes	  
in	  front	  of	  fibroblasts.	  	  
Seventy-­‐two	  hours	  later,	  the	  keratinocytes	  were	  the	  predominant	  cell	  and	  few	  islands	  
of	   fibroblasts	   could	   be	   observed.	   At	   this	   point	   rapid	   tripsinization	   of	   cells	   was	  
performed	   in	   order	   to	   detach	   fibroblast	   (which	   are	  more	  weakly	   attach	   to	   the	   flask	  
base	   than	  keratinocytes)	  and	  keep	  the	  keratinocytes	  attached	  to	   the	   flask	  base.	  Two	  
washes	   of	   the	   cells	   with	   PBS	   at	   37ºC	   was	   performed	   before	   adding	   4	  mL	   of	   0.05%	  
trypsin-­‐0.02%	  EDTA	  (Gibco,	  Rockville,	  MD,	  USA)	  followed	  by	  3	  minutes	  of	  incubation	  at	  
37ºC.	  Trypsin-­‐EDTA	  was	  inactivated	  by	  adding	  culture	  medium	  to	  the	  cell	  culture	  flask.	  
Detached	  cells	  and	  medium	  were	  aspirated	  and	  discharged.	  New	  culture	  medium	  with	  
EGF	   (at	   10	   ng/mL)	   or	   without	   EGF	   depending	   on	   the	   need	   of	   rapid	   growth	   of	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keratinocytes	  was	  added	  to	  the	  flask.	  In	  24	  hours	  in	  case	  EGF	  presence	  or	  after	  48-­‐72	  
hours	   if	  EGF	  was	  not	  added	  to	  the	  medium,	  confluent	  cultures	  of	  keratinocytes	  were	  
obtained	  (figure	  2).	  Cell	  density	  in	  a	  25	  cm2	  cell	  culture	  flask	  at	  this	  stage	  was	  around	  
4*106	   cells/flask.	   Depending	   on	   each	   different	   isolation	   protocol,	   cells	   could	   be	  
passaged	  between	  4	  or	  7	  times	  without	  losing	  their	  proliferation	  potential	  and	  keeping	  
their	  normal	  kerationocyte	  phenotypic	  characteristics.	  
This	  method	  proved	   to	  be	  a	  good,	  easy	  and	  cheap	  method	   to	  obtain	  primary	  canine	  
keratinocytes	  for	  in	  vitro	  studies.	  Other	  less	  invasive	  methods	  were	  tried	  (like	  trying	  to	  
obtain	   hair	   follicle	   keratinocytes	   from	   epilated	   hairs	   or	   superficial	   skin	   scrapings)	  
without	  success.	  Basal	  keratinocytes	  are	  the	  ones	  with	  greater	  proliferative	  potential	  
within	  the	  epidermis	  and	  therefore,	  are	  the	  cells	   that	  have	  to	  be	   isolated	  for	  culture	  
purposes.	  To	  obtain	  basal	  keratinocytes	  full	  thickness	  skin	  samples	  with	  epidermis	  and	  
dermis	  are	  needed.	  The	  reason	  why	  the	   less	   invasive	  methods	  did	  not	  prove	  to	  be	  a	  
good	   source	   of	   keratinocytes	   for	   in	   vitro	   culture	   was	   that	   they	   yielded	   superficial	  
keratinocytes	  instead	  of	  basal	  keratinocytes.	  	  
	  
c.	   Establishment	   of	   a	   method	   to	   measure	   PGE2	   in	   keratinocyte	   cultures	  
supernatants:	  
	  
Seeding	  of	  cells	  in	  24	  wells	  plaques	  
	  
For	   primary	   kerationcytes,	   the	   cell	   seeding	   density	   for	   24	  wells	   plaques	  was	   60,000	  
cells/well	  and	  needed	  between	  5	  and	  10	  days	  to	  be	  80%	  confluent.	  On	  the	  contrary,	  
due	  to	  its	  greater	  proliferation	  potential,	  the	  amount	  of	  CPEK	  cells	  needed	  was	  35,000	  
cells/well	  and	  in	  48	  hours	  were	  80-­‐90%	  confluent.	  	  
	  
Measurement	  of	  PGE2	  concentration	  in	  cell	  culture	  supernatants	  
	  
Two	   commercial	   enzyme	   linked	   immunosorben	   assay	   (ELISA)	   kits	   were	   tried	   with	  
similar	   results:	   one	   from	   R&D	   Systems	   (PGE2	   Assay	   –item	   number	   KGE004-­‐,	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Minneapolis,	  MN,	  USA)	  and	  one	  from	  Cayman	  (PGE2	  EIA	  Kit-­‐Monoclonal	  –item	  number	  
514010-­‐,	  Cayman	  Chemical	  Company,	  Ann	  Arbor,	  MI,	  USA).	  	  
	  
The	  final	  protocol	  to	  measure	  PGE2	  in	  keratinocytes	  supernatants	  was	  the	  following:	  
	  
When	   cells	   in	   wells	   were	   at	   80%	   confluency,	   the	   medium	   was	   replaced	   by	   500	   µL	  
identical	  medium	   supplemented	  with	   10	  µM	  AA	   (Sigma-­‐Aldrich,	   St	   Louis,	  MO,	  USA).	  
Cells	  with	  the	  supplemented	  medium	  were	  incubated	  15	  minutes	  at	  37ºC	  and	  5%	  CO2	  .	  
Afterwards,	  the	  supernatants	  were	  harvested	  and	  centrifuged	  at	  1300	  rpm	  during	  10	  
minutes.	  Samples	  were	  stored	  at	  -­‐80ºC	  until	  processed	  with	  one	  of	  the	  two	  ELISA	  kits	  
following	  the	  manufacturer	  instructions.	  
	  
Celluar	  kinetics-­‐PGE2	  production	  study	  with	  CPEK	  cells:	  
	  
PGE2	   has	   physiological	   roles	   on	   keratinocytes,	   mainly	   on	   its	   proliferation	   and	  
maturation.	  For	  this	  reason,	  a	  kinetic	  study	  on	  cell	  proliferation	  and	  PGE2	  production	  
was	   performed	   using	   the	   CPEK	   cells.	  We	   did	   not	   use	   primary	   kerationcytes	   for	   this	  
study	   because	   working	   with	   primary	   cells	   was	   dificults.	   The	   isolation	   of	   primary	  
kerationcytes	  was	  well	  standardized,	  but	  their	  proliferation	  was	  very	  different	  among	  
isolates,	  making	  kinetics	  studies	  very	  difficult.	  This	   is	  why	  we	  kept	  working	  using	   the	  
only	   the	   CPEK	   keratinocytes.	   Working	   with	   these	   cells	   was	   easier	   since	   their	  
proliferation	  was	  consistent.	  PGE2	  production	  was	  measured	  (as	  explained	  above)	  by	  
triplicate	  on	  CPEK	   cells	   supernatants	   at	   50,	   60,	   74	   and	  97	  hours	   post-­‐seeding	   times.	  
After	   collecting	   the	   supernatants	   for	   PGE2	   concentration	   dermatination,	   cells	   were	  
washed	   with	   PBS	   -­‐/-­‐	   pre-­‐warmed	   at	   37ºC	   and	   500	   µL	   of	   TrypLE	   Express	   (Gibco,	  
Rockville,	  MD,	  USA)	  added.	  The	  cells	  were	   incubated	  during	  10	  minutes	  at	  37ºC	  until	  
detached	   and	   TrypLE	   Express	   was	   inactivated	   by	   adding	   700	  µL	   of	   CnT-­‐09	  medium.	  
Detached	  cells	  and	  medium	  were	  aspirated	  and	  placed	  into	  an	  sterile	  1.8	  mL	  tube	  and	  
20	  µL	  sample	  taken	  to	  perform	  cell	  count	  with	  the	  tripan	  blue	  exclusion	  dye	  test.	  This	  
processs	  was	  repeated	  at	  50,	  60,	  74	  and	  97	  hours	  post-­‐seeding	  time.	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3.2.1.3.	  Results:	  
	  
PGE2	  production	  by	  primary	  keratinocytes	  and	  CPEK	  cells	  at	  80%	  confluency	  
	  
The	   median	   production	   of	   PGE2	   production	   by	   primary	   keratinocytes	   at	   80%	  
confluency	  was	  6600	  pg/mL	  per	  well.	  The	  results	  were	  similar	  that	  the	  production	  of	  
CPEK	  cell	  line,	  which	  was	  7100	  pg/mL.	  
	  
CPEK	  cellular	  kinetics	  
	  
As	  explained	  before,	  cell	  confluency	  to	  80%	  was	  reached	  at	  48-­‐50	  hours	  post	  seeding	  
time.	  The	  number	  of	  cells	  between	  50	  and	  74	  hours	  was	  between	  105,000	  and	  450,000	  
cells,	  showing	  an	  exponential	  growth	  that	  reached	  around	  1*106	  cells	  at	  97	  hours	  post-­‐
seeding	   time	   (Fig.	   3.6).	   Between	  50	   and	   74	  hours,	   there	  was	   no	  mortality	   but	   at	   97	  
hours,	   when	   cell	   confluency	   was	   100%	   with	   focuses	   of	   cornification	   (Fig.3.7),	   cells	  
began	  to	  die	  (table	  3.5).	  	  
	  
PGE2	  production	  by	  CPEK	  cells	  in	  relation	  to	  cell	  number:	  
	  
The	   concentration	   of	   PGE2	   in	   the	   cell	   culture	  medium	   remained	   constant	   over	   time	  
with	   cell	   confluency	   between	   80	   and	   100%	   corresponding	   to	   48	   to	   72	   hours	   period	  
after	  seeding;	  however,	  at	  96	  hours,	  when	  cell	  confluency	  was	  over	  100%	  with	  focuses	  
of	   cornifcation,	   PGE2	   concetration	   in	   the	   cell	   culture	   medium	   decreased	   abruptly	  
(table	  3.5	  and	  figure	  3.8).	  Accordingly,	  when	  the	  concentration	  of	  PGE2	  was	  calculted	  
per	   viable	   cells	   or	   total	   cells,	   the	   concentration	   of	   PGE2	   per	   cell	   declined	   as	   the	  
number	  of	  cells	   raised	   (figures	  3.6	  and	  3.9).	  Because	  cell	  mortality	  was	  very	   low	  and	  
there	  was	  almost	  no	  difference	  between	  total	  cells	  and	  viable	  cells,	  the	  values	  of	  PGE2	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Figure	  3.6.	  Number	  of	  viable	  CPEK	  cells	  at	  different	  post-­‐seeding	  times	  (48	  to	  96	  hours)	  
	  
	  
	  Figure	  3.7.	  CPEK	  cells	  at	  97	  hours	  post-­‐seeding	  time.	  One	  hundred	  per	  cent	  confluency	  
is	  observed	  with	  focuses	  of	  cornification.	  Optical	  microscopy	  (40x).	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Once	   stablished	   the	  method	   to	  measure	   PGE2	   in	   canine	   kerationcytes	   cultures	   and	  
after	   knowing	   the	   kinetics	   of	   PGE2	   production	   in	   non-­‐stimulated	   cells,	   we	   aimed	   to	  
study	   the	   production	   of	   PGE2	   by	   kerationcytes	   stimulated	   with	   different	  
concentrations	   of	   lipopolysaccharide	   (LPS)	   (first	   part	   of	   the	   experiment)	   and	   white	  
blood	   cells	   (WBC)	   (second	  part	  of	   the	  experiment).	  Being	   LPS	  a	  potent	   stimulator	  of	  
innate	  immune	  response	  and	  because	  kerationcytes	  have	  demonstrated	  to	  respond	  to	  
it	  (Chadebech	  et	  al.	  2003,	  Pivarsi	  et	  al.	  2003,	  Kobayashi	  et	  al.	  2005,	  Köllisch	  et	  al.	  2005,	  
Baümer	   and	   Kietamann	   2007,	   Hirasawa	   et	   al.	   2009),	   we	   wanted	   to	   know	   if	   canine	  
kerationcytes	  responded	  to	  LPS	  by	  secreting	  PGE2	  as	  had	  preliminary	  been	  shown	  by	  
Baümer	   and	   Kietamann	   (2007).	   Moreover,	   PGE2	   secretion	   in	   response	   to	   LPS	  
stimulation	  in	  keratinocytes,	  would	  allow	  us	  to	  compare	  it	  with	  stimulation	  with	  canine	  
WBC	   containing	  more	   than	   90%	   of	   neutrophils.	   Results	   of	   experiment	   1	   had	   shown	  
that	   keratinocytes	   expressed	   COX-­‐2	   when	   a	   granulocytic	   infiltrate	   was	   present.	  
Because	   PGE2	   is	   the	   main	   COX-­‐2	   metabolite	   in	   the	   skin,	   our	   hypothesis	   was	   that	  
incubation	  of	  keratinocytes	  with	  neutrophils	  would	  stimulate	  the	  expression	  of	  COX-­‐2	  
and	  secretion	  of	  PGE2	  in	  the	  culture	  medium.	  	  
	  
3.2.2.2.	  Materials	  and	  Methods	  
	  
CPEK	  keratinocyte	  culture:	  
	  
The	   canine	   keratinocyte	   cell	   line	   CPEK	   was	   used	   in	   this	   experiment	   (CELLnTEC	  
Advanced	   Cell	   Sytems	   CA,	   Bern,	   Switzerland).	   CPEK	   cells	   were	   seeded	   into	   24	   well	  
plates	   (35,000	   cell/well)	   and	   cultured	   in	   CNT-­‐09	   medium	   (CELLnTEC)	   until	   80%	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Stimulation	  of	  cultured	  CPEK	  keratinocytes	  with	  3	  different	  concentrations	  of	  LPS:	  
	  
Keratinocytes	  were	   incubated	  only	  with	   CNT-­‐09	  medium	   (controls)	   and	  with	   CNT-­‐09	  
with	  100,	  10	  or	  1	  µg/mL	  of	  lipopolysaccharide	  (LPS,	  Escherichia	  coli;	  0111;	  B4,	  Sigma)	  
and	   incubated	   during	   1,	   6,	   24	   and	   48	   hours.	   After	   each	   incubation	   time	   the	   cell	  
supernatant	  was	   discharged	   and	   fresh	  medium	   supplemented	  with	   AA	   (10	  µM)	  was	  
added	   to	   all	   keratinocytes	   cultures.	   After	   an	   additional	   15	   minutes	   at	   37ºC,	   cells	  
supernatants	  were	  collected	  and	  stored	  at	  -­‐80ºC	  until	  PGE2	  measurament	  was	  carried	  
on.	  
	  
Isolation	  of	  neutrophils	  -­‐white	  blood	  cells	  (WBC)-­‐:	  
	  
Canine	   blood	   from	   a	   healthy	   donor	   was	   collected	   by	   yugular	   venipuncture	   into	   an	  
EDTA	  treated	  collecting	  tube,	  maintained	  in	  ice	  and	  processed	  within	  30	  minutes.	  Red	  
blood	  cell	   lysing	  buffer	   (ACK	  Lysing	  Buffer,	   Lonza	  Group	  Ltd.,	  Basel,	  Switzerland)	  was	  
added	   at	   a	   ratio	   of	   1:2	   (blood:	   buffer	   lysis)	   and	   incubated	   5	   minutes	   at	   room	  
temperature.	  Afterwards,	  the	  lysed	  blood	  sample	  was	  centrifuged	  at	  1200	  rpm	  during	  
8	  minutes	  and	  the	  supernantant	  discharged.	  The	  buffy	  coat	  was	  carefully	  resuspended	  
in	   CNT-­‐09.	   The	   cell	   suspension	   differential	   count	   yielded	   94%	   of	   neutrophils,	   3%	   of	  
monocytes,	  1%	  of	  lymphocytes	  and	  1%	  of	  eosinophils.	  Viability	  of	  the	  cells,	  which	  were	  
in	   a	   concentration	   of	   2.435	   x	   106	   cells/mL,	  was	   greater	   than	   99%	   as	   determined	   by	  
tripan	  blue	  dye	  exclusion.	  The	  whole	  cell	  isolation	  procedure	  was	  carried	  out	  sterilely	  
at	  room	  temperature.	  	  
	  
Stimulation	  of	  CPEK	  keratinocytes	  with	  LPS	  and	  neutrophils:	  
	  
Results	   of	   the	   previous	   experiment	   stimulating	   kerationocytes	   with	   different	  
concentrations	  of	  LPS	  showed	  that	  the	  higher	  concentration	  of	  LPS	  used	  to	  stimulate	  
keratinocytes	  was	  necessary	   to	  obtain	  a	   slight	   increase	   in	  PGE2	  concentration	   in	   the	  
cells	   supernatant	   and	   this	   concentration	   of	   LPS	   did	   not	   cause	   mortality	   among	  
keratinocytes	   (see	   results	   in	   section	   3.2.2.3).	   Because	   that,	   we	   elected	   to	   use	   100	  
µg/mL	  of	  LPS	  in	  this	  experiment.	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CPEK	  keratinocytes	  were	  incubated	  with	  CnT-­‐09	  medium	  alone	  (controls),	  with	  CnT-­‐09	  
medium	  with	  100	  µg/mL	  of	  LPS	  (LPS,	  Escherichia	  coli;	  0111;	  B4,	  Sigma-­‐Adrich)	  or	  with	  
CnT-­‐09	  medium	  and	  WBC	  suspension	  (with	  94%	  of	  neutrophils).	  WBC	  was	  added	  at	  a	  
concentration	   of	   1.2175	   x	   106	   cells/well.	   Incubation	   times	  were	   2,	   24	   and	   48	   hours.	  
After	   these	   times,	   the	   keratinocytes	   incubated	   with	   WBC	   were	   washed	   twice	   with	  
phosphate	   buffered	   saline	   free	   of	   magnesium	   and	   calcium	   (PBS	   -­‐/-­‐)	   in	   order	   to	  
eliminate	  all	  WBC.	  Microscopic	  inspection	  of	  the	  wells	  confirmed	  that	  the	  vast	  majority	  
of	  WBC	  had	  been	  eliminated	  after	  the	  second	  wash	  with	  PBS-­‐/-­‐	  (see	  figure	  3.10).	  CNT-­‐
09	  and	  CNT-­‐09	  with	  LPS	  was	  discharged	  from	  control	  and	  LPS	  stimulated	  keratinocytes.	  
Fresh	   CNT-­‐09	  medium	   supplemented	  with	   arachidoic	   acid	   (10	  µM)	  was	   added	   to	   all	  
keratinocytes	  cultures.	  After	  an	  additional	  15	  minutes	  at	  37ºC,	  cells	  supernatants	  were	  
collected	  and	  stored	  at	  -­‐80ºC	  until	  PGE2	  measurament	  was	  carried	  on.	  
	  
Measurement	  of	  PGE2:	  
	  
PGE2	  concentration	  was	  determined	  in	  culture	  supernatants	  using	  a	  non-­‐radiocactive	  
enzyme-­‐linked	  immuno-­‐assay	  (EIA)	  from	  Cayman	  Chemical	  (Ann	  Arbor,	  MI,	  USA).	  The	  
supernatants	   were	   diluted	   1:50	   in	   	   EIA	   Buffer,	   PGE2	   determined	   according	   to	   the	  
manufacturer’s	  protocol	  and	  results	  were	  expressed	  in	  pg/mL	  PGE2.	  Cross-­‐reactivities	  
were	   <0.04%	   for	   6-­‐keto	   PGF1,	   and	   <0.01%	   for	   LTB4,	   TXB2,	   and	   AA.	   Three	  
determinations	  for	  each	  variable	  was	  done	  and	  each	  one	  was	  read	  twice	  with	  the	  EIA.	  
The	   differences	   in	   PGE2	   concentration	   in	   the	   cell	   supernatants,	   cell	   counts	   and	   cell	  
mortality	  were	  evaluated	  using	  non-­‐parametric	  tests	  (Mann-­‐Whitney	  U	  test),	  with	  P	  <	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Figure	   3.10:	   A:	   control	  CPEK	   keratinocytes	   incubated	  with	  CNT-­‐09.	  B,	  C	   and	  D:	  CPEK	  
keratinocytes	  incubated	  2	  hours	  with	  white	  blood	  cells	  (94%	  neutrophils).	  B	  numerous	  
round	   cells	   are	   observed	   on	   the	   keratinocyte	   underlying	   monolayer	   before	   PBS	  
washes.	  C:	  after	  the	  first	  PBS	  wash,	  much	  less	  WBC	  are	  observed	  on	  the	  keratinocyte	  
monolayer.	   D:	   keratinocyte	   monolayer	   after	   the	   second	   PBS	   wash:	   no	   WBC	   are	  
detected.	  Optical	  microscopy	  (40x).	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3.2.2.3.	  Results	  
	  
PGE2	   production	   by	   keratinocytes	   (CPEK)	   incubated	   with	   LPS	   at	   different	  
concentrations:	  
	  
There	   were	   no	   differences	   among	   the	   concentrations	   of	   PGE2	   in	   the	   cell	   culture	  
medium	  of	  keratinocytes	   incubated	  with	  LPS	  at	  100,	  10	  and	  1	  µg/mL	  or	  without	  LPS	  
(control	  cells)	  (Fig.	  3.11	  and	  table	  3.6).	  The	  concentration	  of	  PGE2	  remained	  the	  same	  
for	  the	  4	  groups	  of	  cells	  until	  24	  hours	  post-­‐stimulation	  (72	  hours	  post	  seeding).	  After	  
that	   time,	   at	   48	   hours	   post-­‐stimulation	   (96	   hours	   post	   seeding),	   some	   of	   the	   cells	  
incubated	  with	  LPS	  at	  100	  µg/mL	  produced	  more	  PGE2	  (Fig.	  3.11	  and	  table	  3.5).	  The	  
curve	  of	  PGE2	  production	  per	  viable	  cell	  was	  the	  same	  as	  for	  the	  previous	  experiment	  
with	  a	  general	  proportional	  reduction	  of	  PGE2	  as	  the	  cell	  density	  increased.	  However,	  
at	   48	   hours	   post-­‐stimulation	   (96	   hours	   post	   seeding),	   two	   samples	   (one	   of	  
keratinocytes	  incubated	  with	  100	  µg/mL	  and	  one	  of	  control	  cells)	  produced	  more	  PGE2	  
(Fig.	   3.12).	   The	   cellular	   proliferation	   remained	  with	   the	   same	   exponential	   growth	   as	  
with	   keratinocytes	   (Fig.	   3.13)	   and	   stabilized	   at	   24hours	   post-­‐stimulation	   (72	   hours	  
post-­‐seeding);	   however,	   the	   cell	   incubated	   with	   different	   concentrations	   of	   LPS	  
prolifered	   more	   than	   control	   cells	   (keratinocytes	   without	   LPS)	   (Fig.	   3.13).	   The	  
proliferation	  curves	  of	  total	  cells	  and	  viable	  cells	  were	  very	  similar;	  indicating	  that	  cells	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Figure	  3.11:	  PGE2	  production	  by	  CPEK	  keratinocytes	  incubated	  at	  different	  
concentrations	  of	  LPS	  (LPS	  100,	  LPS	  10	  and	  LPS	  1	  corresponding	  to	  LPS	  at	  	  100,	  10	  and	  





Figure	  3.12:	  Production	  of	  PGE2	  per	  viable	  CPEK	  keratinocyte	  incubated	  at	  different	  
concentrations	  of	  LPS	  (LPS	  100,	  LPS	  10	  and	  LPS	  1	  corresponding	  to	  LPS	  at	  	  100,	  10	  and	  
1	  µg/mL)	  or	  without	  LPS	  (LPS	  0).	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Table	  3.6:	  CPEK	  keratinocyte	  production	  of	  PGE2	  depending	  on	  LPS	  incubation	  at	  
different	  concentrations	  

































49	   1	   80 280000	   230.000	   9270	   0,04030	  
49	   1	   80 255000	   235000	   10860	   0,04621	  
3	   10	   49	   1	   80 185000	   180000	   11760	   0,06533	  
4 10	   49	   1 80 170000 165000 10110 0,06127 





49	   1	   80 185000	   180000	   9390	   0,05216	  
49	   1	   80 155000	   145000	   9510	   0,06558	  
8	   0	   49	   1	   80 120000	   120000	   8730	   0,07275	  
9	   100	   54	   1	   80 250000	   230000	   9210	   0,03684	  
10	   100	   54	   6	   80-90 215000	   215000	   6840	   0,03181	  
11	   10	   54	   6	   80-90 210000	   205000	   10950	   0,05341	  
12	   10	   54	   6	   80-90 335000	   310000	   8880	   0,02864	  
13 1	   54	   6	   80-90 245000 230000 7710 0,03352 
14 1	   54	   6	   80-90 190000 170000 6600 0,03882 
15 0	   54	   6	   80-90 165000 155000 8190 0,05283 
16 0	   54	   6	   80-90 215000 200000 8520 0,04260 
17 100	   72	   24	   100 730000 715000 8820 0,01233 
18 100	   72	   24	   100 725000 720000 16920 0,02350 
19 10	   72	   24	   100 580000 565000 13560 0,02400 
20 10	   72	   24	   100 620000 530000 12600 0,02377 
21 1	   72	   24	   100 640000 605000 9510 0,01571 
22 1	   72	   24	   100 610000 540000 8580 0,01588 
23 0	   72	   24	   100 535000 335000 7560 0,02256 
24 0	   72	   24	   100 450000 360000 13200 0,03666 
25 100	   96	   48	   100  910000 675000 17370 0,02573 
26 100	   96	   48	   100  900000 780000 67230 0,08619 
27 10	   96	   48	   100  645000 590000 9720 0,01647 
28 10	   96	   48	   100  765000 660000 14280 0,02163 
29 1	   96	   48	   100  765000 645000 16320 0,02530 
30 1	   96	   48	   100  710000 605000 25140 0,04155 
31 0	   96	   48	   100  440000 390000 15060 0,03861 
32 0	   96	   48	   100  415000 405000 36810 0,09089 
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Figure	  3.13:	  	  Number	  of	  total	  CPEK	  cells	  at	  different	  post-­‐stimulation	  times	  depending	  
on	  LPS	  concentration	  in	  the	  cell	  medium.	  LPS	  100,	  LPS	  10	  and	  LPS	  1	  corresponding	  to	  






Figure	   3.14:	   Number	   of	   viable	   	   CPEK	   cells	   at	   different	   post-­‐stimulation	   times	  
depending	   on	   LPS	   concentration	   in	   the	   cell	   medium.	   LPS	   100,	   LPS	   10	   and	   LPS	   1	  
corresponding	   to	  LPS	  at	   	  100,	  10	  and	  1	  µg/mL)	  and	  LPS	  0	  as	  cells	   incubated	  without	  
LPS.	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4.3.2.	   PGE2	   production	   by	   keratinocytes	   (CPEK)	   incubated	   with	   LPS	   and	   neutrophils	  
(WBC):	  
	  
PGE2	  concentration	   in	   the	  keratinocyte	   (CPEK)	  culture	  medium	  after	   incubation	  with	  
WBC	  (in	  which	  neutrophils	  (PMNN)	  represented	  94%	  of	  the	  cells)	  during	  2,	  24	  and	  48	  
hours	   was	   significantly	   more	   elevated	   than	   PGE2	   concentration	   in	   the	   keratinocyte	  
culture	   medium	   after	   incubation	   with	   LPS	   at	   a	   100µg/mL	   or	   in	   keratinocytes	   alone	  
(control	   cells)	   (Fig.	  3.15,	   Fig.	  3.16	  and	   table	  3.7).	   Two	  hours	  of	   incubation	  with	  WBC	  
was	   enough	   to	   produce	   an	   almost	   3	   fold	   production	   of	   PGE2	   by	   keratinocytes	  
compared	   to	   control	   and	   LPS-­‐stimulated	   keratinocytes.	   This	   difference	   in	   PGE2	  
production	   raised	   to	   the	   maximum	   (7.5	   fold)	   at	   24h	   and,	   even	   not	   that	   high,	   the	  
production	  of	  PGE2	  by	  WBC	  stimulated	  keratinocytes	  kept	  5	   fold	  higher	  than	  control	  
and	  LPS-­‐stimulated	  cells	  at	  48	  hours	  incubation	  time.	  Keratinocytes	  incubated	  with	  LPS	  
produced	  more	   PGE2	   than	   control	   cells	   but	   this	   difference	  was	   not	   significant	   (Figl.	  
3.16	  and	   table	  3.7).	  These	   results	  confirmed	  the	   findings	  of	   the	  previous	  experiment	  
that	   found	  no	  significant	  difference	   in	  PGE2	  production	  between	  LPS	   stimulated	  and	  
non-­‐stimulated	  keratinocytes,	  even	  at	  high	  LPS	  concentration	   (100	  µg/mL)	  The	  same	  
difference	  was	  noted	  when	  PGE2	  per	  viable	  cell	  was	  calculated	  (table	  3.7).	  	  
	  
Regarding	   total	   cell	   count,	   there	   were	   no	   differences	   in	   viable	   cells	   in	   different	  
mediums	   in	  any	   incubation	  time,	   there	  was	  difference	   in	  total	  cell	  count	  at	  48	  hours	  
incubation	   time	   between	   control	   cells	   and	   keratinocytes	   incubated	  with	   PMNN	   and	  
there	  were	  almost	  differences	  between	  control	  cells	  and	  kerationcytes	  incubated	  with	  
PMNN	   and	   controls	   cells	   and	   keratinocytes	   incubated	  with	   LPS.	   The	   proliferation	   of	  
cells	  depending	  on	  the	  cell	  medium	  (alone,	  with	  LPS	  or	  with	  neutrophils)	  was	  similar	  
for	  the	  3	  groups	  of	  cells	  at	  2	  and	  24h	  incubation	  times,	  and	  the	  statistically	  significant	  
difference	   noted	   was	   with	   total	   cell	   count	   at	   48	   hours	   incubation	   period	   between	  
keratinocytes	  incubated	  with	  neutrophils	  (717,500	  cells)	  and	  control	  cells	  (450,000)	  in	  
which	  the	  p	  value	  was	  p=0.021	  (table	  3.8).	  The	  presence	  of	  LPS	  or	  neutrophils	  did	  not	  
increase	  the	  rate	  of	  mortality	  of	  keratinocytes	  statistically	  significant	  in	  any	  incubation	  
time,	   despite	   it	   was	   higher	   (but	   not	   statiscally	   significant	  with	   p	   values	   of	   0.057)	   in	  
these	  groups	  compared	  to	  keratinocytes	  at	  48	  hours	  (table	  3.8).	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Figure	  3.15:	  PGE2	  production	  by	  non-­‐stimulated	  CPEK	  keratinocytes	  (kcs)	  and	  
keratinocytes	  incubated	  with	  white	  blood	  cells	  (containing	  96%	  of	  neutrophils	  (PMNN))	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Figure	  3.16:	  PGE2	  concentration	  in	  wells	  supernatants	  	  of	  non-­‐stimulated	  CPEK	  
kerationcytes	  (kcs)	  and	  kerationcytes	  incubated	  with	  white	  blood	  cells	  (containing	  96%	  
of	  neutrophils	  (N))	  or	  with	  100	  µg/mL	  of	  lipopolysaccharide	  (LPS).	  A:	  2	  hours	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Summary	  
	  
Cyclooxygenase	   (COX)-­‐2	   and	   its	   main	   metabolite,	   prostaglandin	   E2	   (PGE2),	   are	  
important	   players	   in	   the	   skin	   physiology	   (maturation	   and	   proliferation	   of	  
keratinocytes)	   and	   pathophysiology	   (wound	   healing,	   skin	   inflammation	   and	  
carcinogenesis).	  Despite	  the	  evidence	  that	  suggests	  that	  COX-­‐2	  derived	  prostaglandins	  
contribute	   to	   carcinogenesis,	   conflicting	   results	   have	   been	   reported	   from	   numerous	  
human	  and	  mammalian	  studies.	  Moreover,	  the	  involvement	  of	  the	  COX-­‐2/PGE2	  route	  
in	   cutaneous	   inflammatory	   processes	   in	   companion	   animals	   have	   not	   been	  
investigated.	  This	  has	  left	  a	  desert	  field	  regarding	  therapeutic	  strategies	  involving	  the	  
pharmacologic	  manipulation	  of	  the	  COX-­‐2/PGE2	  system	  in	  these	  species.	  
	  
In	   this	   thesis	   COX-­‐2	   expression	   on	   cutaneous	   pre-­‐neoplastic	   (actinic	   keratosis	   (AK)),	  
neoplastic	   (squamous	   cell	   carcinoma	   (SCC),	   melanocytic	   neoplasias	   and	   cutaneous	  
epitheliotropic	  T	  cell	  lymphoma	  (CETL))	  and	  inflammatory	  disorders	  with	  an	  epidermal	  
involvement	  was	  studied.	  	  
	  
We	   detected	   COX-­‐2	   expression	   in	   non-­‐neoplastic	   canine,	   feline	   and	   equine	  
kerationcytes	   present	   in	   neoplastic	   or	   inflammatory	   dermatoses.	   COX-­‐2	   expression	  
was	  also	  detected	   in	  pre-­‐neoplastic	  and	  neoplastic	  canine	  and	  feline	  keratinocytes	  of	  
the	   AK	   and	   SCC	   samples.	   A	   low	   number	   of	   canine	   and	   equine	   melanocytes	   in	   the	  
melanocytic	   neoplasias	   also	   expressed	   COX-­‐2.	   However,	   and	   except	   for	   the	   AK	  
samples,	  in	  all	  these	  cases	  COX-­‐2	  expression	  was	  observed	  mainly	  at	  the	  surface	  of	  the	  
samples	  and	  was	  highly	  associated	  to	  the	  presence	  of	  infiltrating	  granulocytes.	  On	  the	  
contrary,	  we	  did	  not	  detect	  COX-­‐2	  expression	  in	  neoplastic	  lymphocytes	  of	  CETL	  or	  in	  
neoplastic	   and	   non-­‐neoplastic	   kerationcytes	   and	   neoplastic	   melanocytes	   in	   the	  
absence	  of	  a	  polymorphonuclear	  infiltrate.	  
	  
We	   set	   up	   an	   in	   vitro	   model	   to	   study	   the	   keratinocyte	   inflammatory	   response	   and	  
evaluated	   the	   in	   vitro	   production	   of	   PGE2	   in	   response	   to	   different	   stimuli.	  
Keratinocytes	  cultures	  were	  stimulated	  with	  different	  concentrations	  of	  LPS	  and	  with	  
canine	  white	  blood	  cells	  (WBC)	  (containing	  more	  than	  90%	  of	  neutrophils).	  We	  could	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observe	  that	  PGE2	  production	  by	  kerationcytes	  was	  highly	  associated	  to	  the	  presence	  
of	  WBC	  (neutrophils)	  in	  the	  culture	  media.	  
	  
Overall,	  our	  results	  suggest	  that	  the	  COX-­‐2/PGE2	  pathway	  may	  be	  involved	  in	  the	  AK	  
pathogenesis	  as	  in	  its	  human	  counterpart.	  However,	  it	  is	  not	  an	  essential	  mechanism	  in	  
the	   carcinogenesis	   process	   in	   SCC,	   melanocytic	   neoplasias	   and	   CETL	   in	   the	   canine,	  
feline	  and	  equine	  species.	  It	  is	  suggested	  that	  COX-­‐2	  expression	  or	  PGE2	  production	  is	  
an	  epiphenomenon	  associated	  to	  the	   inflammatory	  response	   in	  these	  neoplasias	  and	  
in	  neutrophilic	  inflammatory	  dermatoses.	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Resum	  
	  
La	  ciclooxigenasa	  (COX)-­‐2	  i	  els	  seu	  metabòlit	  principal,	  la	  prostaglandina	  E2	  (PGE2),	  són	  
importants	  en	  la	  fisiologia	  cutània	  (maduració	  i	  proliferació	  dels	  queratinòcits)	  i	  la	  seva	  
patofisiologia	   (processos	  de	  cicatrització,	   inflamació	  cutània	   i	   carcinogènesi).	  Malgrat	  
l’evidència	  que	  suggereix	  que	  les	  prostaglandines	  derivades	  de	  la	  COX-­‐2	  contribueixen	  
a	  la	  carcinogènesi,	  els	  resultats	  de	  múltiples	  estudis	  en	  humans	  i	  mamífers	  són	  sovint	  
contradictoris.	  Endemés,	  el	  paper	  de	  la	  ruta	  COX-­‐2/PGE2	  en	  els	  processos	  inflamatoris	  
cutanis	   en	   animals	   de	   companyia	   no	   s’ha	   investigat,	   deixant	   desert	   el	   camp	   de	   les	  
estratègies	   terapèutiques	   que	   involucren	   la	   manipulació	   farmacològica	   d’aquest	  
sistema	  en	  aquestes	  espècies.	  
	  
En	   aquesta	   tesi,	   hem	   estudiat	   l’expressió	   de	   la	   COX-­‐2	   en	   lesions	   cutànies	   pre-­‐
neoplàstiques	   (queratosis	   actíniques	   (QA)),	   neoplàstiques	   (carcinoma	   de	   cèl·∙lules	  
escatoses	   (CCE),	   neoplàstiques	   melanocítiques,	   limfoma	   cutani	   epiteliotròpic	   de	  
cèl·∙lules	  T	  (LCECT))	  i	  en	  dermatosis	  inflamatòries	  amb	  afectació	  epidèrmica.	  
	  
Els	   resultats	   han	   revelat	   expressió	   de	   COX-­‐2	   en	   queratinòcits	   no	   neoplàstics	   canins,	  
felins	   i	  equins	  de	   les	  dermatosis	   inflamatòries	   i	  neoplàstiques	  estudiades.	  L’expressió	  
de	  COX-­‐2	  es	  va	  detectar	  també	  en	  queratinòcits	  pre-­‐neoplàstics	   i	  neoplàstics	  canins	   i	  
felins	   de	   les	  mostres	   de	   QA	   i	   CEE.	   I	   un	   baix	   nombre	   de	  melanòcits	   neoplàstics	   dels	  
processos	   cancerosos	   melanocítics	   també	   expressaren	   COX-­‐2.	   Tot	   i	   així,	   i	   amb	  
l’excepció	   de	   les	   mostres	   de	   QA,	   en	   tots	   aquests	   casos	   l’expressió	   de	   COX-­‐2	   es	   va	  
observar	  sempre	  a	  la	  superfície	  de	  les	  mostres	  i	  majoritàriament	  en	  aquelles	  cèl·∙lules	  
que	   tenien	   un	   infiltrat	   inflamatori	   granulocític	   al	   seu	   voltant.	   En	   canvi,	   no	   vàrem	  
detectar	  l’expressió	  de	  COX-­‐2	  en	  els	  limfòcits	  neoplàstics	  del	  LCECT.	  Tampoc	  no	  vàrem	  
detectar	   expressió	   de	   COX-­‐2	   en	   queratinòcits	   (neoplàstics	   i	   no	   neoplàstics)	   o	  
melanòcits	   neoplàstics	   en	   absència	   d’un	   infiltrat	   inflamatori	   de	   cèl·∙lules	  
polimorfonuclears.	  
	  
Es	   va	   posar	   a	   punt	   un	   model	   in	   vitro	   per	   estudiar	   la	   resposta	   inflamatòria	   dels	  
queratinòcits.	   Amb	   aquest	   model	   es	   va	   estudiar	   la	   producció	   de	   PGE2	   per	   part	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d’aquestes	  cèl·∙lules	  davant	  de	  diferents	  estímuls.	  Aquestes	  cèl·∙lules	  es	  varen	  estimular	  
amb	  diferents	  concentracions	  de	  lipopolisacàrid	  i	  amb	  leucòcits	  sanguinis	  canins	  (que	  
contenien	  més	   d’un	   90%	   de	   neutròfils).	   Amb	   aquests	   estudis	   vàrem	   poder	   observar	  
que	   la	  producció	  de	  PGE2	  per	  part	  dels	  queratinòcits	  era	  molt	  elevada	  quan	  aquests	  
s’havien	  cultivat	  en	  presència	  de	  leucòcits	  circulants	  (principalment	  neutròfils).	  
	  
Tots	  aquests	  resultats	  suggereixen	  que	  la	  via	  COX-­‐2/PGE2	  podria	  estar	  involucrada	  en	  
la	   patogènia	   de	   les	   QA	   tal	   i	   com	   ho	   està	   en	   la	   QA	   humana.	   En	   canvi,	   indiquen	   que	  
aquest	   no	   és	   un	  mecanisme	   essencial	   en	   el	   procés	   carcinogènic	   del	   CCE,	   neoplàsies	  
melanocítiques	   i	   LCECT	   en	   les	   espècies	   canina,	   felina	   i	   equina.	   Els	   nostres	   resultats	  
suggereixen,	   en	   canvi,	   que	   l’expressió	   de	   COX-­‐2	   o	   producció	   de	   PGE2	   és	   un	  
epifenomen	   associat	   a	   la	   resposta	   inflamatòria	   d’aquestes	   neoplàsies	   i	   en	   les	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:10.1Summary
Cyclooxygenase-2 (COX-2) overexpression and its causal role in epidermal carcinogenesis have been demon-
strated in human actinic keratoses (AK) and cutaneous squamous cell carcinoma (SCC). The aim of this study
was to determine immunohistochemically the level of expression of COX-2 in feline and canine AK (n¼ 18),
SCC (n¼ 36) and inflammatory dermatoses (n¼ 24). COX-2 immunoreactivity was detected in all feline and
canine SCC. In all specimens, labelled basal and suprabasal neoplastic keratinocytes were localized within
and below areas of superficial erosion or ulceration and only scattered deeper tumour cells were positively
labelled. In most cases, positive immunoreactivity of keratinocytes was associated with the presence of granulo-
cytes. COX-2 expression was detected in 3/9 canine and 4/9 feline cases of AK and in only one case was associated
with inflammation. Inflammatory dermatoses were characterized by positively labelled epidermal and follicular
basal and suprabasal keratinocytes that were always associated with granulocyte exocytosis. These results indi-
cate that further study of the effect of using COX-2 inhibitors in the management and prevention of feline and
canine cutaneous SCC is warranted. The association between inflammatory cells and COX-2 expressing epider-
mal cells opens a new line of research regarding the role of COX-2 in SCC oncogenesis.Moreover, further studies
should investigate the role of COX-2 in the pathogenesis and management of AK in animals.
 2011 Elsevier Ltd. All rights reserved.Keywords: cat; cyclooxygenase; dog; inflammation; skin neoplasiaIntroduction
Cyclooxygenase (COX) isoenzymes COX-1 and
COX-2 catalyze the initial step in the biosynthesis of
prostaglandins (PGs) from arachidonic acid (Dubois
et al., 1998). While there are notable exceptions, a sim-
plified view is that COX-1 is constitutively expressed
throughout the body and catalyzes the synthesis of
PG involved in homeostasis, whereas COX-2, gener-
ally regarded as the inducible isoform, is found primar-
ily at sites of inflammation and its main role is to aid in
producing PGE2 (Jones and Budsberg, 2000; Rouzer
and Marnett, 2009). A multitude of inflammatory
signals, mitogens and carcinogens can induce COX-2
activity in numerous cell types (Jones et al., 1993).
Human epidemiological, pharmacological, clinical
and experimental studies document the importanceondence to: M. Bardagı. (e-mail: Mar.Bardagi@uab.cat).
75/$ - see front matter
016/j.jcpa.2011.03.012of PG signalling in carcinogenesis and suggest that
the long-term use of non-steroidal anti-inflammatory
drugs (NSAIDs), particularly the highly selective
COX-2 inhibitors, is linked to a lower incidence of sev-
eral types of epithelial neoplasms, including premalig-
nant actinic keratoses (AK) and squamous cell
carcinoma (SCC) (Fischer et al., 1999; Dempke et al.,
2001; Shaheen et al., 2002; Thun et al., 2002; Butler
et al., 2005; Greenhough et al., 2009). As reviewed by
Rundhaug et al. (2007), human and murine studies
have demonstrated that an increase in COX-2 expres-
sion, leading to increased levels of PGE2, is one of the
early events in ultraviolet (UV) light-induced skin car-
cinogenesis and COX-2 overexpression and its causal
role in epidermal carcinogenesis has been demon-
strated in AK and cutaneous SCC (Buckman et al.,
1998; An et al., 2002; M€uller-Decker and
F€urstenberger, 2007). Moreover, studies in vitro have
shown that skin cancer cell growth is suppressed by 2011 Elsevier Ltd. All rights reserved.
12 M. Bardagı et al.inhibition of COX-2 expression, and several trials have
reported significant regression of AK lesions after top-
ical treatment with diclofenac, a potent inhibitor of
COX-2 (Rivers and McLean, 1997; Higashi et al.,
2000; Wolf et al., 2001; Rivers et al., 2002; Gebauer
et al., 2003; Nelson et al., 2004). As reviewed by
Greenhough et al. (2009), the carcinogenic potential
of the COX-2/PGE2 pathway is mediated by its ability
to induce cell proliferation, evasion of apoptosis and
insensitivity to anti-growth signals, promotion of
angiogenesis and tissue invasion and metastasis and
evasion of the anti-tumour immune response.
COX-2 expression has been shown in canine and
equine cutaneous SCC (Pestili de Almeida et al.,
2001; Elce et al., 2007; Thamm et al., 2008), but not
in feline cutaneous SCC or normal canine skin
(Beam et al., 2003; Hamamoto et al., 2009). COX-2
expression in AK in animals has not been investigated.
The initial aim of the present study was to investi-
gate immunohistochemically COX-2 expression in
feline and canine AK. However, since preliminary
results had also shown COX-2 expression in feline
SCC and a possible correlation between COX-2
expression and inflammation, we also aimed to inves-
tigate the expression of COX-2 in feline and canine
SCC and in inflammatory dermatoses and its possible
correlation with inflammatory infiltration.
Materials and Methods
Tissue Samples
Seventy-eight samples were selected from the archive
of the Veterinary Pathology Diagnostic Service of the
Universitat Autonoma de Barcelona. These included
18 cases of AK (nine each feline and canine), 36 cases
of SCC (27 feline and nine canine) and 24 inflamma-
tory dermatoses. Inflammatory dermatoses includedTable
Summary o





Pemphigus foliaceus Feline 2
Pemphigus foliaceus Canine 3
Pustular staphylococcal infection Feline 1
Pustular staphylococcal infection Canine 5
SHPVD without pustules Feline 2
SHPVD without pustules Canine 3
Dermatophytosis Feline 3
Dermatophytosis Canine 5
n/a, not applicable.pemphigus foliaceus (two feline and three canine
cases), pustular staphylococcal infection (one feline
and five canine cases), superficial hyperplastic perivas-
cular dermatitis (SHPVD)without pustules (two feline
and three canine cases) and dermatophytosis (three fe-
line and five canine cases). The clinical history of each
case was reviewed in order to exclude samples from
animals that had received glucocorticoid or NSAID
treatment prior to biopsy sampling.Immunohistochemistry
The standard streptavidinebiotin technique was used
for the detection of COX-2 protein by immunohisto-
chemistry (IHC). Sections (5 mm) from formalin-
fixed and paraffin wax-embedded tissues were
dewaxed and endogenous peroxidase activity was
quenched by exposure to H2O2 3% in distilled water
for 5 min. Bleaching with 0.25%potassiumpermanga-
nate for 30 min followed by 1% oxalic acid for 5 min
was performed subsequently. Heat-induced epitope re-
trieval was carried out at 90e100C in citrate buffer
(pH 6.0) for 10 min with 30 min of cooling at ambient
temperature. The sections were then blocked with 2%
bovine serumalbumin (SigmaeAldrich, StLouis,Mis-
souri, USA). The primary antibody (polyclonal rabbit
anti-murine COX-2; Cayman Chemical, Ann Arbor,
Michigan, USA) was applied, and slides were incu-
bated overnight at 4C. Slides were then incubated
with biotinylated polyclonal goat anti-rabbit second-
ary antibody (Dako, Glostrup, Denmark) for 1 h and
then with an avidinebiotineperoxidase complex
(ImmunoPure; Thermo Fisher Scientific, Rockford,
Illinois, USA) for 1 h. Labelling was ‘visualized’ with
3,30diaminobenzidine tetrahydrochloride (Sigmae
Aldrich) and counterstained with haematoxylin.




COX-2 expression associated with
granulocytic inflammation (% of positive samples)
27/27 (100) 21/27 (77)
9/9 (100) 8/9 (88)
4/9 (44) 0/4 (0)
3/9 (33) 1/3 (33)
2/2 (100) 2/2 (100)
3/3 (100) 3/3 (100)
0/1 (0) n/a
2/5 (40) 2/2 (100)
0/2 (0) n/a
0/3 (0) n/a
2/3 (66) 2/2 (100)
1/5(20) 1/1 (100)
COX-2 Expression in Squamous Cell Carcinoma 13experiment and comprised sections incubated with
normal rabbit serum in place of the primary antiserum.
The anti-COX-2 reagent used in this study has been
shown previously to detect COX-2 in feline macula
densa (Newman and Mrkonjich, 2006).
Results
Expression of COX-2 was observed in samples of AK,
SCC and inflammatory dermatoses. The pattern of
immunoreactivity in keratinocytes was granular cyto-
plasmic and located mainly in the perinuclear zone.
All feline and canine SCC contained positively la-
belled neoplastic cells (Table 1). Labelling was het-
erogeneous throughout the tumour sections. BasalFig. 1. (AeD) Sections of feline SCC. (EeF) Section of canine SCC
areas of (A), (C) and (E), respectively. Expression of COX-2 b
of the tumours (arrows), but scattered deeper positive cells are
with the presence of granulocytes (asterix). IHC.cells and more differentiated cells were labelled,
mainly in and below areas of superficial erosion or ul-
ceration, but positively labelled tumour cells were
also observed to be scattered deeper in all samples
(Fig 1). In most cases, the positive labelling of kerati-
nocytes was associated with the presence of granulo-
cytes (Fig. 1). There was no COX-2 expression at
the non-eroded/ulcerated margins of the tumours.
In 6/27 feline cases and 1/9 canine cases, positively la-
belled neoplastic keratinocytes were observed without
the presence of an associated inflammatory response.
Four out of nine feline and three out of the nine ca-
nine samples of AK expressed COX-2 (Table 1). Im-
munoreactivity was observed in basal epidermal cells,. (B), (D) and (F) are high-power magnifications of the indicated
y neoplastic keratinocytes is observed mainly at the eroded surface
also present (arrowheads). Labelling of keratinocytes is associated
14 M. Bardagı et al.but scattered suprabasal cells were also labelled
(Fig. 2). The positively labelled cells were in the prox-
imity of an inflammatory infiltrate only in one canine
sample.
Of the 24 samples of inflammatory dermatoses
tested, labelled keratinocytes were observed in four fe-
line (two pemphigus foliaceus and two dermatophyto-
ses) and six canine (three pemphigus foliaceus, two
pustular staphylococcal infections and one dermato-
phytosis) cases (Table 1). In all samples, basal and
suprabasal labelled keratinocytes were always associ-
ated with exocytosis of granulocytes into the epidermis
or follicular epithelium (Fig. 3). In the absence of gran-
ulocyte exocytosis the epithelium invariably failed to
express COX-2. In three cases (one feline and two ca-
nine cases of dermatophytoses) there was focal and
mild exocytosis of neutrophils into the follicular epithe-
lium, but no labelled keratinocytes were observed.
Lymphocytic mural folliculitis in dermatophytosis
was not associated with immunoreactivity of the epi-
thelium in any of the samples.Discussion
The results of the present study indicate that COX-2
occurs in feline cutaneous SCC as shown for other an-
imal species (Pestili de Almeida et al., 2001; Elce et al.,Fig. 2. (AeD) Sections of AK. (A) and (B) are from a feline case of AK
powermagnifications of the indicated areas of (A) and (C), resp
and in few suprabasal keratinocytes (arrowheads). IHC.2007; Thamm et al., 2008). Additionally, COX-2
expression was shown for the first time in feline and
canine AK and inflammatory dermatoses.
The expression of COX-2 by feline SCC is in sharp
contrast to the absence of COX-2 expression in feline
SCC reported previously (Beam et al., 2003). The lack
of detectable COX-2 expression in the previous study
of feline cutaneous SCC may have been due to the
small sample size (n¼ 4) or to differences in the meth-
odology, such as the antigen retrieval methods, the
antibody used or prolonged fixation, as already sug-
gested by the authors of that study (Beam et al., 2003).
COX-2 immunoreactivity in neoplastic keratino-
cytes was generally associated with the presence of
granulocytic inflammation and only a minority of
tumour cells showed COX-2 expression in the ab-
sence of inflammation. COX-2 expression was also
more prevalent among cells close to the eroded or
ulcerated surface of the tumours. Because inflam-
matory cells are normally present at the surface of
ulcerated tumours such as SCCs, and most of the la-
belled neoplastic keratinocytes were associated with
granulocytes, this association may help to explain
the distribution of the observed immunolabelling.
A similar pattern of expression has been described
in equine ocular and adnexal SCC, in which
COX-2 labelling was confined to relativelyand (C) and (D) from a canine case of AK. (B) and (D) are high-
ectively. COX-2 expression is observedmainly in the basal (arrows)
Fig. 3. (AeF) Sections from cases of inflammatory dermatosis. (A) and (B) Feline pemphigus foliaceus. (C) and (D) Feline dermatophy-
tosis. (E) and (F)Canine pemphigus foliaceus. (B), (D) and (F) are high-powermagnifications of the indicated areas of (A), (C) and
(E), respectively. COX-2 expression by keratinocytes is associated with the exocytosis of granulocytes into the epidermis and fol-
licular epithelium (arrows). IHC.
COX-2 Expression in Squamous Cell Carcinoma 15superficial cells (Smith et al., 2008). The authors of
that study suggested that a plausible explanation for
this superficial distribution of COX-2 expression is
that it could be related to inflammation; however,
there was no mention of the presence of inflamma-
tory cells in that report. Moreover, the finding in
the present study that some keratinocytes expressed
COX-2 in some of the inflammatory dermatoses
only when there was granulocyte exocytosis into
the epithelium, further supports this relationship.
At this point, we do not know if it is the presence
of inflammatory cells that stimulates COX-2
expression by neoplastic keratinocytes or if it is
COX-2 expression by the tumour that facilitates
the infiltration of inflammatory cells.It has been shown that inflammatory mediators,
such as interleukin (IL)-17, IL-1b, tumour necrosis
factor (TNF)-a and platelet-activating factor, stimu-
late the production of COX-2 by keratinocytes and
other cells (Pei et al., 1998; Biswas et al., 2005; Farley
et al., 2005; Kanda et al., 2005) and IL-1b and TNF-
ahave been shown to induceCOX-2 expression in can-
cer cells (Chen et al., 2000; Cui et al., 2006). This could
help to explain the expression of COX-2 by feline and
canine SCC and inflammatory dermatoses. However,
COX-2 plays an important role in granulocyte recruit-
ment and activation via production of prostanoids
(Biswas et al., 2005). Accordingly, COX-2 could be
produced by the tumour and facilitate the infiltration
of inflammatory cells. In human medicine, a close
16 M. Bardagı et al.relationship between COX-2 expression and infiltra-
tion of inflammatory cells has been observed in colorec-
tal cancer and hepatocellular carcinoma (Cervello
et al., 2005; Naghshvar et al., 2009). Studies in vitro
may help to distinguish between these two
possibilities; however, it is also possible that the two
phenomena may be present at the same time or that
other unknown factors may be implicated in this
interrelationship. In fact, some of the inflammatory
dermatoses did not have COX-2 expression and some
neoplastic cells showed strong labelling without a clear
association with the presence of inflammatory cells.
Another objective of the study was to investigate the
expression of COX-2 by feline and canineAK.Numer-
ous studies have shown that UVB irradiation signifi-
cantly increases COX-2 gene expression at both
mRNA and protein levels in human skin as well as in
cultured keratinocytes (Buckman et al., 1998; An
et al., 2002). Moreover, studies in mice and human
patients have shown that following UV light
exposure, COX-2 expression is induced in the basal
and suprabasal keratinocytes of the interfollicular epi-
dermis and precedes keratinocyte proliferation
(Buckman et al., 1998; Tripp et al., 2003). In the
present study, COX-2 expression was detected in the
basal and suprabasal keratinocytes in some cases of fe-
line and canine AK. Unlike the results for SCCs, in
95% of these samples the labelled keratinocytes were
not associated with the presence of inflammatory cells.
These findings support the possible role of COX-2
in AK and the possible implication of an arachidonic
acid/PG pathway in photocarcinogenesis in canine
and feline patients as has been suggested in man
and mice (Rundhaug et al., 2007). It could be argued
that finding COX-2 expression unassociated with in-
flammation in pre-neoplastic lesions (AK) could facil-
itate infiltration of inflammatory cells in more
advanced lesions (SCC), but this would not explain
why labelling of neoplastic cells in SCC was observed
mainly in areas of surface erosion or ulceration with
the presence of inflammatory cells.
In conclusion, the strong labelling observed in feline
and canine skin SCC indicates the need for further
studies of the effect of using COX-2 inhibitors for the
management and prevention of cutaneous SCC. The
association between inflammatory cells and COX-2
expression by epidermal cells opens a new line of re-
search regarding the role of COX-2 in SCC oncogene-
sis. Moreover, further in-vitro and in-vivo clinical
studies may be indicated in order to investigate the
role of COX-2 and COX-2 inhibitors in animal AK.
Thismay open the door to new therapeutic approaches
for management of this disease in animals, such as the
use of topical diclofenac, which has been demonstrated
to be effective and well tolerated for the treatment ofhuman AK (Rivers and McLean, 1997; Wolf et al.,
2001; Rivers et al., 2002; Gebauer et al., 2003; Nelson
et al., 2004).Conflict of Interest
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